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I Abstract 
 
The current outlook for patients suffering malignant glioma is poor, with sub-
optimal delivery of agents across the blood-brain barrier, migration of tumour 
cells to areas that are not exposed to chemotherapeutic assault and the ability of 
tumour cells to repair DNA damage caused by anti-proliferative agents. The 
objectives were to demonstrate the potential of targeting the mitochondria of 
glioma cells through the use of tricyclic antidepressants and to show that the 
success of this approach is largely dependent on the metabolic capacity of the 
patient and the expression of the norepinephrine transporter on glioma cells. A 
range of tricyclic agents were screened against a panel of tumours using MTT, 
ATP-TCA and Annexin-V assays; the metabolic capacity of seventeen glioma 
patients was assessed through HPLC-MS/MS sampling of plasma Clomipramine 
concentrations and cytochrome P450 drug metabolism enzyme genotyping via 
real-time PCR; the presence of the norepinephrine transporter was elucidated 
through immunohistochemical, immunocytochemical, Western blotting and real-
time PCR techniques and finally apoptotic potential was determined by screening 
tumours (retrospectively and prospectively) via real-time PCR. Chemosensitivity 
results show that Clomipramine (the range for five tumours tested was 42.57 ± 
16.58 µM) and Nortriptyline (the range for four tumours tested was 30.22 ± 
14.81 µM) were the most effective agents when tested in the MTT assay and 
Norclomipramine (the range for five tumours tested was 7.65 ±3.53 µM) and 
Nortriptyline (the range for five tumours tested was 33.15 ± 13.72 µM) were the 
most effective agents when tested using the ATP-TCA assay. Annexin-V flow 
cytometry supported these results and further evidenced that Clomipramine 
induces apoptosis in malignant glioma. 
 III 
The genotypic status of CYP2D6 and CYP2C19, combined with plasma levels of 
Clomipramine/Norclomipramine achieved in vivo, showed that mutations in the 
CYP2D6*2X3 allele significantly affect the metabolism of Norclomipramine 
(p<0.05). Immunohistochemical, immunocytochemical and Western blotting 
techniques demonstrated the presence of the norepinephrine transporter 
(encoded by the SLC6A2 gene) on glioma cells, however real-time PCR results 
suggest that the exons within the SLC6A2 gene contain splice variants. Taqman 
low density array of retrospective tumour samples revealed variation in the 
expression of apoptotic genes, with no discernable pattern, and that it is possible 
to modulate the expression of these genes by exposing SNB-19, DK-MG and 
UPAB glioma cells to tricyclic antidepressants, Procarbazine, Dexamethasone 
and Valproic acid. Evidence from this study demonstrates that tricyclic 
antidepressants provide a new approach to mitochondrially-mediated therapy for 
malignant glioma that express the Norepinephrine transporter, which overcomes 
the resistance to targeting proliferation and growth factors.  
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1.1 Background to Brain Tumours 
 
 
Brain tumours are classified into primary and secondary tumours whereby the 
former originate from the brain itself while the latter metastasise from another 
location in the body. Histologically, primary tumours can be either malignant or 
benign, whereas secondary tumours are, by definition, always malignant. The 
intracranial tumours can be further subdivided into extracerebral and 
intracerebral; extracerebral tumours are generally Meningioma, intracerebral 
tumours are either intrinsic lesions arising from the substance of the brain, the 
majority of which are generically referred to as glioma, or extrinsic lesions such 
as metastases or lymphoma. There are also primary neoplasms considered to be 
neuronally-derived tumours such as the supratentorial primitive neuroectodermal 
tumour (sPNET), medulloblastoma and central neurocytoma but these are less 
frequent than the glial-derived neoplasms and are predominantly seen during 
childhood.  
 
Primary brain tumours represent over one hundred different tumour types with a 
wide divergence of biologies and clinical prognoses, but despite the 
heterogeneity of these neoplasms they all challenge the field of neuro-oncology 
in the same manner. Glioma, so called due to the striking histological similarity 
of their component cellular elements to glial cells (astrocytes, oligodendrocytes 
and ependymal cells), includes Astrocytoma, Oligodendrocytoma and 
Ependymoma. Astrocytomas are the most frequently occurring of the glioma.  
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Malignant or high-grade glioma include Anaplastic glioma (Anaplastic 
Astrocytoma, Anaplastic Oligodendroglioma and Anaplastic mixed 
Oligoastrocytoma) designated World Health Organisation (WHO) Grade III and 
Glioblastoma multiforme (GBM) and Gliosarcoma designated WHO Grade IV 
(Louis, Ohgaki et al. 2007).  
 
Until the development of in vitro and in vivo models, to further elucidate the 
mechanisms underlying central nervous system (CNS) malignancies, little 
information was available regarding their behaviour in situ. The process of 
obtaining human biopsy tissue following surgical resection is not possible in all 
cases due to location of the tumour, for example the brainstem glioma. Because 
of the delicate nerve connections to the motor and sensory systems and its role in 
the regulation of cardiac and respiratory function, tumours of the brainstem are 
usually inoperable.  
 
Performing experiments in vitro provides limited information due to the failure 
to replicate the delicate microenvironment encompassed by the intricacies of the 
blood-brain barrier (B-BB). This is one reason why the formidable clinical 
challenge that malignant brain tumours and brain metastases present has meant 
that no really significant therapeutic advances have been made in the last decade. 
 
This study focuses solely on glioma, for which the prognosis remains poor. 
Unlike the non-CNS cancers, where survival rates generally continue to increase, 
primary brain tumours remain largely incurable and highly lethal.   
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1.2 Classification and Grading of brain tumours 
 
Comprised of both brain and spinal cord tumours, the CNS malignancies 
represent a vast array of tumour types, classified according to perceived lineage, 
histological diversity and prognosis. The WHO classification schema recognises 
intrinsic lesions from each type of neuroepithelial cell, as well as tumours of the 
specialised cells of the pineal gland, those derived from embryonic brain 
precursor cells and tumours of mixed origin including those arising from blood 
vessels.  
 
In addition, extrinsic tumours arise from the meningeal coverings of the brain 
and spinal cord or from the sheaths of the cranial and spinal nerves and 
secondary tumours may also arise from outside the CNS.  
 
The WHO classification of tumours of the nervous system contains more than 
fifty clinico-pathological entities, plus many variants within a particular subtype 
(for example the Meningioma has twenty-two variants), with a great variation in 
biological behaviour, response to therapy and clinical outcome (Louis, Ohgaki et 
al. 2007), however this system (unlike the St. Anne Mayo system) is not criteria-
based.  
 
Of all intracranial CNS tumours, approximately 60% are of neuroepithelial origin 
(glioma), 28% are derived from the brain coverings (Meningioma) and 7.5% are 
located in cranial and spinal nerves. Lymphomas and germ cell tumours account 
for 4% and 1% respectively (Louis, Ohgaki et al. 2007).  
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Four different malignancy grading systems are in current use for tumours of 
astrocytic lineage (WHO, St. Anne/Mayo, Ringertz, Kernohan); the 
Astrocytoma, Anaplastic Astrocytoma and Glioblastoma. The grades are 
assigned on the microscopic appearance of the tumour, however the numerical 
grade can vary depending on which system is referred to. It is important, for this 
reason; to specify which grading system is being used.  
 
The St. Anne/Mayo system (Daumas-Duport, Scheithauer et al. 1988) has proved 
to correlate better with survival than the Kernohan system (Kernohan 1938); it is 
similar to the WHO system (Louis, Ohgaki et al. 2007) but it is criteria-based and 
can only be applied to invasive tumours of astrocytic lineage. The Ringertz 
system (Ringertz 1950), superseded the Kernohan system in 1950, is a three-tier 
system that was prompted by the lack of clear differences in survival times 
between grade III and IV tumours. Interestingly, the St. Anne Mayo system, 
which is the most commonly used grading system, does not take into account 
local infiltrative invasion and location in the brain and yet these features can 
significantly determine outcome.  
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 WHO classification  
 
Juvenile Pilocytic Astrocytoma 
 
Grade I 
Score 0 
 
 
Diffuse, fibrillary, protoplasmic and gemistocystic 
Astrocytoma 
 
 
 
Grade II 
Score 1 
 
Anaplastic Astrocytoma 
 
Grade III 
Score 2 
 
Glioblastoma multiforme & variants 
 
Grade IV 
Score 3 or 4 
Table 1.2.1 Grading of astrocytic tumours according to WHO and St. 
Anne/Mayo systems 
 
The grading system is based upon the recognition of the presence or absence of 
four morphologic criteria: nuclear atypia, mitoses, microvascular proliferation 
(endothelial hyperplasia), and necrosis. The method results in a summary score 
which is translated into a grade as follows: 0 criteria = grade 1, 1 criterion = 
grade 2, 2 criteria = grade 3, 3 or 4 criteria = grade 4. This is based upon the 
number of the four histological features identified in a biopsy by the 
neuropathologist. A grade I tumour, for example, would have none of the 
histological criteria and the diagnosis of grade I would be based upon hyper-
cellularity alone. A grade IV neoplasm would display microvascular proliferation 
and/or necrosis as well as the other four criteria (which arise in lower-grade 
tumours). Unfortunately two important features which exert a major influence 
over prognosis/survival i.e. location within the brain and diffuse invasive 
behaviour, are ignored from these „histological criteria‟ diagnostic systems. The 
histology and clinical data were derived from a previously reported series of 
patients with astrocytomas, treated with radiotherapy at Mayo Clinic between the 
years 1960 and 1969. 
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1.3 Pathology and Genetics of tumour types included in this study 
 
1.3.1 Astrocytic Tumours 
 
Tumours of astrocytic origin constitute the largest proportion of glioma. The 
characteristics and pathogenesis of astrocytic tumours is described in Figure 
1.3.1.1 and they vary greatly in morphology, genetic profile and clinical 
behaviour. The Pilocytic, or juvenile, Astrocytoma (PA; WHO Grade I) is the 
most frequent CNS neoplasm in children, and is predominantly located in the 
cerebellum and midline structures, including the optic tract, brain stem and spinal 
cord. It infiltrates adjacent brain structures but grows slowly and usually has a 
favourable prognosis with five-year survival rates of more than 85% (WHO 
Grade I). Some PAs occur in the setting of neurofibromatosis type 1 (NF1), 
particularly those of the optic nerve (optic glioma).  
 
Other astrocytomas usually develop in the cerebral hemispheres of adults and 
diffusely infiltrate adjacent brain structures. Low grade diffuse astrocytomas 
(WHO grade II) occur in young adults and grow slowly. However, they diffusely 
infiltrate the brain and cannot generally, therefore, be completely surgically 
resected. Morphologically, tumour cells resemble differentiated astrocytes. 
Mutations in protein 53 (p53), a transcription factor that regulates the cell cycle 
and hence acts as a tumour suppressor, are found in two-thirds of astrocytomas 
and are considered an early event. The five-year survival rate of low-grade 
diffuse Astrocytoma is greater than 60%.  
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Anaplastic Astrocytoma (AAs; WHO grade III) often develop from low-grade 
Astrocytoma, grow relatively fast and typically progress to Glioblastoma within 
two to three years, accompanied by genetic alterations, including loss of 
heterozygosity (LOH) on chromosome 19.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.1.1 Flow chart showing the genetic pathogenesis of astrocytic tumours 
Figure adapted from (Ohgaki, Dessen et al. 2004), there are two distinct 
pathways that lead to primary de novo Glioblastoma multiforme and secondary 
Glioblastoma multiforme, with progressive loss of heterozygosity and 
amplifications.  
 
 
 
Cell of origin Cell of origin 
Grade IV Astrocytoma 
Primary de novo GBM 
LOH 10q (PTEN) 
CDK4 
Amplification 
MDM2 
Amplification 
EGFR 
Amplification 
Other LOH and 
amplifications 
Grade IV Astrocytoma 
Secondary GBM 
Grade II Astrocytoma 
Grade III Astrocytoma 
LOH 9q INK4a 
LOH 10q PTEN 
LOH 17q (P53) 
LOH 13q Rb 
Other LOH and 
amplifications 
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1.3.2 Glioblastoma multiforme (WHO grade IV) 
 
This is the most frequent and most malignant nervous system tumour. Secondary 
GBMs develop by malignant progression from low-grade and Anaplastic 
Astrocytoma and are characterized by p53 mutations and LOH on chromosome 
10q (see 1.3). Primary GBMs are more frequent (>80% of cases) and develop 
rapidly in an older age group (mean age, 55 years), with a short clinical history 
of less than three months. Their genetic profile includes amplification and 
overexpression of the epidermal growth factor (EGF) receptor gene, phosphatase 
and tensin homologue (PTEN; a tumour suppressor gene) mutations, 
p16
INK4A
(which regulates the cell cycle by binding and deactivating various 
cyclin-cyclin dependent kinase complexes) deletions and loss of chromosome 10. 
Both GBM types diffusely infiltrate the brain, including the opposite hemisphere 
and show high cellularity and large areas of necrosis despite excessive vascular 
proliferation. Characteristic morphology of these tumour slides is shown in 
Figure 6.2.2.1. 
 
1.3.3 Oligodendroglioma 
 
These neoplasms develop from myelin-producing oligodendroglial cells or their 
precursors and are typically found in the cerebral hemispheres of adults, often 
including the basal ganglia. Histologically, they are isomorphic, with a typical 
honeycomb pattern and delicate tumour vessels (“chicken wire” pattern). 
Characteristic morphology of these tumours can be seen in Figure 6.2.2.1. 
Anaplastic Oligodendroglioma (AOs; WHO Grade III) show features of 
anaplasia and high mitotic activity and carry a less favourable prognosis.  
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Genetic hallmarks of Oligodendroglioma (OGs) are LOH on chromosomes 1p 
and 19q (see 1.3). OGs that carry these genetic alterations show a marked 
sensitivity to deoxyribonucleic (DNA)-based chemotherapy.  
 
1.3.4 Meningioma 
 
These slowly growing, usually benign, neoplasms develop from arachnoidal cells 
in the meninges. There is a prevalence in post-menopausal women, thought to be 
linked to the progesterone receptor (Lusis, Chicoine et al. 2005), particularly in 
respect to those located in the spine. Meningiomas do not infiltrate the brain but 
may cause symptoms of intracranial pressure due to compression of adjacent 
brain structures (WHO Grade I). Preferential sites are the cerebral hemispheres. 
Meningioma can often be cured by surgical resection. Malignant Meningioma 
are much less frequent; they may infiltrate the brain and often recur locally. 
Characteristic morphology of these tumours can be seen in Figure 6.2.2.1. 
 
1.3.5 Paediatric medulloblastoma and supratentorial primitive 
neuroectodermal tumours 
 
 
The medulloblastoma and supratentorial primitive neuroectodermal tumour 
(sPNET) are rare paediatric embryonal tumours, around which controversy exists 
regarding their origin. These two tumour types were studied during the course of 
the project, to provide an insight as to their origin, biological behaviour and 
pathogenesis, and the data was published via peer-reviewed journal (see 
appendix 9.3).  
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1.4 Biology of brain tumours 
 
 
Tumour recurrence, high morbidity and high mortality, despite many 
technological advances associated with malignant brain tumours, may be 
attributed to a number of distinct biological features unique to tumour cells 
including proliferation, angiogenesis (formation of new blood vessels), cellular 
heterogeneity (including differential response to therapeutic agents by various 
sub-populations of cells) and local invasion.  
 
Cell division, proliferation and apoptosis are essentially similar in both normal 
and tumour cells; the tumour cell, however, differs from its normal counterpart in 
that these processes are aberrantly regulated.  
 
Cell proliferation is a key element of cell growth. A number of genetic 
aberrations, such as mutations in the p53 or PTEN tumour suppressor genes or 
amplification of oncogenes such as EGFR, allow tumours to circumvent the cell 
cycle checkpoint and cell arrest signals, blocking the apoptotic pathways and 
allowing the unregulated division of brain tumour cells (Merzak, Raynal et al. 
1994).  
 
Angiogenesis is another essential component of many physiological and 
pathological conditions including proliferation and local spread of brain tumours. 
The neovascularisation of high grade glioma is a characteristic inherent to these 
devastating tumours, and is mediated via physiological substances secreted by 
the brain tumour itself (Plate and Risau 1995). 
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Angiogenesis involves three main stages: blood vessel breakdown (through 
angiopoeitin-1 and its receptor Tie-2), breakdown of extra cellular matrix (ECM) 
and migration of cells to form new blood vessels (which involves matrix 
metalloproteinases; MMPs) and migration of endothelial cells and formation of 
new blood vessels (involving CD44 and integrins) (Tate and Aghi 2009).The 
formation of abnormal, dysfunctional tumour vasculature and glioma cell 
invasion along white matter tracts are major components of the difficulty in 
treating brain tumours effectively and hallmarks of glioma. As a result of 
angiogenesis, tumour vessel structure is markedly abnormal and this causes 
difficulty in delivering chemotherapy (Sathornsumetee and Rich 2007). Vessel 
changes also cause tumour hypoxia and oedematous areas in the brain (Jain, di 
Tomaso et al. 2007).  
 
Finally, one of the most important features of human brain tumours is cell 
invasion. There is increasing evidence that invasive cells transiently arrest from 
the cell cycle during the migratory phase; therefore they are refractory to 
radiotherapy and many chemotherapy regimens. Moreover, invading neoplastic 
glia are protected from a number of cytotoxic drugs by virtue of being located in 
brain areas with an intact B-BB. Invasion is a complex, multi-step process 
modulated by a variety of factors (Bolteus, Berens et al. 2001). Firstly glioma 
cells detach from the primary mass (involving neural cell adhesion molecule 
downregulation and CD44 cleavage) and then mediators, such as integrins, bind 
to the ECM. Glioma cells secrete proteases (similar to MMPs) which degrade the 
ECM and finally cytoplasmic mediators (such as myosin) allow the invading 
glioma cells to alter their shape and become motile (Tate and Aghi 2009).  
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Invading cells frequently migrate away from the main tumour bed, where chemo- 
and radio-therapy are directed, and so are a highly lethal cell population. Overall, 
despite the advances brought about in neurosurgery and neuroradiology, such as 
non-invasive gamma knife and stereotactic radiosurgery, the outcome for patients 
remains dismal due to the complex biology of brain tumours. 
 
1.4.1 Glioma angiogenesis and Vascular Endothelial Growth Factor-A 
 
There are five members of the mammalian vascular endothelial growth factor 
family: VEGF-A, -B, -C, -D and P1GF (placental growth factor). An additional 
ligand, -E, is encoded by the Orf-virus genome. These ligands bind to cell 
surface receptors such as VEGF receptor tyrosine kinases (VEGFR1, -2 and -3) 
and co-receptors (heparin sulphate proteoglycans, neuropilins -1 and -2). VEGF-
A (often simply referred to as VEGF in the literature, and will be referred to as 
such in this thesis) is a pro-angiogenic factor that binds to VEGFR-1 and 
VEGFR-2 receptors, stimulating intracellular signalling, gene expression, cell 
migration and new blood vessel sprouting (Latham, Molina-Paris et al.).  
 
Neuronal cells, astrocytes and tumour cells secrete VEGF (-A), whereas the 
receptors are specifically expressed in vascular endothelial cells (Plate, Breier et 
al. 1994; Plate and Risau 1995; Kargiotis, Rao et al. 2006). Malignant glioma 
cells secrete a variety of angiogenic factors such as VEGF and fibroblast growth 
factor (FGF), which helps them co-opt blood vessels and it is VEGF-A that is 
thought to have a significant role in brain tumour angiogenesis (Jain, di Tomaso 
et al. 2007).  
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The upregulation in gene expression by these tumours has at least four 
mechanisms (Shibuya 2009): 
 
1. a hypoxia/HIF-related mechanism related to low oxygen concentration in 
tumour tissue 
2. stimulation via the epidermal growth factor receptor (EGFR) signalling 
pathway (HIF-independent) 
3. the FoxMIB transcription factor stimulates VEGF in GBMs (HIF-
independent) 
4. the HuR protein is upregulated in hypoxic conditions and suppresses the 
post-transcriptional degradation of VEGF-A mRNA contributing to increased 
VEGF levels 
 
The ability of brain tumours to upregulate the expression of VEGF and VEGFR 
plays a major role in tumour angiogenesis and tumour growth. Because of the 
importance of VEGF signalling in angiogenesis, a process whereby tumours 
form blood vessels and undergo vascularisation, an antibody was developed to 
block this signalling pathway (Sathornsumetee and Rich 2007). Based on the 
results of a phase III clinical trial, Bevacizumab, an anti-VEGF-A neutralising 
IgG has been developed (Avastin™). In combination with agents such as 
irinotecan, it has been shown through phase II clinical trial to be beneficial in 
patients with malignant glioma (Vredenburgh, Desjardins et al. 2007; Norden, 
Young et al. 2008).  
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Problems with anti-angiogenesis strategies such as Avastin are that whilst the 
reduced angiogenesis kills many „standard‟ brain tumour cells, it does not kill 
cancer stem cells. This population of cells gain energy through anaerobic 
respiration as they thrive under low oxygen conditions. Therefore stem cells are 
able to invade post-Avastin therapy and lead to dissemination of the disease 
throughout the brain.  
 
1.5 The Blood-Brain Barrier 
 
The B-BB is formed by brain endothelial cells lining the cerebral 
microvasculature and the association via tight junctions with astrocytes. 
Astrocytic feet, which project from the astrocyte cell body, and are also known 
as „glia limitans‟ surround the endothelial cells of the B-BB and provide 
biochemical support to them. It is an important mechanism for protecting the 
brain from fluctuations in plasma composition, and from circulating agents such 
as neurotransmitters and xenobiotics capable of disturbing neural function 
(Abbott and Romero 1996). The B-BB allows only low molecular weight 
lipophilic agents to penetrate by passive diffusion. Efflux pumps, such as P-
glycoprotein, remove the drug from the CNS and thereby reduce the cellular drug 
accumulation (Tews, Nissen et al. 2000). Drugs that are highly protein bound 
have a decreased penetration of the CNS. Genetic instability and innate 
chemoresistance of tumour cells that are common to all malignancies further 
complicate the issue. The planning of treatment modalities for patients with high 
grade glioma (HGG) is a challenge harder than that of any other cancer due to 
the extreme vulnerability of the CNS.  
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The invasive nature of these highly malignant tumours precludes a surgical cure; 
macroscopically the tumour can appear completely resected when in reality there 
are aberrant cells that have migrated through the parenchyma to establish 
themselves in a new location. The tight junctions of the endothelial and 
astrocytic cell interaction at the B-BB limit the effectiveness of the currently 
available chemotherapeutic agents that otherwise have the potential to target 
invading cells. The B-BB is more effective at restricting the passage of 
substances than endothelial cells in capillaries elsewhere in the body; the 
transmembane proteins constituting the tight junctions, such as occludin and 
claudins dimerise and anchor to the endothelial cells through zo-1. The growth of 
a tumour can disrupt the B-BB which in theory would enable chemotherapeutic 
agents to reach the tumour, but tumour cells tend to migrate away from the main 
tumour site into an area of intact non-neoplastic B-BB and protect themselves 
from chemotherapeutic assault.  
 
In addition, glioma exhibit diffuse infiltration into the normal brain parenchyma 
and the tumour cells often show morphological features similar to reactive glia 
cells, making it difficult to discriminate tumour cells from other neural cell 
populations both in vitro and in vivo. Despite the fact that these malignancies are 
highly invasive in the brain, they rarely metastasise out of the CNS (Thorsen and 
Tysnes 1997). Invasion is the most significant biological feature of intrinsic brain 
tumours that precludes successful treatment (Pilkington 1997; Pilkington, 
Bjerkvig et al. 1997; de Ridder 1999).  
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The potential of Clomipramine hydrochloride (a tricyclic antidepressant 
traditionally used to elevate serotonin levels in the brain and treat depression) 
and the other tricyclic agents, that are the subject of this study, to treat intrinsic 
brain tumours lies within their innate ability to cross the B-BB and, unlike any 
other modality, reach these „guerrilla‟ cells.  
 
1.6 Tried and tested approaches for malignant glioma 
 
Most HGG patients undergo a combination of treatment modalities, including 
surgical resection, radiotherapy (RT) and chemotherapy (CT) following 
histological diagnosis. There exists conflicting data regarding survival and extent 
of surgical resection due to treatment bias in younger patients, or those with less 
eloquent tumour location (Stummer, Reulen et al. 2008). More extensive 
resections often provide higher grade diagnoses (Glantz, Burger et al. 1991), due 
to the large degree of heterogeneity of tumours, however maximal surgical 
removal improves survival in most studies. If greater than 98% of tumour 
volume can be removed there is a significant survival advantage of 13 months, 
whereas is less than 98% tumour volume is removed the survival is 8.8 months 
(Lacroix, Abi-Said et al. 2001).  
 
 
 
 
 
 34 
1.7 Traditional chemotherapy targets glioma cell proliferation 
 
 
Most current chemotherapeutic agents work by preventing replication and 
transcriptional activities through blockade of DNA-helix unwinding or re-
coiling, a fundamental step in the process of proliferation. This study will 
examine some current agents alongside experimental tricyclic drugs that target 
the mitochondrion, to compare sites of action. 
 
 Mode of action Administered CNS Penetration 
BCNU Alkylators of 
DNA & cross-
linking at DNA, 
RNA and 
proteins. 
Intravenously Good 
CCNU Orally Good 
Procarbazine Orally Good 
Temozolomide Orally 30% of serum 
level 
Vincristine Microtubule 
inhibitor 
Intravenously Poor 
Irinotecan Inhibition of 
topoisomerase 
Intravenously Good 
Topotecan 
Etoposide 
Cisplatin Platinum 
analogues; cause 
aquation in DNA 
Intravenously Poor (water 
soluble) Carboplatin 
Oxaliplatin 
Table 1.7.1 A table comparing the mode of action, administration route and CNS 
penetration of the main chemotherapy agents used to target DNA and 
proliferation in malignant glioma.  
 
Details on the efficacy of these agents can be found in sections 1.7.1 to 1.7.4.2. 
Temozolomide is thought of as the best current treatment option for first-line 
chemotherapy, Irinotecan has limited efficacy as a monotherapy but shows 
promise in combination with Temozolomide and Avastin (section 1.7.3.1) 
whereas Topotecan is generally used in combination with radiotherapy (Sasine, 
Savaraj et al.) 
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1.7.1 Nitrosoureas agents 
 
The nitrosoureas, predominantly 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; 
Carmustine) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; 
Lomustine) were, until recently, the chemotherapeutic agents of choice in the 
treatment of HGG. They are lipophilic, non-ionised agents with good CNS 
penetration. They act as DNA-alkylating agents, cross-linking guanine 
nucleobases in DNA double-helix strands, directly attacking DNA. The DNA 
strands are unable to uncoil and separate, the result is that the cells are unable to 
proliferate. BCNU, CCNU and their active metabolites are excreted in the urine 
and few drug interactions are known (Levin, Stearns et al. 1979).  
 
Historically BCNU monotherapy is the gold standard in the treatment of purely 
astrocytic tumours, whereas CCNU combination therapy has been extensively 
studied in AAs and tumours of oligodendroglial origin (Cavaliere and Newton 
2006). The nitrosoureas were the first single agent therapy used to treat glioma 
because they readily cross the B-BB due to their small size, non-ionized state and 
high lipid solubility (Gumerlock 1989). BCNU became the most commonly used 
single-agent CT for recurrent disease and was moved to the adjuvant setting after 
a randomised trial (BTSG 69-01) demonstrated BCNU and RT superior to RT 
alone (Gehan and Walker 1977). Similar results were obtained in studies using 
CCNU (Walker, Green et al. 1980; Chin, Young et al. 1981). One meta-analysis 
suggests that nitrosourea-based adjuvant CT has a modest benefit for patients 
with Anaplastic glioma and a smaller benefit for those with GBM (Levin, Silver 
et al. 1990). 
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1.7.2 Procarbazine, CCNU (Lomustine) and Vincristine (PCV) 
 
Procarbazine and its metabolites also cross the B-BB, with rapid equilibrium 
between plasma and cerebrospinal fluid (CSF) (Newton, Turowski et al. 1999). 
Metabolism in the liver yields azo-procarbazine and hydrogen peroxide which 
results in the breaking of DNA strands. As a single agent, Procarbazine has been 
compared to intravenous (IV) BCNU, Methylprednisolone, and IV BCNU with 
Methylprednisolone, in patients with malignant glioma. The overall median 
survival was similar for the Procarbazine and BCNU groups, but long-term 
survival at up to 24 months was superior in the Procarbazine group (Green, Byar 
et al. 1983). 
 
Vincristine is a water-soluble molecule that penetrates the B-BB poorly (Jackson, 
Sethi et al. 1981). Despite its limited CNS penetration, Vincristine is said to 
show activity as part of multi-agent regimens against low-grade glioma, 
Oligodendroglioma, and Anaplastic Astrocytoma (Evans, Jenkin et al. 1990; 
Levin, Silver et al. 1990; Glass, Hochberg et al. 1992). However, Vincristine has 
never been rigorously evaluated as a single agent for primary brain tumours. 
Vincristine binds to tubulin dimers, inhibiting assembly of microtubule 
structures. Disruption of the microtubules arrests mitosis in metaphase and 
prevents cells from proliferating. 
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Nitrosourea-based combination chemotherapy regimens were developed in the 
1980s and showed promise. PCV was compared to single-agent BCNU as post-
radiation therapy in a randomised trial (Levin, Wara et al. 1985). There was no 
significant difference in overall survival (OS) or time-to-tumour progression 
(TTP) for the group as a whole. However, in the subset of patients with 
Anaplastic glioma (rather than GBM), there was a significant increase (46 
weeks) in TTP and survival for the group receiving PCV. A recent retrospective 
analysis of the Radiation Therapy Oncology Group (RTOG) database, including 
more than four hundred patients with Anaplastic glioma, revealed no survival 
advantage for patients treated with post-radiation PCV versus BCNU (Prados, 
Scott et al. 1999). 
 
Conventional PCV chemotherapy for CNS tumours offers limited anti-tumour 
activity. Randomised trials on malignant glioma in the 1970-90s failed to 
demonstrate a significant increase in survival by the addition of chemotherapy to 
a treatment regimen (Walker 1978; Walker, Green et al. 1980).  
 
PCV is generally palliative and has significant side-effects and limited efficacy. 
Although the benefits of adjuvant CT are modest compared with similar therapy 
for the non-CNS cancers recent findings have shown that there may be a future in 
modalities such as „salvage agents‟ (agents administered in the hope that they 
may extend survival by a few extra months).  
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1.7.3 Topoisomerase inhibitors 
 
1.7.3.1 Irinotecan 
 
Irinotecan, also known as CPT-11, is a camptothecin derivative. It is a prodrug 
that requires de-esterification by carboxylesterases to yield its active metabolite, 
SN-38, which is 1,000 times more potent at inhibiting topoisomerase I (Newton, 
Turowski et al. 1999). The target of drugs of the camptothecin family is DNA 
topoisomerase I, a nuclear enzyme involved in the relaxation of the DNA double 
helix required for replication and transcription activities. They stabilise the 
enzyme-DNA complex and prevent the re-ligation of the single-strand breaks 
created by the enzyme, which are converted to double-strand breaks upon the 
collision with a replication fork during the S-phase. 
 
Topoisomerase I plays a critical role in DNA transcription, replication and repair. 
In early trials of this agent, some responses were documented in patients with 
progressive, persistent, or recurrent malignant glioma (Colvin 1998; Friedman, 
Petros et al. 1999). The ability to selectively target tumour cells lies in the 
contact inhibition phenomenon inherent to „normal‟ cells, whereby they cease 
cell division upon contact with other cells.  
 
Preclinical studies demonstrated that the efficacy of CPT-11 against CNS 
tumours is enhanced when combined with alkylators such as BCNU in a 
schedule dependent manner (Coggins, Elion et al. 1998). It was therefore sought 
to determine whether the anti-tumour activity of CPT-11 could be enhanced by 
BCNU in patients with malignant glioma.  
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In phase I trials, a radiographic response was achieved in five newly diagnosed 
patients (14%) whilst a similar response was seen in five patients with recurrent 
disease. In more than 40% of both newly diagnosed and recurrent patients a 
stable disease (SD) state was achieved. Median TTP was 11.3 weeks for 
recurrent GBM patients and 16.9 weeks for recurrent AA/AO patients (Reardon, 
Quinn et al. 2004). A synergistic effect of CPT-11 combined with TMZ has also 
been reported in preclinical studies (Patel, Elion et al. 2000).  
1.7.3.2 Topotecan 
 
Topotecan is a water-soluble small molecule camptothecin analogue with 
excellent CNS penetration that binds directly to topoisomerase I without 
activation (Newton, Turowski et al. 1999). A phase II trial for adults with newly 
diagnosed or recurrent malignant glioma has demonstrated three partial 
responses (PR; 12%) and 10 with stable disease (SD; 40%) in twenty five newly 
diagnosed patients and three PRs (8%) and ten SDs (26%) in thirty eight patients 
with recurrent disease (Friedman, Kerby et al. 1999). Activity in paediatric 
patients with low- and high-grade glioma, medulloblastoma, and brainstem 
glioma was not demonstrated in a phase II study (Blaney, Phillips et al. 1996). 
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1.7.3.3 Etoposide 
 
Etoposide is highly lipophilic but does not readily cross the B-BB due to its large 
size. Etoposide has been demonstrated to have minimal activity as a single agent 
in some patients with malignant glioma (Fulton, Urtasun et al. 1996; 
Chamberlain 1997). Etoposide (phosphate) directly inhibits topoisomerase II and, 
like CPT-11 selectively targets dividing tumour cells. The use of oral Etoposide 
at 50 mg/m²/day for twenty one days, followed by a fourteen day rest period and 
an additional twenty one days of oral Etoposide (50 mg/m²/day)was 
demonstrated effective and feasible (Chamberlain 1993). Of twelve evaluable 
patients with recurrent brainstem glioma, one presented complete response (CR), 
three PRs and two SDs, for a median duration of response of eight months. 
 
1.7.4 Platinum analogues 
 
1.7.4.1 Cisplatin and Carboplatin 
 
 
Cisplatin and Carboplatin are water-soluble and penetrate the B-BB poorly. 
These DNA-damaging agents cause tumour DNA to undergo „aquation‟ and 
form cross links that displace a chloride ligand in the double helix. This directly 
interferes with mitosis and the subsequent DNA repair is unable to take place, 
thus triggering apoptosis. Like the other „cell-cycle specific‟ agents they do not 
affect normal cells because whilst the duration of the cell cycle is identical in 
both normal and tumour cells, the proportion of cells undergoing division in 
tumour cells is much higher.  
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Cisplatin demonstrated variable activity against a wide range of tumours, 
including AA, GBM, medulloblastoma/sPNET, CNS lymphoma, and germ cell 
tumours (Kornblith and Walker 1988; Kyritsis 1993; Kim, Hochberg et al. 1996).  
In combination with CCNU or cyclophosphamide plus Vincristine, Cisplatin is 
also effective against high-risk and recurrent medulloblastoma (Packer, Sutton et 
al. 1991). Carboplatin is a cisplatin analogue with a similar activity profile and 
comparable cytotoxicity in vitro. As a single agent, Carboplatin has demonstrated 
efficacy in paediatric patients for both low-grade glioma and recurrent malignant 
primary brain tumours (Allen, Walker et al. 1987; Friedman, Krischer et al. 
1992). In adults, single-agent carboplatin has shown minimal activity for the 
treatment of recurrent malignant glioma (Yung, Mechtler et al. 1991). 
 
1.7.4.2 Oxaliplatin 
 
Oxaliplatin, like Cisplatin and Carboplatin, is a platinum-based cytotoxic agent. 
However, unlike other platinum-based agents it does not appear to cause 
ototoxicity, nephrotoxicity, cardiac toxicity or alopecia in adults. Data for 
malignant glioma are limited to nine patients with recurrent GBM (Soulie, 
Raymond et al. 1997).  
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1.7.5 The structures of traditional glioma chemotherapy agents that target 
proliferation 
BCNU CCNU 
Procarbazine 
Vincristine 
Irinotecan 
 
Topotecan 
Etoposide 
 
Cisplatin Carboplatin 
Oxaliplatin 
Temozolomide 
 
Figure 1.7.5.1 Traditional chemotherapy agents currently approved for use in 
glioma 
BCNU, CCNU, Procarbazine, Vincristine, Cisplatin, Carboplatin, Oxaliplatin 
and Temozolomide are reactive chemotherapy agents that interfere with normal 
cellular processes and enhance cell death once they have reacted with their target 
molecule. They are, however, fairly indiscriminate and have powerful side 
effects. Irinotecan, topotecan and Etoposide are interactive agents that depend on 
lock-and-key recognition processes to interfere with cellular pathways. This 
makes them very specific agents but limited in efficacy due to the existence of 
parallel pathways for most critical processes. The most effective interactive 
drugs exhibit long-term high-affinity biological activity so that they can reach 
their target before being degraded and block the normal molecule from binding.   
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1.8 Recent approaches that have shown modest results 
 
1.8.1 An oral agent to target proliferation 
 
 
Temozolomide (Temodal
®
; TMZ), now approved by the National Institute for 
Clinical Excellence (NICE) for use in both newly diagnosed and recurrent 
glioma, is an orally-administered DNA alkylating agent. The results of the first 
clinical trial, published in 2001, showed it to exert a modest effect both as a 
single approach and adjuvant to radiotherapy (Brada, Hoang-Xuan et al. 2001; 
Lanzetta, Campanella et al. 2003). The potential for this licensed drug is high 
given the convenience of an oral preparation that can be taken at home; by 
combining it with other clinically significant agents it may be possible to 
optimise its anti-tumour activity.  
 
Temozolomide is an oral agent, which is reported to, at least partially, cross the 
B-BB. It is an imidazotetrazine derivative of 5-(3,3-Dimethyl-1-
triazenyl)imidazole-4-carboxamide(Dacarbazine; DTIC), which spontaneously 
hydrolyses to its biologically active form 3-methyl-(triazen-1-yl) imidazole-4-
carboxamide (MTIC). The mechanism of anti-tumour actions is the disruption of 
DNA replication via methylation at specific residues including 06 position of 
guanine, N7 position of guanine and N3position of adenine.  
 
Temozolomide is now being evaluated in multiple new clinical trials in 
combination with wide variety of additional therapeutic agents including other 
chemotherapeutic agents, cell signalling inhibitors, anti-angiogenic agents and 
therapeutics designed to overcome mediators of chemotherapy resistance. 
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1.8.2 Targeting the platelet-derived growth factor receptor 
 
Gleevec (STI571, Imatinib mesylate; Novartis) is an oral, small-molecule 
adenosine triphosphate (ATP) mimetic that inhibits the kinase activity of several 
oncogenes, including BCR-ABL, c-ABL, c-KIT and PDGF receptors. It 
selectively inhibits the catalytic activity of the platelet derived growth factor 
receptor (PDGFR) and c-kit tyrosine kinases (Holdhoff, Kreuzer et al. 2005). 
 
Gleevec did not possess any significant anti-tumour activity when studied in 
glioma by Wen et al. (2006), and was highly unsuitable for use in patients taking 
enzyme-inducing anti-epileptic drugs (EIAEDs) as they required far higher doses 
than patients not taking an EIAED, suggesting that the metabolism of Gleevec 
was severely impaired (Wen, Yung et al. 2006). Conversely Reardon et al. 
(2005) found that combination of Gleevec with a ribonucleotide reductase 
inhibitor was well tolerated and produced some anti-tumour activity (Reardon, 
Egorin et al. 2005). Gleevec was also found have anti-tumour activity and act 
synergistically with Clomipramine in C6 glioma cells (Bilir, Erguven et al. 
2008). Anti-tumour activity of Gleevec was also observed in a subset of HGG, 
and the results showed that sensitivity correlated with PDGFR expression 
(Hagerstrand, Hesselager et al. 2006). Since PDGFR-alpha and –beta were only 
expressed in 25 and 19 cases respectively in a series of one hundred and one 
brain tumours (Haberler, Gelpi et al. 2006) this finding would account for the 
low response rate in clinical trials.  
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1.8.3 Bypassing the blood-brain barrier with impregnated wafers 
 
Gliadel (polifeprosan 20 with Carmustine implant) wafers, inserted into the 
resection cavity at recurrence of tumour, can be used following TMZ therapy 
(Brandes, Tosoni et al. 2004). Adjuvant systemic CT increases survival of 
primary malignant glioma patients beyond 12-18 months.  
 
The results of a multi-institutional phase I trial evaluating the safety of surgically 
implanted biodegradable impregnated polymers, as the initial therapy for 
malignant brain tumours, were first reported in 1990. The first study combined 
locally delivered BCNU and concurrent standard external beam radiation 
therapy. Median survival in this group of older patients (mean age = 60) was 
forty two weeks, eight patients survived one year, and four patients survived 
more than eighteen months. This interstitial chemotherapy with Gliadel appeared 
to be safe as an initial therapy (Brem 1990). Gliadel is the only interstitial CT 
treatment approved for malignant glioma. Analysis of a large trial by Westphal 
and colleagues (2006; n = 240) showed that malignant glioma patients treated 
with Gliadel wafers at the time of initial surgery in combination with RT 
demonstrated a survival advantage at two and three years follow-up compared 
with placebo (Westphal, Ram et al. 2006). 
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1.8.4 Blocking the vascular endothelial growth factor receptor with a 
monoclonal antibody 
 
Avastin
®
 or bevacizumab is a humanised monoclonal antibody targeted against 
VEGF (-A). A phase II trial of Avastin co-administered with Irinotecan (see 
section1.7.3.1) produced a radiographic response and survival benefit 
(Vredenburgh, Desjardins et al. 2007; Vredenburgh, Desjardins et al. 2007). A 
trial of Avastin in fifty-five glioma patients, who were taking various other forms 
of chemotherapy alongside, showed a complete response in 2.3% of patients, 
partial response in 31.8% of patients, minimal response in 29.5% of patients and 
stable disease in 29.5% of patients. The agent was well tolerated and showed 
long term disease control (Norden, Young et al. 2008).  
 
1.8.5 Modulating the immune response to tumours with antibodies and 
cytokines 
 
Immunotherapy with monoclonal antibodies targeting tumour-specific antigens 
has emerged in the last two decades as a novel potential adjuvant treatment for 
all types of neoplasia. Results from ongoing Phase I/II clinical trials are 
encouraging, as disease stabilisation and patient survival prolongation have been 
observed (Reardon, Akabani et al. 2006). Advances in preclinical and clinical 
research indicate that treatment of brain tumours with monoclonal antibodies can 
be increasingly adjusted to the characteristics of the targeted tumour and its 
environment. This aspect relies on the careful selection of the target antigen and 
corresponding specific monoclonal antibody, and antibody format (size, class, 
affinity), conjugation to the appropriate toxin or radioactive isotope (half-life, 
range), and proper compartmental administration.  
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Following the discovery in 1989 that the radioiodinated anti-tenascin monoclonal 
antibody 81C6 was observed to have selective uptake by tumour cells (Zalutsky, 
Moseley et al. 1989), one group has further established the efficacy and tolerance 
of81C6 (131I-m81C6) when injected into the surgically created resection cavity 
of patients with newly diagnosed and recurrent malignant brain tumours.  
 
Their current approach involves administering a 
131
I-m81C6dose to deliver 44Gy 
to the 2-cm resection cavity perimeter and is based on dosimetry analyses 
demonstrating that a 44 Gy boost dose by 131I-m81C6achieved optimal tumour 
control while minimizing toxicity (Reardon, Akabani et al. 2006).  
 
In the phase II study, 20 patients with newly diagnosed malignant glioma (14 
GBM, 6 AA) received 
131
I-m81C6 administered to achieve a 44 Gy boost. Grade 
3/4 toxicities were limited to haematotoxicities with three leucopoenia, one 
neutropoenia and one thrombocytopenia. A median survival of 93.6 weeks was 
observed for GBM, it has not been reached yet for AAs. 
 
Transforming growth factor-beta (TGF-beta) is a pro-invasive and 
immunosuppressive cytokine that plays a major role in the malignant phenotype 
of glioma. One novel strategy of disabling TGF-beta activity in glioma is to 
disrupt the signalling cascade at the level of the TGF-beta receptor I (TGF-
betaRI) kinase, thus abrogating TGF-beta-mediated invasiveness and immune 
suppression.  
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One study, which involved the implantation of SMA-560 cells (derived from a 
spontaneous murine Astrocytoma)  into the striatum of VM/Dk mice (albino, 
inbred strain containing Prn-i locus) and subsequent administration of SX-007, 
an orally active, small-molecule TGF-betaRI kinase inhibitor, showed twenty 
five percent of the animals to be disease-free at the end of the study (Tran, Uhl et 
al. 2007). The data suggests that SX-007 exerts a therapeutic effect via the 
reduction of TGF-beta 1 mediated invasion and reversal of TGF-beta 2-mediated 
immune suppression. By reversing immune suppression immune surveillance is 
restored and hence the tumour is ablated.  
 
Promising results were also seen when the antifibrotic drug 5-methyl-1-phenyl-2-
(1H)-pyridone (pirfenidone) elicited a growth-inhibitory effect and reduced TGF-
beta2 protein levels in human glioma cell lines (Burghardt, Tritschler et al. 
2007). 
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1.8.6 Delivering chemotherapy directly to the tumour site 
 
One of the latest advances in the treatment of brain tumours is the trial of 
convection enhanced delivery (CED), which overcomes the need for selection of 
agents that can cross the B-BB. This method was originally introduced and 
refined in the early 1990s by researchers at the National Institute of Health (NIH) 
and involves drug infusion under high pressure using intracranial catheters. CED 
allows for delivery of high concentrations of therapeutic agents directly into 
brain tumours and surrounding parenchyma. This method eludes the B-BB and 
allows the use of regional drug therapy, while at the same time limiting systemic 
toxicity (Ferguson and Lesniak 2007). 
 
Catheter enhanced delivery has been improved with the emergence of patient-
specific algorithms, according to target-tissue anatomy and patient physiology, 
whereby the trajectory of the catheter is determined using magnetic resonance 
diffusion tensor imaging (Sampson, Raghavan et al. 2007).  By using 
123
I-labeled 
human serum albumin, high-resolution single-photon emission computed 
tomographic images were obtained at and coregistered with magnetic resonance 
imaging scans to determine the distribution according to catheter site (Sampson, 
Brady et al. 2007). Intra-tumoural infusions were anisotropic and resulted in 
limited coverage of the enhancing tumour area and adjacent peritumoral regions, 
whereas intracerebral infusions resulted in broad distribution across the 
parenchyma. A necrotic core is a prevalent occurrence in a tumour and the results 
from Smith and Humphrey (2006) present findings that show it can profoundly 
alter the interstitial fluid pressure and velocity distributions in its vicinity.  
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Because the necrotic core does not have a functional vasculature there can only 
be interstitial fluid transport in that region. The pressure decrease is markedly 
less in the necrotic core because no fluid can be reabsorbed into the vasculature 
there, thus the interstitial fluid velocity is significantly higher than when there is 
no necrotic core. Ironically the presence of a necrotic core is thought 
advantageous to convection-enhanced delivery because the convective flow 
reaches a larger region of the tumour (Smith and Humphrey 2006). By placing 
the infusion site proximally to the tumour the flow of drug is propelled outward. 
This is in contrast to the findings of Baxter and Jain who showed that the 
necrotic core had little or no impedance on reducing the elevated tumour 
interstitial fluid pressure (Baxter and Jain 1990).  
 
The convective fluid velocity is not high over a large region but the advantage is 
that it can be used to deliver macromolecules, proteins and other high molecular 
weight compounds that are normally denied access to the brain parenchyma by 
the B-BB. Therefore CED shows huge potential in the delivery of 
chemotherapeutic agents, perhaps with an intra-tumoural catheter plus a number 
of proximal catheters, designed to target both the tumour and the invading cells. 
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1.8.7 Reprogramming glioma cells with gene therapy 
 
 
Gene therapy is a particularly attractive and novel approach towards the 
treatment of single-mass brain tumours due to their lack of propensity to 
metastasise. Despite the strong resistance towards systemic therapies, due to the 
B-BB, it is possible to inject therapeutic adenoviruses intra-tumourally using safe 
and fast procedures. Oncolytic adenoviruses are genetically manipulated human 
adenoviruses that acquire a replication phenotype in cancer cells, but show a 
more restrictive phenotype in normal cells. Several features of wild-type 
adenoviruses can be modified to acquire tumour replication properties (Chiocca 
2002).  
 
In the 1990‟s, retroviral vectors were found to give suboptimal delivery of 
therapeutic genes to cancer cells, however when substituted with adenoviral 
vectors it was found that they were not able to transduce a high enough number 
of tumour cells to result in a dramatic therapeutic effect. By directly injecting the 
tumour with a cell line actively producing a adenoviral vector carrying a gene 
conferring drug sensitivity to the tumour, mammalian cells can be „infected‟ and 
cause the cell to incorporate the new genetic material into their genome (Culver 
1993). One pro-drug study employed NIH 3T3 cells and the herpes simplex virus 
enzyme thymidine kinase. HSV-tk sensitised the tumour cells to an antiviral drug 
(Ganciclovir, GCV) which is a natural substrate for HSV-tk (Oldfield, Ram et al. 
1993). The enzymatic process induced by GCV leads to death of the cell 
expressing the herpes TK activity, i.e., death of the tumour cells. Since the HS-tk 
enzyme which is normally present in mammalian cells has very low affinity for 
GCV, systemic toxicity related to this mechanism is not observed.  
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Gene therapy has some striking advantages (see table Table 1.8.1), firstly the 
adeno-viral vectors selectively target cells which are actively synthesising DNA. 
Thus surrounding normal, and hence non-proliferating, cells will remain 
unaffected. Secondly the transduced tumour cells will be destroyed by the host 
immune system and GCV treatment. This also eliminates the potential for 
mutagenesis initiated by the insertion of foreign genetic material.  
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Target 
 
Advantages Disadvantages 
Tumour 
suppressor 
genes 
 Most tumours have one or more inactivated tumour suppressor genes 
 Restoration of tumour suppressor gene function can correct tumour 
phenotype 
 Restoration of certain genes, such as p53, has a bystander effect (the 
inhibition/killing of non-transduced cells) 
 Apoptotic pathways are restored resulting in greater sensitivity  
 Poor penetration and delivery in solid 
tumour mass 
 Limited use as a single agent 
 Efficacy is not universal  
 Leaky replication observed in normal 
cells 
Suicide genes  Non-toxic prodrugs can be administered in high doses without 
significant effects to normal cells 
 Toxic drug transfers to neighbouring tumour cells via gap junctions, 
causing bystander effect 
 Drug-induced premature cell death 
(following chemotherapy) results in 
impaired viral replication 
 Timing, if used in combination with 
chemotherapy, is critical 
RNA 
Interference 
(RNAi) 
 It is both an endogenous regulatory mechanism and a tool to 
therapeutically suppress over-expressing genes 
 Vector-based approaches have high transfection efficiency, continuous 
production of siRNA in cells and sustained protein suppression 
 Delivery of double-stranded RNA is 
inefficient 
 Cell type specificity 
 High cost of double-stranded RNA 
Angiogenesis  Tumours are dependent on angiogenesis for growth and metastasis  Efficacy is limited due to redundant 
signalling pathways  
Cytokines & 
dendritic cells 
 Cytokines activate responder cells 
 In combination, cytokines synergise to facilitate tumour regression 
 Adenoviral-transduced dendritic cells can exhibit adjuvant effects and 
induce dendritic cell activation and maturation 
 Ex vivo treatment of dendritic cells circumvents pre-existing antiviral 
immunity 
 Cytokines have a short in vivo half-life 
and sub-therapeutic levels at the 
tumour site 
 Transduction rates of adenoviruses to 
dendritic cells is low resulting in low 
efficacy 
 
Table 1.8.1 Potential targets of gene therapy  
The advantages and disadvantages of five targets of gene therapy are detailed, showing the huge potential of adenoviral therapy in treating 
malignant glioma. The most promising results have been found when using gene therapy in combination with chemotherapy, however the dosing 
schedule is critical for optimal adenoviral delivery (Folkman 1990; Heise, Sampson-Johannes et al. 1997; Addison, Bramson et al. 1998; 
Emtage, Wan et al. 1999; Narvaiza, Mazzolini et al. 2000; Okada, Tsukada et al. 2001; Liu, Huang et al. 2002; El-Deiry 2003; Milhavet, Gary et 
al. 2003; Aghi and Martuza 2005; Boucher, Im et al. 2006; Lumniczky and Safrany 2006; Iorns, Lord et al. 2007; Sharma, Tandon et al. 2009).  
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The drawbacks of the HSV-tk/GCV study published in 1993 are that the studies 
were performed in rats for only twenty-eight days (Ram, Culver et al. 1993). The 
proliferative nature that rat brain tumours display shows that they possess 
differing characteristics to their invasive human counterparts and so are not an 
ideal model for such experiments.   
 
Studies have also been performed using the native HSV in GBM. The 
replication-competent HSV mutant HSV1716 was injected directly into the 
tumours of high-grade glioma patients. Because replication is a cytolytic process, 
cell death is brought about once the adenovirus has been incorporated into cells. 
Of twelve patients studied in this manner, all tolerated the therapy well with no 
side effects. The study showed the potential for gene therapy using native HSV 
(Rampling, Cruickshank et al. 2000; Papanastassiou, Rampling et al. 2002).  
 
Adenovirus transduction is dependent on the coxsackie virus-adenovirus receptor 
(CAR) expression in cells. Low uptake efficiency is seen when using native 
adenoviral vectors; it is possible to increase the uptake in endothelial cells by re-
targeting the adenovirus with a fibroblast growth factor 2 (FGF-2) ligand (Gupta, 
Wang et al. 2006). This means that gene therapy using native HSV could have an 
antiangiogenic effect in brain tumours. The latest studies using adenoviral 
vectors involve the deletion of viral genes that interact with tumour suppressor 
genes, the modification of the ability to infect cancer cells with more potency, 
and the inclusion in the viral genome of elements of transcription that are 
sensitive to transcription factors upregulated in cancer cells (Alemany, Balague 
et al. 2000).  
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Although they occur at a relatively low incidence, brain tumours contribute 
significantly to morbidity, often affect children and overall have a poor 
prognosis. Due to marked resistance to RT and CT, the prognosis for patients 
with GBMs is very poor. The majority of patients die within nine to twelve 
months and less than 3% survive more than three years. Many genetic alterations 
involved in the development of nervous tissue tumours have been identified and 
may lead to novel therapeutic approaches, including gene therapy. 
 
There have also been advances contributing to the increased knowledge 
surrounding molecular abnormalities and resistance to radio and chemotherapy 
has led to a new approach of targeting aberrant signal transduction pathways 
(Sathornsumetee and Rich 2006). Targeting the underlying pathogenesis, via a 
small-molecule inhibitor or monoclonal antibody, may provide the way forward 
in treating this devastating, and largely incurable disease. 
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1.9 Approaching the mitochondrion as a new target for malignant glioma 
 
 
Mitochondrial membrane permeabilisation is the critical event in the process 
leading to physiological or chemotherapy-induced apoptosis. This event is 
governed, in part, by the mitochondrial permeability transition pore (MPTP). The 
composition of the MPTP differs in normal and malignant cells; ANT2 (adenine 
nucleotide translocator; gene the expression of which is repressed in quiescent 
cells) is transcribed in proliferating tumour cells (Giraud, Bonod-Bidaud et al. 
1998; BarÃ¡th, Albert-Fournier et al. 1999), the peripheral benzodiazepine 
receptor (PBR) and mitochondrial creatine kinase are overexpressed in some 
tumours (O'Gorman, Beutner et al. 1997; Kanazawa, Tanaka et al. 1998; 
Schiemann, Schwirzke et al. 1998; Venturini, Zeneroli et al. 1998; GaliÃ¨gue, 
Jbilo et al. 1999). Overexpression of PBR confers a relative resistance to 
oxidative stress (Carayon, Portier et al. 1996). More importantly functional Bax 
is frequently reduced in cancer cells (Rampino, Yamamoto et al. 1997; Brimmell, 
Mendiola et al. 1998; Ouyang, Furukawa et al. 1998; Yagi, Akiyamaâ¡ et al. 
1998) and Bcl-2 is overexpressed in a large percentage in neoplasms (Reed 1994; 
Kroemer 1997; Reed 1997), strengthening the hypothesis that the control of the 
MPTP can be altered in tumours.  
 
It is increasingly evident that DNA-targeted agents are effortlessly circumvented 
by sophisticated DNA repair mechanisms inherent to brain tumours (Pilkington, 
Parker et al. 2008). Therefore the specific delivery of drugs to mitochondria may 
provide the foundation to treat these devastating tumours.  
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A recurring problem with conventional chemotherapy is that they exploit 
endogenous apoptotic pathways that are frequently subject to alterations such as 
mutations (p53), blockade of death receptors (CD95/CD95L pathway) and over 
expression of Bcl-family members. A solution would be to target cell death 
further downstream of events that are commonly aberrated.  
 
1.10 The role of mitochondria in determining the fate of glioma cells 
 
Mitochondria exert dual functions in the regulation of cell survival and cell 
death. They are the powerhouse of the cell for the production of energy, and are 
therefore vital for the survival of the cells in addition to them being the gateway 
of the intrinsic pathway of apoptosis (Kroemer, Galluzzi et al. 2007). In light of 
the critical regulatory role of mitochondria in the control of cell death and the 
fact that mitochondrial functions are frequently altered in malignant glioma, 
agents that target the mitochondria are considered promising in the elimination of 
tumour cells that are resistant to conventional therapies (Gogvadze, Orrenius et 
al. 2009). Whilst the mitochondrion is largely-dependent on nuclear-encoded 
factors, some functional independence remains, which means that mitochondria-
targeting drugs offer the advantage to act independent of upstream events that are 
often blocked in cancers. Thus, mitochondriotoxic compounds are likely to be 
effective in otherwise refractory tumours and may overcome problems of multi-
drug resistance (Fulda 2010).  
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The mitochondrial membrane consists of phospholipid bilayers (the exact 
composition of which is detailed in table Table 1.10.1 below), termed the outer 
mitochondrial membrane (OMM) and inner mitochondrial membrane (IMM). 
The OMM contains an array of protein and lipid complexes including 
translocases of the outer membrane (TOMs), adaptor proteins, antioxidants, lipid 
transferases, ion channels and members of the Bcl-2 family either as resident 
integral proteins (Bak) or as cytosolic translocates (Bax or tBid) (Colombini 
1980; Thomas, Gebicki et al. 1989; Fisk and Yaffe 1997; Colquhoun 1998; 
Santel and Fuller 2001; James, Parone et al. 2003). The OMM is responsible for 
fatty acid degradation, tryptophan metabolism and monoamine neurotransmitter 
metabolism (via monoamine oxidase). 
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 Inner mitochondrial 
membrane (%) 
Outer mitochondrial 
membrane (%) 
Phosphatidyl choline 38.4 45.6 
Phosphatidyl ethanolamine 24.0 32.6 
Phosphatidyl inositol 16.2 10.2 
Phosphatidyl serine 3.8 1.2 
Phosphatidic acid 1.5 4.4 
Cardiolipin 16.1 5.9 
Table 1.10.1 The phospholipid compositions of the inner and outer mitochondrial 
membranes 
 
The inner membrane contains a higher proportion of cardiolipin where it 
supports the function of a large number of enzymes involved in the electron 
transport chain (Lomize 2008).The IMM contains proteins with five different 
functions: redox proteins associated with oxidative phosphorylation, ATP 
synthases which generate ATP, transport proteins that regulate metabolites to and 
from the matrix, protein import machinery and fusion and fission proteins (Raff, 
Barres et al. 1994). The high proportion of cardiolipin (which contains four fatty 
acids rather than two) makes the IMM impermeable, unlike the OMM it does not 
contain porins and virtually all molecules require specific transporters to enter 
the matrix (Raff, Barres et al. 1994). The IMM contains coenzyme Q – 
cytochrome c reductase, cytochrome c, NADH dehydrogenase and succinate 
dehydrogenase which are all enzymes involved in oxidative phosphorylation (the 
product of which is ATP, produced in the matrix) and also means that the IMM is 
the site of production of reactive oxygen species (ROS) superoxide and hydrogen 
peroxide (Lomize 2008). The IMM is also the site responsible for the electron 
transport chain (see 1.12), the energy released from which drives the flow of 
protons through the membrane in a process called chemiosmosis and results in a 
membrane potential across the membrane (Raff, Barres et al. 1994). 
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Figure 1.8.7.1 Mitochondrial regulation of apoptotic cell death in glioma (Mayer 
and Oberbauer 2003) 
 
The main components of the permeability transition pore are the VDAC and the 
adenine nucleoside translocator (see 1.18) which are adjacent in the outer and 
inner mitochondrial membranes, respectively. Besides these abundant proteins, 
peripheral benzodiazepine receptor and Bax/Bcl-2 in the outer mitochondrial 
membrane and cyclophilin D and cardiolipin in the inner mitochondrial 
membrane complete the PT complex. The big apoptogenic proteins such as 
cytochrome c (12 kDa), second mitochondria-derived activator of caspases/direct 
inhibitor of apoptosis (IAP)-binding protein with low pI (smac/Diablo; 100 kDa), 
AIF (57 kDa), and others are predominantly stored in vesicles created by 
infolding of the IMM (intercristal space). During apoptosis induction, the ANT 
conductance and permeability increase to 700 pS and 1.5 kDa, respectively. This 
leads to osmotic swelling of the mitochondrial matrix by water influx succeeded 
by compression of the intercristal space. Cytochrome C, Smac/DIABLO and AIF 
are released from their intercristal storage into the intermembrane space. The 
ejected proteins cytochrome c, caspases, ATP, and the cytoplasmic apoptosis 
protease activating factor-1 (APAF-1) associate in the cytosol to huge 
apoptosome complexes (700 kDa), which cleave downstream caspases.  
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The mitochondrion is however considered an „innocent bystander‟ during 
permeabilisation of the outer membrane because the mechanism is entirely 
controlled by the Bcl-2 family of proteins. Pro-apoptotic Bcl-2 family members 
(see 1.23) Bid, Bax and Bak mediate the permeabilisation of the OMM. 
Apoptotic signalling cleaves Bid (via caspase 8 or granzyme B) which activates a 
highly truncated form (tBid) which localises to the OMM. There, tBid induces 
the oligomerisation and insertion of Bax into the OMM or the oligomerisation of 
Bak, and subsequent of cytochrome c (Wei, Zong et al. 2001).  Rupture of the 
OMM is essential for mitochondrial demise and apoptosis will not be triggered 
simply by virtue of damage to either membrane or damage targeted to 
mitochondrial DNA (but may signal other forms of cell death such as necrosis) 
(Chipuk, Bouchier-Hayes et al. 2006). The mitochondrial membrane potential of 
tumour cells is reduced in comparison to non-neoplastic cells, providing a 
window of opportunity for mitochondria-specific agents to enter the cell, disrupt 
ATP turnover and initiate cancer cell-specific apoptosis (Pilkington, Parker et al. 
2008). 
 
Mitochondria have long been known to be sensitive to a large variety of drugs, 
nutrients and hormones. Investigations into the disruption of oxidative 
phosphorylation, changes in mitochondrial gene expression, alterations in 
membrane function or induction of free radical damage have shown that a 
number of drugs, originally developed for other purposes, act via the 
mitochondrial DNA or membrane (Fulda 2010).  
 
 62 
Mitochondria have significant roles in bioenergetics and vital signalling of the 
mammalian cell. Consequently, these organelles have been implicated in the 
process of carcinogenesis; the alterations of cellular metabolism and cell death 
pathways. Multiple molecular routes of malignant transformation appear to result 
in the common ability of many tumours, especially the fast-growing 
Glioblastoma and Astrocytoma (Lowry, Berger et al. 1983; Dastidar and Sharma 
1989), to take up large amounts of glucose.  
 
Defects in the execution of the apoptotic programme enable neoplastic cells to 
survive beyond their intended lifespan, allowing them time to accumulate genetic 
alterations that affect the mitochondrial role in apoptosis. Virtually all-known 
cytotoxic anticancer drugs, when effective, induce apoptosis of malignant cells 
so unravelling the pathways leading to mitochondrial membrane permeabilisation 
thus offering new targets for drug development. Most tumours carry defects in 
their apoptotic pathways and should, therefore, be more poised for cell death so 
the mitochondrion of tumour cells is an attractive target.  
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1.11 The generation of adensine triphosphate provides a selective target in 
tumour cells 
 
Adenosine triphosphate is generated in two ways in normal cells: oxidative 
phosphorylation in mitochondria and glycolysis in the cytoplasm. All cells use 
both pathways but rely overwhelmingly on oxidative phosphorylation, switching 
to glycolysis at times of oxygen deprivation. A key biological difference between 
normal differentiated cells and tumour cells is altered metabolism, whereby 
tumours cells acquire a number of stable genetic and epigenetic alterations to 
retain proliferation and survive in hypoxic conditions (Wolf, Agnihotri et al. 
2010). A classic adaptation is a shift to aerobic glycolysis from mitochondrial 
oxidative phosphorylation. Aerobic glycolysis in tumour cells characterised via a 
high uptake of glucose and low oxygen consumption, despite the availability of 
oxygen was first described in 1930 by Otto Warburg, and is called „The Warburg 
Effect‟. Warburg noticed that whereas normal cells generate 10% of their total 
cellular ATP through glycolysis, tumour cells generate up to 50% of their ATP 
through the same process even when oxygen is present (Wolf, Agnihotri et al. 
2010). Targeting key metabolic enzymes involved in modulation of the 
„Warburg‟ effect and characterisation of glycolytic metabolism within glioma 
tissue therefore may be novel and lead to therapeutic approaches for the 
treatment of these tumours (La Schiazza, Lamari et al. 2008). 
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1.12 Oxygen sensing by mitochondria at complex III 
 
 
The catabolic pathways of the cell (glycolysis, citric acid cycle, fatty acid 
oxidation and amino acid oxidation) all lead to the production of two high-energy 
electron donors, nicotine adenine dinucleotide (in the reduced form, NADH) and 
flavine adenine dinucleotide (in the reduced form, FADH2). Electrons from 
NADH and FADH2 are passed through the electron transport chain to oxygen, 
which is further reduced to water. During electron transport, the enzymes of the 
electron transport chain create a proton gradient across the inner mitochondrial 
membrane. This gradient is used by the enzyme ATP synthase to produce ATP 
(Lambert and Brand 2009). The electron transport chain is comprised of four 
enzymes (complexes I, II, III and IV), which are all present on the inner 
mitochondrial membrane. Complex I (NADH dehydrogenase) removes two 
electrons from NADH and transfers them to the electron carrier, ubiquinone. The 
reduced product is called ubiquinol. Complex II (Succinate dehydrogenase) 
removes electrons from succinate and transfers them to ubiquinone via FAD. 
Complex III (Cytochrome bc1 complex) removes two electrons from the reduced-
state electron carrier ubiquinol and transfers them to two molecules of the 
electron carrier cytochrome C. Complex III also moves four protons across the 
inner mitochondrial membrane. Complex IV (Cytochrome C oxidase) removes 
two electrons from the two molecules of cytochrome C and transfers them to 
molecular oxygen, producing water (Alberts, Johnson et al. 2007).  
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During the process of electron transport across the four complexes, protons (H+ 
ions) are released into the intermembrane space between OMM and IMM. A 
total of six protons, two each from complexes I, III and IV, travel across the 
membrane to the intermembrane space and down an electrochemical gradient to 
complex V (ATP synthetase) whereby they pass back through to the matrix. This 
process is known as chemiosmosis (Mitchell 1961) and the energy produced 
from the flow of protons through complex V is sufficient to produce three 
molecules of ATP.  
 
 
Figure 1.8.7.1 Schematic representation of the electron transport chain showing 
five complexes within the mitochondrial membrane (Ophardt 2003) 
The transport of electrons across the chain is initiated via the reaction of an 
organic metabolite (from the mitochondrial matrix) with coenzyme NAD+ 
(nicotinamide adenine dinucleotide). Of relevance to this study is complex III 
which, in normal cells, would sense that conditions are becoming hypoxic (a sign 
that a cell is nearing the end of its life) and release reactive oxygen species to 
trigger apoptosis. It may be that the process of oxygen sensing is deviated in 
tumour cells but Clomipramine hydrochloride, which exerts its effects via 
complex III (Daley, Wilkie et al. 2005), is able to trigger the release of ROS by a 
different mechanism. The conversion of MTT tetrazolium salt to formazan by 
complex II, using electrons generated from the reduction of NADH by complex 
I, is shown in white.  
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In eukaryotes, complex III of the electron transport chain consists of an assembly 
of 11 proteins encoded by nuclear and mitochondrial genes The function of 
complex III is to accept electrons from ubiquinol, to transfer them to cytochrome 
C, and to translocate protons across the inner mitochondrial membrane (Iwata, 
Lee et al. 1998).  
 
It has also been suggested that the electron transport chain; and complex III in 
particular, acts as an oxygen sensor in the mitochondria by releasing ROS in 
response to hypoxia. The increase in ROS production is paradoxical since the 
concentration of oxygen, a substrate for ROS production is decreased under 
hypoxia.  
 
Oxygen sensing via complex III and the triggering of apoptosis via ROS release 
is important near the end of life, since tumour growth requires angiogenesis 
which is triggered by the onset of hypoxia within the tumour (Chandel, 
McClintock et al. 2000; Chandel and Schumacker 2000; Srinivas, Leshchinsky et 
al. 2001; Chandel 2002; Bell, Emerling et al. 2005; Brunelle, Bell et al. 2005; 
Guzy, Hoyos et al. 2005; Guzy and Schumacker 2006).  
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1.13 Tricyclic agents with known Blood-Brain Barrier penetration as 
candidates for targeting mitochondria 
 
There are a number of antidepressant and antipsychotic agents that are known to 
cross the B-BB, so the screening of such agents to assess their potential as anti-
tumour agents in glioma would seem to merit attention. 
 
1.13.1 Antidepressants have an affinity for the serotonin and 
norepinephrine transporters 
 
Clomipramine is a tertiary amine antidepressant that has been shown to 
selectively kill tumour cells in vitro. Traditionally, it is prescribed for depression 
with agitation, obsessive compulsive disorder, panic attacks, narcolepsy and 
chronic pain.  
 
Figure 1.13.1.1 Chemical structure of Clomipramine Hydrochloride 
 
Clomipramine is the 3-chloro derivative of Imipramine. Clomipramine is a 
strong, but not completely selective serotonin reuptake inhibitor, as the primary 
active metabolite Norclomipramine acts preferably as a norepinephrine reuptake 
inhibitor (Stahl 2000).  
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Amitriptyline (sold as Triptafen
®
) is a TCA drug. It inhibits serotonin and 
noradrenaline reuptake almost equally. Amitriptyline is approved for the 
treatment of endogenous depression and involutional melancholia. Adult typical 
dosages are 75 to 200 mg daily, with half this initially for elderly or adolescents. 
It may also be used to treat nocturnal enuresis (bed wetting).  
 
Figure 1.13.1.2 Chemical structure of Amitriptyline Hydrochloride 
Nortriptyline is a second generation tricyclic antidepressant marketed as the 
hydrochloride under the trade name Allegron
®
. It is used in the treatment of 
depression and childhood nocturnal enuresis. In addition it is sometimes used for 
chronic pain modification, migraines, and labile affect in some neurological 
conditions. 
 
Figure 1.13.1.3 Chemical structure of Nortriptyline Hydrochloride 
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Doxepin is a psychotropic agent with tricyclic antidepressant and anxiolytic 
properties, known as brand-name Sinequan
®
 (Pfizer Inc.). Doxepin inhibits the 
reuptake of serotonin and noradrenaline from the synaptic cleft (dual action).  
 
Figure 1.13.1.4 Chemical structure of Doxepin Hydrochloride 
 
Imipramine (sold as Tofranil
®
) is an antidepressant medication, a TCA of the 
dibenzazepine group, mainly used in the treatment of clinical depression and 
enuresis. Imipramine, a tertiary amine, inhibits the reuptake of serotonin more so 
than most secondary amine tricyclics, meaning that it blocks the reuptake of 
neurotransmitters serotonin and noradrenaline almost equally. Imipramine is 
converted to Desipramine upon metabolism. 
 
Figure 1.13.1.5 Chemical structure of Imipramine Hydrochloride 
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1.13.2 Other tricyclic compounds in clinical use that may show cytotoxic 
activity against malignant glioma 
 
Promethazine is a first-generation H1 receptor antagonist antihistamine and 
antiemetic medication. It is available over the counter in the United Kingdom, 
Switzerland, and many other countries (Phenergan
®
). Promethazine also has 
strong anticholinergic and sedative effects. Previously it was used as an 
antipsychotic, although it is generally not administered for this purpose now; 
Promethazine has only approximately 1/10 of the antipsychotic strength of 
chlorpromazine. 
Chlorpromazine was the first antipsychotic drug, used during the 1950s and 
1960s. Used as chlorpromazine hydrochloride and sold under the trade name 
Largactil
®
, it has sedative, hypotensive and antiemetic properties as well as 
anticholinergic and antidopaminergic effects. It also has anxiolytic (alleviation of 
anxiety) properties. Today, chlorpromazine is considered a typical antipsychotic. 
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1.14 Clomipramine hydrochloride: a tricyclic antidepressant with the 
potential to selectively trigger apoptosis in tumour cells 
 
Previous research into Clomipramine hydrochloride, a tricyclic antidepressant 
(TCA) which has been used to competitively inhibit the serotonin and 
norepinephrine transporters for over forty years, has shown that it has the ability 
to induce apoptosis in malignant glioma and Neuroblastoma cells in vitro (Daley, 
Wilkie et al. 2005; Levkovitz, Gil-Ad et al. 2005; Parker and Pilkington 2006). 
Clomipramine is demethylated by the liver to its active metabolite 
Norclomipramine (Desmethylclomipramine). In the 1970s, it was found that 
TCAs showed selective inhibition of mitochondrial activity in yeast cells (Wilkie 
1979). It was surmised that the wide ranging actions of the TCAs in vivo was due 
to interactions with membranes and membrane-bound enzymes, in particular the 
mitochondrial membrane (Linstead 1971).  
 
These lipophilic compounds, which were first shown to block oxygen 
consumption in yeast and human fibroblasts (Linstead 1971; Wilkie 1979), exert 
their effect via the inhibition of complex III of the mitochondrial respiratory 
chain (Daley 2001; Daley, Wilkie et al. 2005). By blocking the mitochondrial 
electron transport chain, the tricyclics are thought to initiate an increase in 
superoxide production and hence hydrogen peroxide production, decreased 
membrane potential and possibly mitochondrial permeability transition pore 
(MPTP) formation (Pilkington, Parker et al. 2008). As a consequence, 
cytochrome C is released and activation of pro caspase 9, caspase 3 and 
endonuclease G results in DNA degradation and apoptotic death.  
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It has been demonstrated that the tricyclics, in particular Clomipramine, initiate 
the intrinsic pathway of caspase-3-dependent apoptosis (Daley 2001; Daley, 
Wilkie et al. 2005). Here, Clomipramine initiates stress-induced apoptosis 
through its effect on phosphorylated proto-oncoprotein c-jun (p-c-jun, part of the 
JNK-AP-1 signal transduction pathway) and causes it to translocates to the 
nucleus (Behrens, Sibilia et al. 1999; Levkovitz, Gil-Ad et al. 2005).The intrinsic 
pathway of cytochrome C is triggered which activates caspase 9 and converges 
on executioner caspase 3 leading to apoptotic cell death (Daley 2001). 
 
The differential effect seen, whereby Clomipramine initiates apoptosis in 
neoplastic glial cells whilst leaving normal glial cells and neurones unaffected, 
can be attributed to the capability of normal cells to recover (Wilkie 1979). Other 
mechanisms responsible for the selective killing of tumour cells by clomipramine 
might be the higher number of mitochondria in tumour cells, so uptake of 
Clomipramine would be greater, or the altered pH of tumour cells.  
 
Clomipramine has also been observed to have potential for use in B-cell 
lymphomas. When tested in seventeen derived B cell lines, it was more effective 
than the selective serotonin reuptake inhibitor (SSRI) Fluoxetine in all but one 
case. Exposure of cells to Clomipramine resulted in rapid and concentration 
dependent increases in non-viable cells and caspase activity. In eight of the cell 
lines tested >50% antiproliferative response was seen at a concentration of 20µM 
(Meredith, Holder et al. 2005). Normal B cells, derived from tonsil tissue, 
assayed in parallel were unaffected by Clomipramine. Thus Clomipramine offers 
anti-tumour potential in both CNS tumours and B-cell lymphoma.  
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Recently Clomipramine has been studied in rat C6 glioma cells, in combination 
with Gleevec (see 1.8.2). Through Annexin-V FITC flow cytometry and 
chemosensitivity testing in both monolayer and spheroid cultures it was possible 
to show synergism between the two agents and the mechanism of action was 
elucidated to be through inhibition of DNA synthesis and inhibition of cyclic 
adenosine monophosphate (cAMP) (Bilir, Erguven et al. 2008).  
 
Many in vitro studies show that antidepressants have potent anticancer 
properties, with all agents in this class differing in potency according to 
mechanism of action and cell type in which they were studied (Volpe, Ellison et 
al. 2003; Levkovitz, Gil-Ad et al. 2005; Arimochi and Morita 2006). Irrespective 
of their mechanism of action, the antidepressants have shown the ability to kill 
neoplastic cells (Levkovitz, Gil-Ad et al. 2005; Arimochi and Morita 2006), halt 
proliferation (Volpe, Ellison et al. 2003) and drive previously chemotherapy-
resistant cells to be sensitive (Peer and Margalit 2006).  
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1.15 Drawbacks when selecting tricyclic antidepressants for use in patients 
with malignant glioma 
 
 
There are many established and new documented problems associated with 
administration of tricyclic antidepressants. These compounds lack specificity and 
therefore exert many unpleasant side-effects. They also have many interactions; a 
particular problem seen in patients with brain tumours (who are likely to suffer 
seizures) is the interaction with anticonvulsants such as Carbamazepine. A high 
proportion of brain tumours present in elderly patients (Pilkington 2001) and 
therefore contraindications such as congestive heart failure, myocardial 
infarction and hypotension are more prevalent.  
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 Observations in tricyclic antidepressants 
Contraindications MAOIs, acute intoxication, anxiety, epilepsy, liver disease, 
kidney disease, hypotension, cardiovascular dysfunction, 
pre-existing bone marrow depression, hyperthyroidism and 
paediatric patients under the age of 18 
Side effects Drowsiness, anxiety, emotional blunting (apathy/anhedonia), 
confusion, restlessness, dizziness, akathisia, hypersensitivity, 
changes in appetite and weight, sweating, sexual 
dysfunction, muscle twitches, weakness, nausea and 
vomiting, hypotension, tachycardia, and rarely, irregular 
heart rhythms. Twitching, hallucinations, delirium and coma 
are also some of the toxic effects caused by overdose 
Interactions  Anticholinergics: TCAs increase the anticholinergic 
effects 
 Antihypertensives: TCAs antagonise clonidine and 
guanoethidine 
 Carbemazepine: TCA levels are decreased due to 
induction of hepatic enzymes by Carbamazepine 
 Cimetidine: TCA levels are increased due to inhibition of 
hepatic enzymes by Cimetidine 
 Lithium: increases risk of neurotoxicity (tremor, ataxia, 
seizures) 
 MAOIs: additive serotenergic effects 
 Sympathomimetics: enhances response to norepinephrine 
and potentiates arrhythmia 
 SSRIs: TCA levels increased due to inhibition of 
microsomal enzymes by SSRIs 
 Thyroid medication: increases risk of arrhythmia if given 
in combination with levothyroxine 
Specificity Not very specific (hence large number of side effects), 
inhibition of: 
 Na channels 
 Ca channels 
 5HT-2, 2A, 2C, 6, 7 
 D1, D2 & D3 
 Alpha-1 & alpha-2 adrenergic receptors 
 NMDA receptors 
 
Table 1.15.1 Established and new problems when choosing an antidepressant for 
use in malignant glioma 
There are a number of contraindications, side effects and interactions listed for 
the tricyclic antidepressants; however close-monitoring of patients on these drugs 
can alleviate any long-term problems.  
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1.16 The norepinephrine transporter (NET): the link between tricyclic 
antidepressants and apoptosis in glioma? 
 
The NET was the first of the monoamine transporters to be cloned (Pacholczyk, 
Blakely et al. 1991) and since then is has been discovered that such sodium and 
chloride ion-dependent transporters use the electrochemical gradient of sodium 
between the inner and outer leaflets of the cell membrane to pump 
neurotransmitters from low concentrations outside the cell to much higher 
concentrations inside the cell.  From previous studies it is clear that the uptake 
and subsequent metabolism of neuronally-released NE by glial cells is crucial in 
maintaining and regulating extracellular NE concentrations (Inazu, Takeda et al. 
2003). They may exert significant control of noradrenergic activity by 
inactivating NE that escapes neuronal re-uptake in sites distant from terminals, 
and thus are cellular targets for the antidepressant drugs that inhibit NE uptake.  
The neuronal NET (also known as the noradrenaline transporter; NAT) is a 
member of a family of twelve trans-membrane sodium- and chloride-ion 
dependent neurotransmitter transporters that aid in the termination of 
noradrenergic neurotransmission by the reuptake of NE into the pre-synaptic 
terminals from which it was released (Bonisch, Boer et al. 1990; Blakely, De 
Felice et al. 1994; Bonisch and Bruss 1994). NETs are molecular targets for 
several psychoactive agents, including cocaine, amphetamines and the tricyclic 
antidepressants (which act as NE reuptake inhibitors) (Axelrod, Whitby et al. 
1961; Iversen 1965; Ritz, Lamb et al. 1987).  
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The NET transporter is also expressed in non-neuronal tissues where it is 
responsible for the removal of circulating catecholamines; these sites include the 
lungs (Bryan-Lluka, Westwood et al. 1992; Tseng and Padbury 1998), placenta 
(Ramamoorthy, Prasad et al. 1993; Bzoskie, Yen et al. 1997; Padbury, Tseng et 
al. 1997), adrenal medulla  (Bonisch, Martiny-Baron et al. 1990; Bonisch, Paulus 
et al. 1991; Cubells, Kim et al. 1995) and PC-12 cells (Bonisch, Boer et al. 1990; 
Bonisch, Paulus et al. 1991; Bruss, Porzgen et al. 1997). 
 
It has been shown that normal brain astrocytes contain transport systems capable 
of removing various neurotransmitters from the synaptic cleft by transporters 
present in the plasma membrane. Because of their location around synapses and 
at the periphery of capillaries their uptake systems are important for regulating 
the neuronal environment. Reports on the uptake of [
3
H]NE by astrocytes 
involving an active mechanism suggested a functional uptake, RT-PCR 
demonstrated that astrocytes expressed mRNA for the cloned NET protein and 
Western blots indicated that anti-NET polyclonal antibody recognised a major 
band of 80kDa in rat astrocytes which all suggest that neuronal NET is 
functionally expressed in cultured rat astrocytes (Inazu, Takeda et al. 2003).  
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1.17 Apoptosis 
 
In theory, apoptosis can be divided into two main pathways, both being defined 
by the biochemical action of proteases called caspases, which lead to eventual 
cell death. The „extrinsic‟ pathway is driven by the activation of extracellular 
death receptors located on the cell surface, such as Fas (CD95; Apo1), TNFR1 
(p55; CD120a), DR3 (Apo3, WSL-1, TRAMP, LARD), DR4, DR5 (Apo2, 
TRAIL-R2, TRICK2, KILLER) and CAR1, involving the recruitment and 
activation of initiator caspase-8 and –10. The apoptotic signal is initiated by 
notable ligands (FasL, TRAIL and TWEAK) recognised specifically, and in most 
cases exclusively, by their corresponding death receptors (Fas, DR4 or 5 and 
TweakR respectively) (Wiley, Cassiano et al. 2001).  
 
Conversely the „intrinsic‟ pathway, which occurs at the mitochondrial 
membrane, is initiated by a disruption in the mitochondrial membrane potential, 
followed by the release of cytochrome C into the cytosol which, in turn, 
contributes to the formation of a protein complex, namely an apoptosome.  
 
This multimeric complex, formed from the interactions of cytochrome C, 
protease-activating factor-1 (Apaf-1), pro-caspase-9 and dATP eventually allows 
the activation of caspase-9 (Zou, Henzel et al. 1997; Li, Zhu et al. 1998; Polster 
and Fiskum 2004).  
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Figure 1.13.2.1 The multimeric apoptosome complex(Dash 2009) 
The pro-apoptotic (indicated in red) and anti-apoptotic (indicated in blue) 
proteins involved in the regulation of apoptosis. Formation of the PT pore and 
subsequent release of cytochrome C initiates formation of the apoptosome and 
triggers caspase activation.  
 
The common downstream pathway for both intrinsic and extrinsic activation 
involves effector caspases, adaptor molecules, such as Apaf-1 and regulatory 
molecules such as Bcl-2 proteins and inhibitors of apoptosis (IAPs) (Eldadah and 
Faden 2000). Both the intrinsic and extrinsic pathways converge downstream on 
„executioner‟ caspases, mainly caspase-3, which is responsible for the cleavage 
of structural cytoplasmic and nuclear proteins, with consequent cell death and 
collapse. Both the extrinsic and intrinsic pathways are calcium-dependent and the 
stimulation of calcium-dependent proteases can result in a disruption of 
cytoskeletal organisation and the formation of „blebs‟ (surface protrusions).  
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Central to apoptotic death is the interchange of cycling calcium ions between the 
endoplasmic reticulum and the mitochondria controlled by co-ordinated activity 
of ion channels (Taylor, Lawrence et al. 1993). Calcium-mediated phospholipase 
activation can result in the impairment of mitochondrial function with the 
collapse of membrane potential and cessation of ATP synthesis. The activation of 
a calcium and magnesium dependent nuclear endonuclease (DNA fragmentation 
factor 40) is associated with chromatin cleavage and appears to play a crucial 
role in apoptosis (Orrenius, McCabe et al. 1992).  
 
During apoptosis the nucleus breaks up into DNA fragments of 180-200kD and 
the endoplasmic reticulum transforms into vesicles, which are released as 
apoptotic bodies into the extracellular space. The apoptotic bodies, containing 
cell organelles and nuclear fragments, are phagocytosed by surrounding 
microglia and astrocytes (Haanen and Vermes 1996). 
 
1.18 The Mitochondrial Permeability Transition Pore in apoptosis 
 
 
From a molecular perspective, the MPTP consists of the voltage-dependent-
anion-channel (VDAC; also known as mitochondrial porin) in the OMM and the 
adenine-nucleotide-translocator (ANT) in the IMM (Grimm and Brdiczka 2007). 
Permeability transition is a sudden and sustained increase of the permeability of 
the IMM for solutes less than 1.5kD. The result is the breakdown of the 
mitochondrial membrane and cessation of ATP synthesis. The blockade of the 
respiratory chain results in the formation of ROS.  
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The second effect is an osmotic one, with the high concentration of solutes in the 
mitochondrial matrix drawing in water molecules from the cytosol (Grimm and 
Brdiczka 2007). Subsequent to this factors are released (cytochrome C and 
Smac) that execute the suicide programme of apoptosis. The proteins associated 
with permeability transition are the link between the proteins that regulate 
apoptosis and the major effectors of apoptosis, the caspases. Therefore they 
represent an excellent therapeutic target.  
 
1.19 Mitochondrial Outer Membrane Permeabilisation in apoptosis 
 
The activation of caspases in the mitochondrial pathway require mitochondrial 
outer membrane permeabilisation (MOMP), an event that is considered to be the 
„point‟ of no return‟ during apoptosis as numerous proteins diffuse from the 
matrix between the OMM and IMM to the cytosol. In normal cells, which 
undergo apoptosis, MOMP occurs through the formation of a channel through 
which large protein molecules (such as cytochrome C and Direct Inhibitor of 
Apoptosis-Binding protein with Low pI; DIABLO) can escape into the cytosol. 
The channel is thought to be comprised of Bax or Bad (because they lack the 
BH-4 homology domain) in combination with Bid (which is activated by 
caspase-8 cleavage to its active form, tBid) (Antonsson, Conti et al. 1997; 
Schendel, Xie et al. 1997).  
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1.20 Extrinsic and intrinsic pathways of apoptosis 
 
The two pathways of apoptosis (extrinsic pathway, triggered when an 
extracellular ligand such as TNF-α, Fas and TRAIL binds to a death receptor 
such as CD95/Fas/Apo1, TNFR1, TNFR2 and DR3-6; intrinsic pathway, 
triggered by any stimuli that signal cellular damage, such as ionising radiation, 
cytotoxic agents, hypoxia, DNA damage and growth factor withdrawal) 
(Degterev, Boyce et al. 2003) are irreversible once triggered, so it is important 
that the apoptotic pathway exists in all human cells as an endogenous, heavily 
regulated mechanism by which cells essentially self-destruct (Degterev, Boyce et 
al. 2003). The ability to undergo programmed cell death has a role in several 
normal physiological processes such as embryogenesis and immunity. Whereas 
the expression of anti-apoptotic proteins is an important physiological safeguard 
to prevent cellular destruction, these proteins play a pathologic role in many 
malignancies, in glioma in particular. High levels of anti-apoptotic proteins have 
been shown to both result in resistance to chemo- and radio-therapy and to 
cancer progression (Schmitt 2003).  
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1.21 The role of inhibitor of apoptosis-inducing proteins in apoptosis 
 
The IAPs represent the last cellular safeguard against apoptosis and block both 
the extrinsic and intrinsic pathways by inhibiting caspase activity (Degterev, 
Boyce et al. 2003). There are eight members of the IAP family of proteins that 
have been identified and their principle role is to bind to the caspases. XIAP, c-
IAP1, c-IAP2 and Bruce (Apollon) have been shown to be highly expressed in a 
number of malignant glioma cell lines (Chen, Naito et al. 1999; Wagenknecht, 
Glaser et al. 1999). During MOMP the IAPs are activated by the release of 
second mitochondria-derived activator of caspase (Smac)/DIABLO and Omi 
from the mitochondria, which work to prevent the binding of IAPs to the 
caspases and thus allow the cascade to proceed (Kim, Emi et al. 2005). 
 
1.22 The role of caspases in apoptosis 
 
Caspases, cysteine proteases, are present in all cells as latent enzymes. They are 
recruited to receptor-associated complexes whose formation is initiated via 
oligomerisation (for example TNF receptors, FAS and Apaf-1). Activation via 
dimerisation or dimerisation accompanied by proteolytic cleavage generates a 
cascade that cleaves proteins critical for cell survival. Caspases -8, -9 and -10 
(and sometimes -2 and -5) are termed initiators and are located upstream of the 
effectors, namely caspases -3, -6 and -7.  
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Research in apoptosis has established a central role for the caspase enzymes. The 
determination of the structures of caspase-1, caspase-3 and caspase-8 has greatly 
enhanced the knowledge surrounding the function and specificity of the whole 
caspase family. This provides a starting point for elucidating the role of the 
caspase enzymes and the design of selective inhibitors to treat caspase-mediated 
diseases (Grutter 2000).  
 
1.23 The role of Bcl-2 Family in apoptosis 
 
Bcl-2 is the prototype for the family containing pro-apoptotic (Bax, Bak and 
Box) and anti-apoptotic (Bcl-2, Bcl-xL and Bcl-w) proteins that govern 
mitochondrial membrane permeabilisation and determine commitment to 
apoptosis (Zamzami, Brenner et al. 1998). The Bcl-2 family exert their effects on 
apoptosis via surveillance of mitochondrial membrane potential and govern 
cytochrome C release into the cytosol by binding to a mitochondrial porin 
channel(also known as voltage dependent anion channel; VDAC), which once 
there activates caspase-9 and caspase-3.  
 
Zamzami et al (1998) also suggest that the release of cytochrome C is mediated 
by the effects of the mitochondrial permeability transition (PT) pore located on 
the inner leaflet of the mitochondrial membrane. This work is further supported 
by the theory that the Bcl-2 gene family activate or deactivate the PT pore 
through regulation of mitochondrial ATP and calcium flux (Zamzami, Brenner et 
al. 1998; Weeber, Levy et al. 2002). 
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The Bcl-2 homology domains are known to be crucial, as deletion affects 
apoptosis and survival rates. The structure of the Bcl-2 family is a hydrophobic 
helix surrounded by amphipathic helices, some of the members also possess 
transmembrane domains (Oltersdorf, Elmore et al. 2005).  
 
1.24 Interactions between extrinsic and intrinsic pathways 
 
In some cells, notably hepatocytes, the extrinsic pathway can intersect the 
intrinsic pathway through caspase-8 cleavage mediated activation of the pro-
apoptotic protein Bid (Yin, Wang et al. 1999; Kaufmann, Tai et al. 2007). The C-
terminal truncated form of Bid (tBid) translocates to the mitochondria and 
promotes further caspase activation (caspase-9, -3, -6 and -7) through the 
intrinsic pathway. In these situations, loss of Bid or overexpression of Bcl-xL 
inhibits cell death (Yin, Wang et al. 1999).  
 
Certain cell types (such as some neuronal populations) can survive the 
cytochrome C release step, at least for a limited amount of time (Martinou, 
Desagher et al. 1999; Potts, Vaughn et al. 2005). In such cells the activity of 
caspases is stringently regulated by caspase-inhibiting IAPs. In these cases 
apoptosis requires the release of DIABLO from the mitochondria to counteract 
the IAP inhibition and thereby allow caspase activation (Youle and Strasser 
2008).  
 
 
 86 
1.25 The regulation of apoptosis 
 
Intact apoptosis pathways protect cells against transformation to a neoplastic 
state and provide the mechanisms by which cytotoxic agents exert their effects 
(Goldsmith and Hogarty 2005). Deregulated proliferation alone is not sufficient 
for tumour formation but when these pathways are disrupted through alterations 
in the cell death machinery, they act alongside deregulated oncogenes, such as 
Ras, to promote tumour initiation and resistance to therapy (King 2009).  
 
Tumour cells possess a number of mechanisms for evading normal programmed 
cell death (PCD). The Bcl-2 family (see 1.23) are able to manipulate cell death 
via the MPTP, which is involved in the regulation of the matrix, calcium ions, 
pH and voltage within the mitochondria. Some members can induce (pro-
apoptotic; Bax, Bak, Diva, Bcl-Xs, Bik, Bim, Bad, Bid and Egl-1) or inhibit 
(anti-apoptotic; Bcl-2, Bcl-XL, Mcl-1, CED-9, A1 and Bfl-1) cytochrome C 
release from the mitochondria, which then initiate caspase-9 and -3 activity. 
Neoplastic glial cells express a much higher proportion of anti-apoptotic proteins 
from the Bcl-2 family which protect from caspase activation. Progression of 
tumours and grade of malignancy are linked to the degree of expression of Bcl-2 
family proteins (Deininger, Weller et al. 1999). Other mechanisms possessed by 
tumour cells via which they can inhibit apoptosis are the expression of inhibitor 
of apoptosis proteins (IAPs) (LaCasse, Baird et al. 1998). The IAP Survivin is 
highly tumour-specific and in Neuroblastoma tumours interacts with 
Smac/DIABLO by binding to caspase-9 which inhibits apoptosis (Igney and 
Krammer 2002).  
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1.26 Detection of apoptosis 
 
The Annexin-V assay is able to detect the degree of apoptosis occurring in a cell 
population and is based upon the presence of phosphatidylserine (PS), made by 
the two PS synthases PSS1 and PSS2, which is normally located on the inner 
leaflet of the plasma membrane, but undergoes transbilayer movement during 
apoptosis and becomes exposed on the cell surface (Grandmaison, Nanowski et 
al. 2004).  
 
Annexin-V FITC binds to the exposed PS residues in a calcium dependent 
manner, after a rise in nuclear calcium concentration that causes the translocation 
of the calcium regulated proteins to the nuclear envelope (Raynal, Kuijpers et al. 
1996). This mechanism, usually a pivotal step in the recognition and removal of 
apoptotic cells by phagocytes (Zwaal, Comfurius et al. 2005), allows the 
attachment of the Annexin V-FITC probe and allows the visualisation of 
apoptotic cells via flow cytometry. Annexin V-FITC has an affinity for PS and 
attaches in a calcium-dependent manner.  
 
1.27 Caspase-independent programmed cell death 
 
 
As with caspase-dependent cell death, caspase-independent cell death relies on 
MOMP taking place. The process may utilise less tractable mechanisms, such as 
loss of mitochondrial function or release of inter-membrane space proteins to 
catalyse death but it still results in reduced energy production and cell death 
(Chipuk, Bouchier-Hayes et al. 2006).  
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The identification of five isoforms of apoptosis inducing factor (AIF) has 
allowed the characterisation of the nuclear functions of this protein. The 
mitochondrial release, nuclear translocation and DNA fragmentation associated 
with AIF have been extensively demonstrated in several systems and cell lines to 
date (~ 900 Medline references to date, 2005). Expressed as a precursor of 
67kDa, AIF is placed within the N-terminal prodomain of the protein (Susin, 
Lorenzo et al. 1999) and once inside the mitochondrion is processed to a mature 
form of 62kDa by proteolytic cleavage (Otera, Ohsakaya et al. 2005). 
 
AIF is required for the maintenance and maturation of the electron transport 
chain, specifically complex I (Vahsen, Cande et al. 2004). After a cell death 
insult, AIF translocates from the mitochondria to the cytosol and nucleus (Susin, 
Lorenzo et al. 1999; Mate, Ortiz-Lombardia et al. 2002; Ye, Cande et al. 2002). 
Once in the nucleus, AIF interacts with DNA and/or RNA to cause caspase-
independent chromatin condensation and large scale DNA fragmentation (Susin, 
Lorenzo et al. 1999; Ye, Cande et al. 2002).  
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Apoptosis inducing factor does not display intrinsic endonuclease properties, its 
DNA-degrading activity appears to depend on downstream nuclease Endo G, a 
DNase of mitochondrial origin released in a caspase-independent manner in pro-
apoptotic conditions (Wang, Yang et al. 2002).  Other proteins, such as heat-
shock protein 70 (Hsp70), regulate the pro-apoptotic function of AIF (Ravagnan, 
Gurbuxani et al. 2001; Gurbuxani, Schmitt et al. 2003; Ruchalski, Mao et al. 
2006). In fact, Hsp70 is the main inhibitor of caspase-dependent and caspase-
independent PCD (Beere, Wolf et al. 2000; Ravagnan, Gurbuxani et al. 2001; 
Daugaard, Rohde et al. 2007).  
 
The expression of AIF is inhibited by Bcl-2 19KDa interacting protein 3 (BNIP3) 
whereby it associates with PTB-associating splicing factor (PSF) and HDAC1 
(histone deacetylase 1) contributing to transcriptional repression of the AIF gene. 
The reduction in AIF expression results in decreased apoptosis in glioma cells, 
and therefore increased resistance to cell death (Burton, Eisenstat et al. 2009).  
 
One of the pivotal events in programmed cell death is the release of proteins AIF, 
cytochrome C, Endo G, Omi/HtrA2 and Smac/DIABLO, yet how they exit the 
mitochondria remains unresolved (Hengartner 2000; Zamzami and Kroemer 
2001; Kuwana, Mackey et al. 2002; Henry-Mowatt, Dive et al. 2004; Uren, 
Dewson et al. 2005; Gogvadze, Orrenius et al. 2006; Munoz-Pinedo, Guio-
Carrion et al. 2006). It is possible that the proapoptotic proteins Bax and Bak 
participate in this process (Letai, Bassik et al. 2002), through allosteric changes 
brought about in response to death signals (Gross, McDonnell et al. 1999).  
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It is also known that AIF requires proteolytic cleavage to yield a 57kDa form that 
can be released from the inner mitochondrial membrane (Otera, Ohsakaya et al. 
2005; Uren, Dewson et al. 2005), this is achieved though the activation of 
calpains and cathepsins (Polster, Basanez et al. 2005; Yuste, Moubarak et al. 
2005). Calpains (non-lysosomal) and cathepsins (lysosomal) are cysteine 
proteases that control AIF cleavage in a calcium-dependent (Polster, Basanez et 
al. 2005; Takano, Tomioka et al. 2005; Yuste, Moubarak et al. 2005; Cao, Xing 
et al. 2007) and calcium-independent manner (Yuste, Moubarak et al. 2005; 
Yacoub, Park et al. 2006), respectively.  
 
1.28 The regulation of apoptosis by tumour suppressor p53 
 
p53 is one of the most frequently mutated of tumour suppressors in human 
tumours and has been intensely studied for years(Lane and Crawford 1979; Oren 
and Levine 1983; Chumakov 1987; Kinzler and Vogelstein 1989; Lane 1992). It 
is a major orchestrator of the cellular response to stress through its regulation of 
apoptosis (Fridman and Lowe 2003), cell cycle arrest (Wagner, Kokontis et al. 
1994), senescence (Wynford-Thomas 1996), DNA repair (Marx 1994) and 
genetic stability (Achanta, Sasaki et al. 2005). For many years it was thought that 
p53 relied upon its function as a transcription factor to regulate these stress types 
(Levine 2001), however in the last eight years it has been revealed that it directly 
participates in the intrinsic apoptosis pathway by interacting with members of the 
Bcl-2 family to induce MOMP (Erster and Moll 2004; Vaseva and Moll 2009).  
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The first studies to reveal a transcription-independent function of p53 on 
apoptosis showed that p53 regulates caspase activity and upon receiving a stress 
signal, translocates from the cytoplasm to the mitochondria where it interacts 
with members of the Bcl-2 family to inhibit or activate them. MOMP then takes 
place which in turns triggers the caspases and chromatin degradation (Ding, 
McGill et al. 1998; Gottlieb and Oren 1998).  
 
1.29 Molecular alterations in brain tumours 
 
Brain tumours arise from the accumulation of several genetic and epigenetic 
events over a long time period. Identifying the molecular alterations that 
distinguish cancer cells from normal cells will ultimately help to define the 
nature and pathology of tumours. Two different approaches of biomarker 
discovery have been employed: the first approach looks at markers from specific 
pathways one-by-one and the second approach is that of a high-throughput 
screening method, however molecular alterations add complexities to either 
approach.  
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1.29.1 Single nucleotide polymorphisms and their effect on response to 
therapy 
 
A SNP is a DNA sequence variation occurring when a single nucleotide (A, T, C 
or G) in the shared sequence differs between paired chromosomes in an 
individual. The two alternate forms are termed „alleles‟. Since most DNA does 
not encode proteins the majority of SNPs cause only „silent‟ variation which has 
no visual phenotypic effect. However some SNPs on an allele can have an effect, 
in this case drug response and distribution. Single nucleotide polymorphisms are 
highly abundant, and are estimated to occur at one out of every one thousand 
bases in the human genome (Sachidanandam, Weissman et al. 2001). In addition 
to diagnostic applications SNPs are useful markers in population genetics. 
 
1.29.2 Splice variants and their effect on response to therapy 
 
Pre-mRNA splicing is an essential, precisely regulated process that occurs 
following gene transcription and before mRNA translation. Spliceosomes 
recognise the boundary between exonic and intronic sequences in pre-mRNA and 
catalyse the cut-and-paste reaction that removes introns and joins exons. Once 
exon recognition is completed, the connected exons are exported out of the 
nucleus as a mature mRNA that can be translated into protein. Alternative pre-
mRNA splicing is responsible for the production of multiple mRNAs from a 
single gene, subsequently multiple protein isoforms, and this process is essential 
for the generation of protein diversity.  
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Up to 60% of all human genes present at least one alternative splice variant, and 
alternative splicing could potentially generate more transcripts from a single gene 
than the total number of genes in an entire genome (Black 2003). The 
physiological activity of splice variant products compared to the wild-type 
protein may be completely different. Whole functional domains may be added or 
deleted from the protein coding sequence. The apoptosis genes Bcl-(x)L, 
Caspase-9, and Caspase-2 encode both pro- and antiapoptotic variants (Syken, 
De-Medina et al. 1999; Wu, Tang et al. 2003). It is also possible that splice 
events transform membrane-bound proteins into soluble proteins, as is the case 
for the fibroblast growth factor receptors (Jang 2002). For the vast majority of 
alternative splice events, their functional significance is still unclear. However 
identifying the presence of new splice variants in diseases such as cancer may 
lead to a clearer understanding the differences observed in response to therapy.  
 
1.30 Rationale for targeting the mitochondria with tricyclic antidepressants 
Traditional chemotherapy approaches currently offer little long-term benefit for 
most malignant glioma and is frequently associated with adverse side-effects that 
diminish the quality of life. Hence, new approaches are needed that can provide 
long term management for malignant brain tumours, whilst permitting a decent 
quality of life (Fisher and Buffler 2005). 
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Targeting DNA directly is a difficult area because tumour cells possess so many 
DNA-repair mechanisms and no two tumours have the same method of 
circumventing cell death, this is evident in the poor results seen in clinical trials 
for DNA-acting agents such as Temozolomide and Gliadel. An alternative 
approach is to indirectly cause cellular degradation by disrupting the normal 
mitochondrial balance of Bcl-2 proteins and caspases and evidence in support of 
this hypothesis will be presented in this study.  
 
Despite the vast array of research carried out in the field of neuro-oncology the 
incidence of brain tumours continues to rise and the prognosis remains dismal. It 
is well known that heterogeneity of both tumours within patient cohorts and the 
cells within a single tumour, the presence of the blood-brain barrier and the 
invasive phenotype of tumours are the main contributing factors that preclude 
successful treatment. The application of a „one fits all‟ approach to the treatment 
of brain tumours clearly does not work, with only subsets of patients responding 
in clinical trial. To remove the problem of B-BB penetration from the equation it 
is necessary to employ agents that are known to have good B-BB penetration 
(see table Table 1.7.1). In this context the use of archival agents with the 
propensity to cross the B-BB may be of significance. An added, possible 
advantage is that this approach is far less costly than the continual development 
of expensive new agents that fall at the first hurdle.  
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Moreover, B-BB disruption in the disease state cannot be relied upon for entry of 
drugs into the non-neoplastic CNS which harbours invasive populations of 
unseen tumour cells. Thus, the screening of tricyclic agents is deemed a viable 
study. The tricyclic agents are known to access to the CNS, and are also capable 
of targeting aberrant „guerrilla‟ tumour cells that have invaded the normal brain 
parenchyma and thus survive chemotherapeutic assault.  
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1.31 Hypotheses, aims and objectives of this study 
 
Hypotheses 
 
1. that tricyclic antidepressants are able to induce cell death effectively in 
glioma 
 
2. that P450 genotype influences chemosensitivity in malignant glioma 
 
3. that the norepinephrine transporter expression in glioma influences sensitivity 
to tricyclic antidepressants 
 
4. that mitochondria are a potential target for therapy in malignant glioma 
 
 
Aims 
 
1. To compare drug efficacy and potency of different tricyclic antidepressants 
and demonstrate the differences in sensitivity between glioma cell lines and 
early passage cultures 
 
2. To analyse paired plasma and whole blood samples derived from glioma 
patients taking Clomipramine and demonstrate that mutations in the CYP450 
enzymes responsible for metabolising Clomipramine affect response to 
tricyclic antidepressant therapy 
 
3. To demonstrate the presence of the human norepinephrine transporter in 
malignant glioma 
 
4. To examine the expression of a number of pro- and anti-apoptotic genes in 
malignant glioma  
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Objectives 
 
 To investigate the efficacy and potency of eight compounds with tricyclic 
structure on established cell lines SNB-19 and DK-MG, early passage 
cultures UPAB, UPMC and UPJM and normal human astrocytes CC-2565 
using the MTT, ATP-TCA and Annexin V assays 
 
 To obtain clinically relevant Clomipramine concentration values using repeat 
plasma samples from seventeen glioma patients via HPLC-MS/MS and, 
using paired blood samples, prepare extracts of genomic DNA to analyse for 
mutations in the CYP450 enzymes (2D6 and 2C19) responsible for 
metabolising Clomipramine using a multiplex real-time PCR assay 
 
 To demonstrate the presence of the norepinephrine transporter on normal 
human astrocytes, Glioblastoma multiforme, Astrocytoma, 
Oligodendroglioma, Meningioma and Schwannoma tumours using 
immunohistochemical, immunocytochemical, Western blotting and real-time 
PCR techniques 
 
 To screen cDNA synthesised using mRNA extracted from a retrospective 
panel of formalin-fixed paraffin-embedded glioma samples for the presence 
of pro- and anti-apoptotic markers and examine patterns of expression using 
micro fluidic Taqman low density array cards pre-loaded with primers 
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2 General materials & methods 
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2.1 Materials 
 
 
Reagents Company Code 
   
Adenosine Triphosphate Sigma Aldrich FLAAS-1VL 
Amitriptyline Hydrochloride Sigma Aldrich A-8404 
Annexin V-FITC Kit BD Biosciences 556419 
Chlorpromazine Sigma Aldrich C-8138 
Clomipramine Hydrochloride Sigma Aldrich C-7291 
DAB Liquid Chromogen Biogenex HK130-5K 
Dilution buffer DCS, Hamburg In house 
Dimethyl Sulphoxide Sigma Aldrich 414885000 
DMEM:F12 media Invitrogen 12634-010 
Doxepin Hydrochloride Sigma Aldrich D-4526 
Dulbecco’s Modified Eagle’s Medium Invitrogen 61965-026 
Foetal Bovine Serum Sigma Aldrich F-7524 
Glutamax Invitrogen VX35050038 
Hanks Balanced Salt Solution with 
phenol red 
Invitrogen 14170-070 
Hanks Balanced Salt Solution 
without phenol red 
Invitrogen 14175-046 
Imipramine Hydrochloride Sigma Aldrich I-0899 
Luciferase Labtech International LAB-LA-12 
 
Luciferin Labtech International LAB-BT11-
100 
MTT Powder Sigma Aldrich M-5655 
Mycoalert Kit™ Cambrex Biosciences LT07-318 
Norclomipramine Hydrochloride Sigma Aldrich N-1280 
Norepinephrine Transporter 
Antibody 
Chemicon MAB5620 
Nortriptyline Hydrochloride Sigma Aldrich N-7261 
Nuclease-free water Promega P-1193 
Penicillin/Streptomycin Sigma-Aldrich P-0187 
Plasmocin™ Invivogen Ant-mpt 
Power Block™ Biogenex BS-1310-25 
Promethazine Hydrochloride Pharmacy  -  
Recovery Cell Culture Freezing 
Media 
Invitrogen 12648-010 
Sodium Hydroxide Pellets Sigma Aldrich S-5881 
Staurosporine Sigma Aldrich S-6942 
Supersensitive™ Link-label IHC 
detection system 
Biogenex QD-200-0XE 
Taqman drug metabolism genotyping 
reaction mixture 
Applied Biosystems  -  
Taqman universal master mix (no 
UNG) 
Applied Biosystems 4364341 
Taqman universal master mix Applied Biosystems 4364338 
TCER DCS, Hamburg In house 
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TE-Buffer Promega V-6231 
Trypan Blue Sigma Aldrich T-8154 
Tryple™ with phenol red Invitrogen 12605-028 
Tryple™ without phenol red Invitrogen 12604-043 
   
Plasticware   
   
1.5ml sterile eppendorf tubes VWR 306030806   
14.0 ml Corning PP Centrifuge Tube Fisher Scientific FB55950 
25 cm
2
Corning tissue culture flasks Fisher Scientific TKT500010Q 
7.0 ml Sterile PP Bijou Fisher Scientific FB51523 
75cm
2
Corning tissue culture flasks Fisher Scientific TKV123031L 
FACS Tube BD Biosciences 352003 
Greiner barcoded cryovial 1.0 ml 
internal thread 
Greiner 123279-250 
Mr Freezy Cryopreservation vessel Fisher Scientific CRY120010T 
PP 96-well u-bottom microplates Marathon 353072 
96-well PCR microplates Abgene AB-0900 
0.2ml PCR Tubes Sigma Aldrich P-3114 
   
Other   
   
Ethanol Sigma Aldrich 459844 
Barricidal™ Fisher Scientific CMD040020G 
DNA-Zap Ambion 9890 
Industrial Methylated Spirit Sigma Aldrich 458600 
Whatman FTA® Cards Fisher Scientific FDA367005P 
Whatman FTA Cards Fisher Scientific FDU367010W 
Whatman Micropunch Fisher Scientific FDU365040U 
White 96-well plates Thermo Electron 7905 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 101 
2.2 Methods 
 
2.2.1 Tissue Culture 
 
All cell culture was performed in a laminar flow hood under sterile conditions. 
Barricidal™ was used to sterilise all surfaces that came into contact with biopsy 
material or cell cultures. The cells, both early passage cultures and established 
cell lines (see Table 2.3.1), were initiated in-house from brain tumour biopsy 
tissue (LRECs 00-173, 02-056 and 04-066) were cultured initially in 
Plasmocin™ for two weeks and tested using a Mycoalert Kit™ to ensure they 
were free of mycoplasma and bacterial or fungal infection. All cells were then 
cultured in Dulbecco‟s Modified Eagle‟s Medium (DMEM; with the addition of 
Glutamax) and 10% heat inactivated foetal bovine serum (FBS; necessary to 
establish reactive astrocytes in culture) without the addition of 
antibiotic/antimycotic. Antibiotics and antimycotics were omitted from all tissue 
culture reagents apart from transport media because brain tumours are „sterile‟ 
tumours due to their CNS location (unlike, for example, a colorectal tumour) and 
as long as a high standard of aseptic technique is maintained contamination is not 
an issue. Since compounds such as these are unable to cross the B-BB (except in 
certain cases of meningitis) it ensures a more accurate in vitro environment. All 
tissue culture reagents were aliquoted into sterile duran bottles or sterile bijou 
bottles and labelled for use with one cell culture only to avoid cross-
contamination. Cells were maintained and propagated in a humidified tissue 
culture incubator, designated specifically for decontaminated human brain 
tumour cells only, at 37
o
C with 5% CO2/95% air atmosphere.  
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2.2.2 Biopsy Tissue 
 
Glioma cells were derived from primary cultures of human biopsy material taken 
at the time of surgery in the neuro-surgical theatres of Hurstwood Park 
Neurological Centre, Haywards Heath. All biopsied glioma tissues, from which 
the early passage cultures were derived, underwent histological confirmation by 
a neuropathologist and were classified according to standard WHO criteria. 
Samples were transported in transport media (DMEM with 1% antibiotic-
antimycotic) in Royal Mail „safeboxes‟ immediately following surgery; 
processing took place within forty-eight hours of surgical resection. The surgical 
biopsies were manually disaggregated with two scalpels under sterile conditions 
to form suspensions, from which primary monolayer cultures were established. 
Cells were routinely propagated in DMEM with the addition of FBS. Tissue 
culture medium was maintained at physiological pH by equilibration with 95% 
air/5% CO2.  
 
2.2.3 Biopsy tissue that has previously been exposed to radiotherapy and 
chemotherapy 
 
 
Frequently glioma biopsies are derived from patients that have already received 
radio- and/or chemo-therapy which causes them to be resistant to culture in vitro. 
The cores of such biopsies are largely necrotic and selecting tissue for 
disaggregation is difficult. However, the surgeon was able to dissect areas of 
„infiltrative edge‟ which results in a higher chance of success. Biopsies that had 
previously been exposed to therapy were disaggregated as described in 2.2.2 and 
incubated at 37
o
C/5% CO2 for 5 days.  
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Following the initial settling period, 1.0 ml of the culture medium in which the 
cells were growing was removed every 24 hours and replaced with 1.0 ml fresh 
culture medium, thereby avoiding removal of essential growth factors and 
cellular messengers. Where possible, cyst fluid, taken alongside the biopsy, was 
added to the culture medium to ensure the growth media mimicked the in vivo 
conditions as closely as possible. As a result, a number of recurrent Glioblastoma 
multiforme tumours were established in culture. 
 
 
Figure 2.2.3.1 Recurrent Glioblastoma multiforme UPRH tissue taken from a 
right temporal lobe excision 
 
Recurrent GBM UPRH was taken from a 39-year old male following excision 
biopsy from the right temporal lobe in Feburary 2005. Biopsies had been taken 
from this tumour on two previous occasions, the first in March 2005 and a 
subsequent biopsy had been taken (date not listed on report) and a Gliadel wafer 
had been inserted (see 1.8.3). The patient had received post-operative radio- and 
chemo-therapy following the initial de-bulking surgery in 2004. The biopsy 
report for this sample confirms large amounts of necrotic tissue and some fields 
of high-grade mixed Astrocytoma/Oligodendroglioma.  
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2.2.4 Passaging Cells 
 
The cultured cells were routinely sub-cultured (passaged) when they reached 
„confluency‟ (which means the surface of the flask is completely covered with 
cells. Cells should not be allowed overgrow as they lose their contact inhibition 
and enter lag phase of growth. The DMEM was aspirated using a sterile pipette 
and discarded and cells were washed using 2.0mls of Hanks Balanced Salt 
Solution (HBSS) to remove any residual FBS-containing media and cell debris. 
Cell-cell adhesion is mediated by a series of homotypic interacting glycoproteins 
(cell adhesion molecules), some of which are calcium dependent and hence 
sensitive to dissociation agents which remove the calcium ions. Thus if 
subsequently using the cells in a study that requires the presence of calcium, for 
example the Annexin-V assay, it was necessary to equilibrate the cells in a 
calcium buffer prior to analysis. Tryple (Tryple™; a recombinant-enzyme-based 
cell dissociation alterative to crude trypsin which bypasses the need for 
inactivation using FBS) was used to harvest the cells without damaging the 
membrane integrity or „strip‟ the receptors from the cell surface (1.0 for a 75cm3 
flask; 0.5ml for a 25cm
3
 flask). During the one minute dissociation period the 
flasks were placed into the incubator to maintain the optimum temperature. The 
cell suspension was aspirated into a sterile 14.0ml centrifuge tube and the flasks 
rinsed with 2.0ml DMEM twice to ensure all cells were removed. The cell 
suspension was then divided equally between flasks and fresh media added. Cells 
were not centrifuged into a pellet unless subsequently cryopreserving them; 
centrifugation was avoided at all times when working with early passage cultures 
to minimise damage to the cell. 
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2.3 Glioma cells used in the study 
 
Name Designation Populatio
n 
Doubling 
Time (hrs) 
Sex 
(Age) of 
patient 
Origin Passage 
obtained 
at (if not 
‘in-
house) 
SNB-19*
†
 Glioblastoma 
multiforme 
(Grade IV) 
18 Male 
(47) 
DSMZ p20 
DK-MG* Glioblastoma 
multiforme 
(Grade IV) 
20 Female 
(67) 
DSMZ p23 
UPAB Glioblastoma 
multiforme 
(Grade IV) 
21 Male 
(73) 
In-house N/A 
UPMC Glioblastoma 
multiforme 
(Grade IV) 
24 Female 
(69) 
In-house N/A 
UPJM Anaplastic 
Astrocytoma 
(Grade II/III) 
N/A Male 
(42) 
In-house N/A 
CC-2565 Normal human 
astrocytes 
31 Male 
(18) 
Cambrex 
Biosciences 
p1 
SH-SY5Y Neuroblastoma 28 Female 
(4) 
ECACC p8 
Table 2.3.1 Cells used in the study 
The prefix UP denotes the University of Portsmouth where the early passage 
cultures were initiated from biopsy tissue. The * denotes cells donated by Dublin 
City University)which were established cell lines from the DSMZ cell bank.
 
†
SNB-19 has been shown to be identical to U251MG (Garraway, Widlund et al. 
2005) SH-SY5Y was purchased from the ECACC cell bank and is a thrice-
cloned derivative of SK-N-SH (Biedler, Helson et al. 1973). Population doubling 
times were generated from growth studies over 120 hours (see 2.3.1). Established 
cell lines are tumours that have been serially passaged twenty times in culture. 
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2.3.1 Establishing population doubling times of cells used in the study 
 
To establish population doubling times for cells used in the study, growth 
patterns were monitored over 5 days. In brief, 100,000 cells were seeded into 
25cm
3
flasks (in triplicate) then harvested (according to 2.2.4) and counted (see 
2.3.5) every 24 hours. The growth of UPJM was inconsistent and the effect of 
harvesting cells frequently diminished cell numbers and resulted in no data for 
this tumour.  
 
Figure 2.3.1.1 A representative plot showing population doubling data for SNB-
19 
The red bars show that by selecting values from the y-axis (number of cells) it is 
possible to highlight a period of exponential growth and  extrapolate values on 
the x-axis (time in days) to give the number of hours in which the population 
doubled. In this instance the time taken for the population to double was from 54 
– 72 hours, therefore the population doubling time is 18 hours. 
 
 
 
 
100,000
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10,000,000
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Poly. (mean)
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2.3.2 Phase contrast pictures of cells used in the study 
 
 
A:  CC-2565 p3 (normal astrocytes)  
 
B: SNB-19 p21 (established) 
 
C: DK-MG p24 (established) 
 
D: UPAB p7 (early passage) 
 
E: UPMC p5 (early passage) 
 
F: UPJM p4 (early passage) 
 
All phase contrast pictures were taken at 200X magnification on a Zeiss phase 
contrast microscope. A) Normal human foetal astrocytes (cerebral, non-
neoplastic) grown to 50% confluence in a tissue culture flask. The cells were 
grown as an adherent monolayer; these cells had been passaged three times. B) 
Tumour cell line SNB-19 was grown to 75% confluence in an adherent 
monolayer, the cells had been passaged twenty-one times. This cell line was 
actively dividing (mitotic bodies are indicated by arrows), the cells are flattened 
with ruffled edges and other cells had long processes. C) Tumour cell line DK-
MG grown to confluence, in an adherent monolayer, the cells had been passaged 
twenty-four times. The cells are closely packed and display heterogeneous 
morphology. D) Early passage culture UPAB (not established) shown here at 
50% confluence after seven serial passages. There are a number of mitotic f 
visible (shown by arrows); the cells appear homogeneous and have long, slender 
extending processes. E) Early passage culture UPMC (not established) shown 
here at 50% confluence after five serial passages. The cells are actively diving 
(mitotic figures are visible), and there are cells present with multiple processes. 
F) Early passage culture (UPJM) shown at 50% confluency, these cells are 
heterogeneous in nature. Some cells appear flattened whilst others show long, 
fine processes. The cell sizes also vary.  
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2.3.3 Cryopreservation 
 
Cells previously harvested according to the procedure described above were 
centrifuged for five minutes at 1000rpm/200g. The supernatant was aspirated and 
the cell pellet re-suspended in 1.0ml of recovery cell culture freezing medium; 
RCCFM Gibco). The addition of 10% glycerol to RCCFM, which is the main 
difference from traditional freezing media, enables a much higher percentage of 
viable cells to be resurrected. The cell suspension was transferred into a barcoded 
cryovial (Greiner Bio-one) and all tubes placed in a „Mr Freezy‟ at -80oC for 
twenty-four hours to allow the temperature to decrease slowly, buffered by the 
isopropanol surrounding the tubes.  
2.3.4 Thawing Cells 
 
The cryovial containing the required culture was taken from liquid nitrogen 
storage, placed in a clean glass beaker (one cryovial per beaker to ensure no 
cross-contamination) and left to warm in a 37
o
C incubator for up to five minutes. 
The cell suspension was then transferred to a flask containing the appropriate 
volume of pre-warmed media (5.0 mls for a 25cm
3
 flask and 12.0 mls for a 75 
cm
3
 flask) and left to settle overnight.  
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2.3.5 Cell Counting 
 
In order to plate cells for a cytotoxicity assay or seed the correct number into 
flasks for flow cytometry it was necessary to quantify the concentration of cells. 
The monolayers were harvested as previously described and centrifuged for five 
minutes at 1000rpm/200g to form a pellet. The pellet was re-suspended into 
1.0ml media and from this 100µl was placed into a cuvette, 500µl plain media 
added and analysed as a 1:6 dilution using the trypan blue dye-exclusion assay.  
 
The cell concentration (cells per millilitre) was calculated by the Vi-Cell XR and 
by using this number; it was possible to calculate how much of the cell 
suspension should be added to fresh media for downstream experiments: 
 
Vol.  = Volume of cell suspension (µl) x Number of cells required for assay 
Number of cells/ml 
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Figure 2.3.5.1 The Vi-Cell XR (Becton Dickinson) 
Automated trypan blue dye exclusion testing apparatus with cell size gating and 
„Bioprocess‟ function which plots growth curve and enables population doubling 
time evaluation 
 
 
Figure 2.3.5.2 A screen capture taken during analysis of SNB-19 
The Vi-Cell XR has the capability to distinguish individual cells within a cell 
clump. It circles viable cells in green (as seen above) and non-viable cells in red. 
It is not possible to remove dead cells from the cell suspension so only the viable 
cell number contributed to the final concentration.  
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2.3.6 Annexin V/Propridium Iodide Flow Cytometry 
 
Cells grown to 90% confluence in 25cm
3
 flasks were incubated with varying 
concentrations of drug for up to six hours and harvested by firstly removing the 
complete media to centrifuge tubes (to ensure that all cells were subject to 
analysis), before using 5.0mls of clear Tryple™. During the two-minute 
dissociation period, flasks were placed in the incubator (37
o
C, 5% CO2) to 
maintain the optimum temperature. The Tryple™ was removed by centrifugation 
at 1000rpm/200g after the addition of DMEM with 10% FBS added.  
 
The cell pellet was re-suspended in 1.0ml of calcium binding buffer (according 
to the manufacturer‟s kit instructions), used to replace the calcium ions lost 
during dissociation with Tryple™ (which are essential for the attachment of the 
probe), before removing 500µl of the single cell suspension to a FACS tube.  
 
Controls used in the analysis were performed by omission of the drug incubation 
in one flask (negative control), and addition of 1µM Staurosporine to one flask 
(positive control). Five micro litres of Annexin V FITC (proprietary solution, 
concentration not provided) and 5µl of Propridium iodide (50 µg/ml) were added 
to all tubes, by placing a drop of the fluorochrome on the side of the tube and 
inverting it. The tubes were incubated for 15 minutes at room temperature, in the 
dark. Subsequent to this, 400µl of calcium binding buffer was added to each tube 
and analysed by the BD FacsCalibur (Becton Dickenson, UK) within 1 hour. 
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2.3.7 Staurosporine as an apoptosis stimulus positive control 
 
Staurosporine, which is traditionally used for its antibiotic properties, has the 
ability to inhibit protein kinases through the prevention of ATP binding to the 
kinase. This is achieved through the stronger affinity of Staurosporine to the 
ATP-binding site on the kinase. Staurosporine is a prototypical ATP-competitive 
kinase inhibitor in that it binds to many kinases with high affinity, though with 
little selectivity (Karaman, Herrgard et al. 2008). This lack of specificity has 
precluded its clinical use as an anticancer agent, but has made it a valuable 
research tool. In research, Staurosporine is used to induce apoptosis. The 
mechanism of how it mediates this is not well understood, however it has been 
found that one way in which Staurosporine induces apoptosis is by triggering 
Bax-activated caspase-3-dependent apoptosis(Chae, Kang et al. 2000; Zhang, 
Gillespie et al. 2004). 
2.3.8 Cell density seeding titration 
 
To ensure that exponential growth was maintained for the duration of the assay, 
and avoiding cells becoming fully confluent and entering senescence, a cell 
number titration was performed. Cells were seeded in 96-well tissue plates and 
propagated in DMEM with the addition of 10% FBS. The titration was 
performed before the first MTT experiment was carried out on any new tumour, 
and then always plated at exactly the same density.  
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Cells were harvested as outlined in section 2.2.4 and seeded into a 96-well flat 
bottomed plate (see plate layout 2.3.9). Cells were seeded in eight rows from A-
H at the following densities: 250, 500, 750, 1000, 2000, 3000, 4000 and 5000 
cells/well. Cells were incubated and left to grow for 96-hours (the same time as 
the MTT assay takes). After a 96-hour period the wells were examined under 
phase contrast microscope to see which density was most appropriate for the 
individual cells.  
 
2.3.9 MTT Assay 
 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide, or MTT 
assay measures continued metabolic activity of cells over a fixed time period. 
The reduction of the tetrazolium salt to formazan (via the succinate 
dehydrogenase enzyme present in cells) is measured to calculate metabolic 
viability or proliferative ability after the removal of a cytotoxic agent.  
 
MTT is cleaved to formazan by the „succinate-tetrazolium reductase‟ system 
which belongs to the mitochondrial respiratory chain and is active only in viable 
cells. The reaction involves a direct transfer of electrons from reduced pyridine 
nucleotide to the respective diaphorase which in turn presumably transfers the 
electrons to the tetrazolium salt, reducing it to the insoluble formazan (shown in 
Figure 1.8.7.1). Recent evidence suggests that mitochondrial electron transport 
may play a minor role in the cellular reduction of MTT.  
 
 114 
Since most cellular reduction takes place in the cytoplasm, and probably involves 
the pyridine nucleotide cofactors NADH and NADPH, the MTT assay can no 
longer be considered strictly a mitochondrial assay. There are a number of 
concerns surrounding the MTT assay, regarding the possible interference of the 
MTT dye with the test compounds and the fact that cells deemed viable by trypan 
blue dye-exclusion are not detected by the MTT assay (Ahmad, Ahmad et al. 
2006).  
 
Cells were seeded into 96-well tissue culture plates, at between 750 – 4000 
cells/well according to population doubling time (the longer the population 
doubling time, the higher the density).They were harvested before becoming 
100% confluent (completely covering the surface area of the tissue culture flask) 
so that they were in exponential growth phase. The cells were left to settle for 24-
hours to ensure they adhere and had resumed exponential growth before 
exposing to varying concentrations of the test agent for, in this particular assay, 
48 hours (to allow maximal cell kill and to  ensure that any cell kill via second 
messengers could occur). It was important that cell seeding density was titrated 
upon first use of any new tumour so that the cells did not become confluent, and 
hence stop proliferating, during the assay. After a 24-hour recovery period (to 
allow the discrimination of cytotoxic agents from agents that are cytostatic) the 
MTT dye (1 mg/ml; Sigma Aldrich) was added, incubated for four hours and 
then analysed by spectrophotometry at 570nm.  
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Cells were harvested by adding 1.0 ml Tryple™ to all wells for one minute then 
removal of the cell suspension and the two subsequent 5.0 ml DMEM washes of 
all wells (to ensure all cells have been recovered). The cell suspension was 
centrifuged, the supernatant removed and the pelleted cells resuspended in fresh 
clear DMEM (DMEM without the addition of phenol red is required to ensure no 
background absorbance wavelength when reading plates) and plated in 96-well 
microtitre plates (see Figure 2.3.24.1) according to the density titration, seeded in 
200µl of DMEM (without phenol red). Test agents were assayed in triplicate, 
whereby each of four agents were tested per plate.  
 
Cells were left for 72 hours to adhere and reach exponential growth phase, after 
which the medium was replaced by fresh medium containing a range of 
concentrations of the test agent and incubated for 48 hours at 37
o
C. Drug 
solutions were subsequently removed and replaced with 200 µl fresh plain 
DMEM for 24 hours.  
 
To analyse the plates the DMEM was removed from all wells and replaced with 
100µl MTT solution (1mg/ml) for 4 hours before the addition of 100µl dimethyl 
sulphoxide (DMSO). The plates were then placed on a shaker for 30 minutes to 
allow the DMSO to dissolve the formazan crystals before reading the absorbance 
of the plates at 570nm on a Polarstar Optima Plate Reader. One row was left 
untreated with the drug, and one row was treated with 0.5µM NaOH, these 
served as positive and negative controls respectively. All results from the assay 
were automatically transferred to Excel and the appropriate statistical tests 
applied. 
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2.3.10 ATP-TCA Assay 
 
The Adenosine Triphosphate-Tumour Cell Assay (ATP-TCA) involves plating 
out primary cell cultures or cell lines in the presence of single agents or a 
combination of two or more agents, and measuring the residual cellular ATP 
concentration after a 6-day incubation period. Six days is the required incubation 
time when assaying primary cells obtained directly from surgical biopsy to allow 
all cell types apart from the tumour cells of interest to die, i.e. lymphocytes and 
neurons. It is necessary therefore to run the assay in exactly the same manner for 
all cells regardless of passage number to allow a true comparison to be made and 
for good laboratory practice to be maintained. Cellular ATP is one of the most 
sensitive end-points for measuring cell viability because ATP levels decrease 
markedly immediately upon cell death (Maehara, Anai et al. 1987). ATP 
determination is measured by bioluminescence using the luciferase „firefly‟ 
reaction and can measure both proliferating and non-proliferating malignant 
cells. The luciferase firefly reaction takes place with oxidation of luciferin to 
oxyluciferin and light (luciferin + O2→ oxyluciferin + light), catalysed by the 
firefly luciferase enzyme. ATP acts as a co-factor in this reaction, the levels of 
which determine the levels of light emitted as a result. The reaction takes place in 
the following two stages: 
 luciferin + ATP → luciferyl adenylate + pyrophosphate  
 luciferyl adenylate + O2 → oxyluciferin + AMP + light 
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The reaction is very efficient, converting virtually all energy input to light. The 
resulting light (luminescence) is detected using a luminometer (Gould and 
Subramani 1988).  Multi-centre studies performed on the ATP assay have 
demonstrated a high evaluability rate of >93% with different tumour types (Cree 
and Kurbacher 1999). An ATP luminescence assay was used to measure 
chemotherapeutic drug sensitivity and resistance of SNB-19, DK-MG, UPAB, 
UPMC and UPJM (see Table 2.3.1 for six days in serum-free media 
(DMEM:F12 in a 1:1 ratio) and 96-well polypropylene microplates. Row A acted 
as a negative control whereby a maximal inhibitor (a 1:5000 dilution of triton-X 
100 in plain serum-free media which inhibits all cell growth) was applied to the 
cells and Row H acted as a positive control whereby the test agent was omitted 
and substituted with plain DMEM:F12. In rows B-G the four test agents were 
applied in triplicate at 200, 100, 50, 25, 12.5 and 6.25% of the test dose 
concentration (TDC; 100µM, determined by the plasma levels achieved in vivo
1
). 
The plates were incubated for six days at 37 
o
C with 5% CO2, and the remaining 
cellular ATP extracted with tumour cell extraction reagent (TCER; a proprietary 
reagent from DCS, Hamburg, which contained ammonium meta-vanadate, hepes 
buffer and triton-x 100).   
 
 
1
 *The 100% TDC value for any agent to be tested using the ATP-TCA is 
routinely determined from the cMax values obtained through phase I clinical 
trial. Since the tricyclic antidepressants have been through clinical trial for 
depression and not brain tumours the cMax values were checked against the 
data obtained in chapter 4, whereby plasma levels were measured in patients 
taking Clomipramine hydrochloride on a long-term basis for brain tumours. 
Te TDC of 100µM is at the low end of the range of concentrations that were 
achieved in vivo.  
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Aliquots of the extract were transferred to a white 96 well polystyrene plate to 
which an equal amount of luciferin-luciferase (both from Labtech International; a 
buffered solution containing both compounds and buffered with trizma-succinate 
and HEPES prepared in-house) was added. The resulting luminescence was read 
in a luminometer (MPLX, Berthold Diagnostic Systems, Germany) and the data 
transferred to an Excel (Microsoft) spreadsheet for analysis.  The results were 
expressed as the percentage inhibition at each concentration tested. 
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2.3.11 Constructing a standard curve for the ATP-TCA assay 
 
 
An ATP standard curve was run before reading the adenosine triphosphate- 
tumour cell assay (ATP-TCA) plates, to ensure that all reagents and equipment 
were working correctly. For this protocol 50µl dilution buffer (a proprietary 
buffer from DCS, Hamburg, comprising sterile water with 1% HEPES added) 
was added to nine wells of a white 96-well microplate.  
 
 
Then 25µl of previously diluted ATP (Sigma Aldrich; 10µl of 100mcg/ml 
solution added to 4.0ml dilution buffer to give a 250ng/ml stock) was added to 
the first well and then serially diluted in the eight successive wells by 
transferring 25µl each time and mixing. The final resulting ATP concentrations 
were 83.33, 27.76, 9.253, 3.084, 1.028, 0.342, 0.114, 0.038 and 0.012 ng/ml 
ATP. To these nine wells 50µl luciferin-luciferase reagent was added and then 
the plate was placed into a luminometer (MPLX, Berthold Diagnostic Systems, 
Germany) for the light output, which is directly proportional to the ATP 
concentration, to be measured. 
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2.3.12 Drug concentrations used in this study 
 
Drug Source FW Mass 
(mg) 
Moles Volume 
(µl) 
Molarity TDC 
(µM) 
800% 
TDC 
(µM) 
Vol req'd 
for 800% 
TDC 
Total 
vol  
CAM 
(ml) 
Solvent 
Clomipramine  Sigma; C-7291 351.3 1000 2.8466 10000 284.657 100 800 14.052 5 Water 
Norclomipramine  Sigma; N-1280 337.29 25 0.0741 1000 7.412019 100 800 53.9664 0.5 Ethanol 
Amitriptyline  Sigma; A8404 313.86 1000 3.1861 10000 318.6134 100 800 12.5544 5 Ethanol 
Nortriptyline  Sigma; N-7261 299.84 500 1.6676 10000 166.7556 100 800 23.9872 5 Ethanol 
Doxepin  Sigma; D-4526 315.84 1000 3.1662 10000 316.616 100 800 12.6336 5 1M 
HCl/Water 
Chlorpromazine  Sigma; C-8138 355.33 500 1.4071 10000 140.7143 100 800 28.4264 5 Water 
Promethazine  NHS Pharmacy 320.88 25 0.0779 1000 7.791075 100 800 51.3408 0.5 N/A 
Imipramine  Sigma; I-0899 316.87 1000 3.1559 10000 315.5868 100 800 12.6748 5 Water 
Procarbazine  NHS Pharmacy 257.76 50 19.39 10000 34.14 4.26 44 8.8 5 Water 
Dexamethasone NHS Pharmacy 516.40 4 7.74 1000 7.7459 0.415 8 5.14 5 Water 
Valproic Acid NHS Pharmacy 144.21 100 -  1000 -  346.72 2773.76 20 5 Water 
 
The range of concentrations used in the MTT assay and ATP-TCA assay were 6.25 – 200 µM and the range for flow cytometry was 20-100 µM. 
All drugs were made up in the appropriate solvent, aliquoted and stored at -20
o
C. 
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Since there is no existing data concerning in vivo human brain levels of tricyclics 
it was extremely difficult to determine the concentrations at which to test the 
tricyclic agents. The MTT and ATP-TCA assay concentrations were formed 
following examination of the plasma levels taken from a series of anecdotal 
patients (values can be found in Table 4.3.1) and the cyst fluid level taken from a 
brain tumour patient, 100 µM was deemed the test dose concentration that could 
easily be achieved in vivo.  
 
2.3.13 Eluting gDNA samples for CYP450 genotyping of patients taking 
Clomipramine hydrochloride 
 
 
Whatman FTA
®
 Cards were used for the long-term storage of biological samples, 
in this case whole blood. The cards reduce the possibility of sample degradation 
due to temperature variation, leakage and spoilage. Extracted DNA may also 
degrade, and as such samples are unable to be re-analysed. These commercially 
available cards impregnated with reagents designed to lyse cells, prevent growth 
of bacteria and protect DNA.  
 
The Whatman FTA cards were suitable for use in this study as they were easy to 
send in the post, the patients only had to provide a small amount of blood and it 
could be stored and transported easily. Whatman FTA cards have been designed 
for use by either adding a 2.0mm punched disc directly to a PCR reaction 
mixture or alternatively eluting the DNA from the paper matrix before use.  
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In this assay it was necessary to quantify the DNA before adding to the 96-well 
plate as all samples needed to contain the same amount of material (40ng) for 
optimisation with the primer probe genotyping assay.  
 
The FTA cards had been loaded with finger prick whole blood samples, taken by 
a trained phlebotomist, from eighteen brain tumour patients who were taking 
Clomipramine. After ensuring the blood had been loaded uniformly onto the card 
(allowing the lysing and antimicrobial agents to work to full capacity) 2.0mm 
punches were taken using a Whatman Harris micro-punch, with care being taken 
in between punches to decontaminate the blade and cutting mat with DNA-Zap. 
The discs were placed into sterile 1.5ml eppendorf tubes and then washed three 
times with 100µl Whatman FTA Purification Reagent to remove any lysed 
erythrocytes and any other debris. The discs were then washed twice in 100µl 
TE-buffer before being dried in a heating block, with the tube lids open, for ten 
minutes at 50
o
C. The DNA was then eluted by placing each dried disc into a 
fresh eppendorf tube and adding nuclease-free water for 10 minutes at 95
o
C. The 
DNA was quantified using the ND-1000 Nanodrop Spectrophotometer.  
 
2.3.14 Using the Nanodrop Spectrophotometer 
 
 
Purity and quantity of nucleic acids (previously extracted as described in 2.3.13) 
was checked by spectrophotometry at 260 nm and 280 nm using a Nanodrop 
ND-1000 spectrophotometer. By loading 1.4µl of the sample onto the pedestal it 
was possible to quantify the concentration of genomic DNA (gDNA), 
complementary DNA (cDNA) or ribonucleic acid (RNA).  
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2.3.15 Dewaxing tissue sections 
 
 
To enable the staining of tissues preserved in formalin-fixed paraffin-embedded 
(FFPE) blocks, 4 µm sections were cut on a microtome and processed using a 
Leica XL Stainer (Leica Microsystems, Germany) according to the 
manufacturer‟s instructions to remove the paraffin wax. In brief, slides were 
immersed three times in Clearene
®
 (a selected blend of terpenes formulated 
specifically to replace xylene and toluene in histology laboratory procedures; 
NHS Supplies) and then immersed twice with fresh 100% industrial methylated 
spirit (IMS). IMS is miscible with Clearene and two repeat incubation steps (both 
with fresh IMS) ensured the complete removal of Clearene and also the 
rehydration of the tissue section.  
2.3.16 Dehydrating tissue sections 
 
To enable visualisation of tissue sections subsequent to any staining procedure it 
is necessary to remove all water from a tissue section and mount it in a xylene-
based resin. In brief, slides were immersed three times in 100% IMS (to remove 
any water) and then immersed five times with Clearene (to clear the slides). Five 
Clearene steps are necessary to ensure complete removal of any residual IMS.  
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2.3.17 Haematoxylin and Eosin Staining 
 
 
A haematoxylin and eosin stain was carried out on all FFPE tissue sections to 
visualise the morphology of the tumour, this enabled the selection of an area of 
interest (AOI) from which two 0.6 mm punches could be extracted. A 
„regressive‟ method was employed whereby the tissue was deliberately over-
stained and then differentiated in acid alcohol until only the nuclei were stained 
with good chromatin detail. The slides were subsequently „blued‟ in tap water to 
give a good contrast to the eosin counter-stain which stained non-nuclear tissue 
components varying shades of red and pink. Slides containing one 4 µm section 
were taken to water on a Leica XL Stainer as described in section 2.3.15. The 
automatic staining programme selected consisted of two five minute incubations 
with Harris‟ Haematoxylin, a wash step with alkaline tap water to „blue‟ the 
tissue and a brief rinse step with 1% acid alcohol. The slides were then checked 
microscopically to ensure only the nuclei were stained. The sections were 
returned to the machine, washed in alkaline tap water, stained with eosin for five 
minutes and washed a final time with tap water. The slides were then dehydrated 
and cleared according to the method in section 2.3.16. 
2.3.18 Immunoperoxidase staining 
 
In order to visualise the presence of antigens, in this case the NET protein, on 
tissue samples, immunoperoxidase staining can be carried out. Antibodies 
corresponding to the NET protein are conjugated to a colour-producing 
peroxidase enzyme and reveal the distribution and localisation of differentially 
expressed proteins in fixed tissue.  
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Due to the cross-linking present in tissues that have been fixed with formalin, it 
was necessary to pre-treat the sections to „unmask‟ or retrieve‟ the antigens. The 
immunoreactivity was restored via a thirty minute incubation with pH 6.0 citrate 
buffer in a pressure cooker. In addition to antigen retrieval it was also necessary 
to block non-specific staining in the tissue.  
 
To visualise the presence of the norepinephrine transporter (NET) on human 
brain tumour cells, 4 µm tissue sections cut from FFPE blocks were stained using 
an immunoperoxidase technique. A ready-to-use Supersensitive™ kit from 
Biogenex was used to stain the slides, and manufacturer instructions followed at 
all times. In brief, the first stage was the application of a primary antiserum (150 
µl of 1:500, determined by in-house antibody titration) onto the section 
(previously cut from FFPE tissue blocks) which contained the NET antibody 
(raised in a mouse). The site of interaction between primary antibody and 
specific antigen was then detected by first applying a mixture of biotin-labelled 
anti-mouse immunoglobulins (from the ready to use multilink kit) and then 
applying a pre-formed complex of streptavidin and horseradish peroxidase 
(HRP). Due to the strong affinity that streptavidin has for biotin, the two stages 
bind and so the peroxidase was then visualised by way of the DAB-H202 
reaction. The bound HRP catalysed the oxidation of DAB by H202,and 
consequently there was accumulation of insoluble brown product at the site of 
the antigen. Three blocking steps were used in this technique: 
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1) Endogenous and naturally occurring peroxidase was blocked by placing 
the slides in a mixture of alcohol and H202 (ready to use, RTU, 
proprietary formulation supplied with kit) after dewaxing 
2) Non-specific staining during the primary antibody incubation was 
blocked by incubating the slides with Powerblock™ (Launch 
Laboratories) subsequent to peroxidase blocking and prior to application 
of the primary antibody 
3) Non-specific strept(avidin) and biotin binding of the primary and 
secondary antibodies was blocked by incubating the slides with a few 
drops of an avidin blocker and then a biotin blocker (both from Vector 
Laboratories) subsequent to the Powerblock™ step and prior to applying 
the primary antibody.  The procedure ensures all endogenous biotin, 
biotin receptors, or avidin binding sites present in tissues are blocked 
prior to the addition of the labelled avidin reagent 
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2.3.19 IHC Antibodies & Reagents 
 
Antibody Company Type Dilution 
Norepinephrine 
Transporter 
Chemicon Ascites Monoclonal 1:1000 
Power Block™ Biogenex Universal 
blocking 
reagent 
 -   -  
Supersensitive™ 
Link-label IHC 
Detection 
System 
Biogenex Multilink kit  -   -  
DAB Liquid 
Chromogen 
Biogenex Chromogen  -   -  
 
 
2.3.20 Immunocytochemical staining of the norepinephrine transporter in 
glioma cells 
 
Where fixed biological tissue is not available for IHC staining, 
immunocytochemical (ICC) staining can be performed. The ICC technique is 
used to stain fresh cells grown in culture and differs from IHC because the cells 
lack the extra cellular matrix (ECM) which would normally surround them in 
vivo. The advantages to this technique are that it can stain tumours for which no 
FFPE tissue has been stored; the protocol takes around three hours. Cells are first 
fixed and then blocked with serum, the same species as the secondary antibody 
was raised in, to stop non-specific binding. Like IHC, this method is indirect and 
a primary antibody binds to the NET protein antigen via a specific epitope. A 
secondary antibody, with Alexafluor 488 covalently linked, binds to the primary 
antibody and an immunopositive signal can be visualised via confocal 
microscopy. The cells were fixed using 1.0 ml of 4% paraformaldehyde solution 
for two minutes at room temperature before washing with PBS. Potential non-
specific binding was blocked with 10% goat serum (one hour at room 
temperature) before washing with PBS.  
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The first stage was the application of a primary antibody for one hour at room 
temperature before washing with PBS. The site of interaction between primary 
antibody and specific antigen was then detected by application of an Alexafluor 
488-conjugated secondary antibody for 30 minutes (in the dark). After washing 
cells with PBS the nuclei were counterstained with hoescht blue before washing 
one final time with PBS. The coverslips were then mounted onto slides using 
vectashield and visualised using a Zeiss LCM710 confocal microscope with Zen 
2009 acquisition software.  
 
2.3.21 Detection of norepinephrine transporter proteins via western blotting 
 
SDS-page electrophoresis allows the separation of sample proteins for western 
blotting. The proteins are electrophoretically separated based upon weight and 
electrical properties as they migrate through a polyacrylamide gel matrix. Once 
separated, proteins can be electrophoretically transferred to a membrane for 
immunoblot assay. 
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2.3.22 Preparing the SDS gel 
 
An 8% gel was prepared according to Table 2.3.2 below and poured into a 1.0 
mm glass chamber, which had previously been cleaned with detergent and 100% 
ethanol. The gel was left to cast for 20 minutes. Gel were prepared and stored 
overnight in wet tissue paper and foil, at 4
o
C, for use the following day.  
 
 Volume (mls) 
Water 4.6 
30% acrylamide 2.7 
1.5M tris (pH 8.8) 2.5 
10% SDS 0.1 
10% ammonium sulphate 0.1 
TEMED 0.006 
Table 2.3.2 The reagents required to prepare an 8% SDS gel  
The first four reagents listed in the table are mixed together, swirled and placed 
inside a fume cabinet before addition of the final two reagents. The gel mixture is 
swirled and poured into the glass slide immediately as cross-linking occurs as 
soon as TEMED in added.  
 
2.3.22.1 Quantifying protein levels in glioma cell lysates using the Bradford 
Assay 
 
The cell lysates were measured for protein content using the Bradford Assay. In 
brief, 1 µl cell lysate was mixed with 150 µl Bradford dye and left to stand for 
three minutes before the optical density was measured at 595nm. A standard 
curve (previously constructed using known concentrations of bovine serum 
albumin) was used to calculate protein concentrations. The final amount of 
sample per well was adjusted to 20 ug.  
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2.3.22.2 Protein detection via western blot technique 
 
Protein samples were mixed with loading buffer (0.5% beta-mercaptoethanol 
added to 15 µl Laemmli buffer; Bio-Rad, Hemel Hempstead, UK) and heated at 
96 
o
C for four minutes. The samples were then separated for 90 minutes at 140V 
in an electrophoresis chamber containing 1X buffer (see Table 2.3.3below). The 
samples were then electroblotted onto Hybond Polyvinylidene fluoride (PVDF) 
membranes (Amersham Pharmacia, Little Chalfont, Bucks, UK) at 370mA for 
120 minutes (at 4
o
C).  
 
The blots were placed in a 5% non-fat milk solution (in TBST, see Table 2.3.3) 
for one hour before probing with the primary antibody overnight at 4
0
C. 
Following three washes with TBST, the membrane was incubated with a 
secondary horseradish peroxidise (HRP) conjugated antibody for 3 hours.  The 
specific signal was visualised using the ECL Plus kit (Amersham-Pharmacia 
Biotech, Piscataway, NJ, USA) and  captured using the chemiluminescence 
imaging station Chemi-Genius 2 (Syngene, Cambridge).  
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 Reagents 
Electrophoresis buffer (5X) For 500ml: 
 
 7.55g tris base (128 nM) 
 47g glycine (1.25M) 
 2.5g SDS (17.3mM-0.5%) 
 adjust to pH 8.3 with HCl 
 
Transfer buffer (5X) For 1000ml: 
 
 15.14g tris base (125mM) 
 72g glycine (0.96M) 
 2.5g SDS (8.7mM-0.25%) 
 adjust to pH 8.3 with HCl 
 
For 1X: 
 
 200ml of 1X transfer buffer 
 200ml of methanol 
 600ml water 
 
Tris buffered saline (TBS; 10X) For 500ml: 
 
 24.23g tris base 
 40/03g sodium chloride 
 adjust to pH 7.6 with HCl 
 
For 500ml 1X TBS tween-20 (TBST): 
 
 50ml TBS (10X) 
 0.5ml Tween-20 (0.05%) 
 450ml H2O 
 
Loading buffer (Laemmli; 2X)  125mM tris base 
 20% glycerol 
 4% SDS 
 0.0002 bromofenol blue 
 5% fresh beta-mercaptoethanol 
 
Table 2.3.3 The composition of buffers used for the Western blotting technique 
To preserve the quality of buffers, they are made up at 5X concentration and 
diluted to 1X working concentrations immediately prior to use, as required.  
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2.3.23 Quantitative Real Time Polymerase Chain Reaction 
 
The polymerase chain reaction (PCR) is a process whereby nucleic acid, in this 
case, DNA is amplified many thousand-fold, thus generating sufficient material 
for experimental analysis. For genotyping, genomic DNA is used to determine 
any polymorphic alterations and for gene expression studies, messenger RNA 
(mRNA) is detected using primers that span an exon. Quantitative real time PCR 
(qRT-PCR) has been developed from basic PCR, to allow the measurement of 
PCR products as they accumulate. Detection of a fluorescent signal, generated 
each time the target sequence is amplified, i.e. one cycle, allows quantification. 
The cycle number at which the fluorescence reaches a threshold value of ten-
times the standard deviation of baseline fluorescence emission is used for the 
quantitative measurement. This cycle number is termed the threshold cycle (Ct) 
value and is defined as the fractional PCR cycle number at which the fluorescent 
signal is greater than the minimal detection level.  
 
2.3.23.1 Genotyping via quantitative polymerase chain reaction 
 
Genomic DNA, obtained by the method described in section 2.3.13 was 
amplified in 96-well plates by qRT-PCR on a Biorad iCycler instrument (Biorad 
Laboratories, UK). Each PCR reaction had a final volume of 25µl comprising 
11.25µl DNA (40ng per well or nuclease-free water if a no-template control), 
13.75µl of Taqman Drug Metabolism Genotyping Reaction Mixture (Applied 
Biosystems, UK) diluted ten-fold in Taqman Universal Master Mix (without the 
addition of Amperase UNG). Each two-step PCR cycle comprised of denaturing 
(15 seconds at 92
o
C) and annealing/extending (90 seconds at 60
o
C).  
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At the end of each run a final melt curve cycle was performed (cooling to 50
o
C 
and then increasing stepwise 1
o
C to 95
o
C) was performed to exclude the presence 
of primer-dimer artefacts. The results were analysed and statistical tests carried 
out according to the methods described in section 4.2.4.  
 
2.3.23.2 Extraction of ribonucleic acid for use in gene expression studies via 
Quantitative Real Time Polymerase Chain Reaction 
 
RNA extraction was performed using an Ambion Recoverall kit™.  Briefly, the 
sample lysates were slow thawed at +4˚C and gently vortexed prior to the 
addition of 550 µl of 100 % ethanol in each tube. Debris was removed from the 
lysate/ethanol mix by pre-filtering with a Nucelospin® filter spin column with 
collection tube. 700 µl of each sample lysate/ethanol mix was loaded into 
corresponding labelled filter column, sealed and microfuged at 11,000rpm (11 
000g) for 1 minute.  The remaining lysate/ethanol mix was loaded into the 
corresponding filter tube and microfuged again as described above.  
 
The 700µl of filtrate was loaded into an Ambion Recoverall kit™ cartridge for 
RNA isolation, previously inserted in collection tubes, and the lysate/ethanol mix 
pipetted onto the centre of each cartridge.  The cartridges were centrifuged at 
10,000rpm (10 000g) for 60 seconds, the flow through discarded and the filter 
cartridge re-inserted into the same collection tube.  This was repeated two 
additional times until all the lysate had been processed for each sample. The 
cartridges were washed according to the manufacturer‟s instructions and the flow 
through discarded.   
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DNase treatment of the immobilised nucleic acids was performed by the addition 
of 60µl of DNase mix to the centre of each filter cartridge. After thirty minute 
incubation at room temperature, the cartridges were washed as previously 
described.  Finally, the filter cartridge was placed into a fresh collection tube and 
50 µl of heated (95 ºC) nuclease free water placed into the centre of the filter.  
Following sixty seconds incubation at room temperature, the filters were 
microfuged for 60 seconds at 13,000rpm/13 000g.  This was repeated to give a 
final volume of 100 µl total RNA.   
 
Purity and quantity was checked by spectrophotometry at 260 nm and 280 nm by 
placing 1.4 µl of eluent on the sampling pedestal of a scanning NanoDrop ND-
1000 spectrophotometer (see 2.3.14). Aliquots of each sample were stored at -
80ºC or reverse transcribed to produce cDNA in a two step RT-PCR reaction.  
 
2.3.23.3 Reverse Transcription of extracted RNA for gene expression studies 
via Quantitative Real Time Polymerase Chain Reaction 
 
Reverse transcription was performed using an ABI High-Capacity cDNA 
Archive Kit according to the manufacturer‟s instructions.  Briefly, a 75 µl aliquot 
of master mix was added to a 0.2 ml PCR tube, to which an equal volume of 
purified RNA, diluted in nuclease free water, was added. For RT negative wells, 
a 15 µl master mix aliquot was prepared where the multiscribe RT enzyme was 
substituted with nuclease-free water. To this was added 15 µl of diluted RNA in 
nuclease-free water.  The final RNA concentration in the RT mix was 1-20 ng/µl. 
The tubes were kept in a chilled cooling block until ready to load into the thermal 
cycler (Hybaid Omn-E).   
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Cycling conditions were step 1, 25 °C x 10 min, step 2, 37 °C for 120 min. After 
removal from the thermal cycler, the tubes were pulse spun in a microfuge at 
12,000rpm (12 000g) for 30 seconds and stored overnight at +4 ºC. Synthesised 
cDNA content was measured using a NanoDrop spectrophotometer prior to use.  
 
2.3.24 Statistical analyses 
 
All raw data was transferred into Microsoft Excel and statistical analyses were 
performed using Graphpad Instat 3 and Graphpad Prism 5. Please see individual 
chapters for further details of the exact tests performed.  
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3 Comparing chemosensitivity assays for measuring the 
efficiency of agents with potential for killing glioma cells 
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3.1 Introduction 
 
 
Data available from previous research has shown Clomipramine to successfully 
induce apoptotic cell death in malignant glioma cells using the oxygen electrode 
(Hansatech Instruments), DNA laddering, caspase assays and mitochondrial 
membrane potential assays. It has also been observed that Clomipramine exerts 
its effects independently of p53 regulation (Daley 2001). There exist a number of 
antidepressant and antipsychotic agents that are known to cross the B-BB, some 
of which have been suggested as having potential as anti-tumour agents. By 
comparing three methods for chemosensitivity testing, namely the MTT assay 
(method adapted from (Freshney 2005), ATP-TCA assay (Cree 1998) and the 
Annexin-V Assay (protocol developed in-house) it might be possible to identify 
the most sensitive method for rapidly assessing the potential of new agents. The 
published data on the ATP-TCA describe it to be a superior method to the MTT 
assay based upon sensitivity, reproducibility, linearity, precision to measure as 
few as 39 cells per well (Andreotti, Cree et al. 1995). The inclusion of foetal 
bovine serum in assay media increases growth and survival of both normal and 
malignant cells, whereas the serum-free system of the ATP-TCA assay supports 
only malignant cells via endogenous cell factors (Andreotti, Linder et al. 1994). 
Traditional assays can deliver slightly ambiguous results as homogenous high 
passage cell lines provide little insight into the mechanism of cell kill (and 
whether indeed cells die via apoptosis or necrosis) as the apoptotic threshold is 
lowered with increasing passage number (Parker and Pilkington 2006).Alongside 
the viability assay it is important to consider whether the agent is causing 
apoptosis or necrosis and this can be done rapidly using the Annexin-V assay 
with Staurosporine as a control.  
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Previous research in our laboratories, and others, has shown that Clomipramine 
hydrochloride, a TCA in use for over forty years, has the ability to induce 
apoptosis in malignant glioma cells in vitro (Daley 2001; Daley, Wilkie et al. 
2005; Levkovitz, Gil-Ad et al. 2005; Meredith, Holder et al. 2005; Parker and 
Pilkington 2006).Thus, following the initiation of a clinical trial of Clomipramine 
in patients with primary GBM and grade III Astrocytoma, based at King‟s 
College Hospital, London (LREC 01-235), it was important to attempt to predict 
the efficacy of a given drug treatment, especially in the case of glioma which are 
often characterised by a poor prognosis.  
 
The complexity of the mechanisms behind invasion of neoplastic cells into the 
brain has been an encumbrance to the development of new therapeutic modalities 
for malignant brain tumours. Current drug strategies are found to be ineffective 
in targeting the invading cell population, since they are prevented from entry to 
the normal brain by the B-BB. They are able to reach the tumour site due to local 
disruption of the blood-brain-tumour-barrier (BBTB), due in part to the secretion 
of angiogenic factors during co-option of blood vessels, however guerrilla cells 
are protected by virtue of their position in an area of intact B-BB. Radiotherapy 
affects dividing cells but has only been shown to improve survival time in 
primary adult brain tumours – it is not generally used at all in children under the 
age of three years.  
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Inexpensive archival drugs such as Clomipramine and Amitriptyline, which we 
know can cross the B-BB, have hitherto been overlooked as potential anti-glioma 
agents. These mitochondrially-acting agents show great potential as they do not 
suffer chemoresistance in the same manner as the DNA-acting agents, which are 
compromised via the innate propensity of neoplastic glial cells to rapidly and 
effectively repair DNA damage.  
 
Prior to clinical trial the general way to assess if a new agent has potential to kill 
tumour cells in vivo in man is to carry out in vitro studies on human brain tumour 
cells. This gives an indication of the efficacy of the drug should it reach the 
tumour bed. The in vitro assays do not take into consideration the B-BB or the 
blood brain tumour barrier (BBTB), which are the major reasons for the failure 
of CT, but it is known that the B-BB can be disrupted by the growth of a tumour 
(Galanis and Buckner 2000), thus allowing the drug to reach the CNS. Research 
has also been carried out into increasing the permeability of the B-BB, via 
osmotic induction (combined with pre-treatment of calcium and sodium channel 
blockers)(Neuwelt, Frenkel et al. 1979; Neuwelt 1980; Gumerlock, Belshe et al. 
1992; Siegal, Rubinstein et al. 2000), mannitol (Neuwelt, Frenkel et al. 1979; 
Zunkeler, Carson et al. 1996) and bradykinin (Raymond, Robertson et al. 1986; 
Bartus, Elliott et al. 1996; Elliott, Hayward et al. 1996; Koga, Inamura et al. 
1996; Matsukado, Inamura et al. 1996; Emerich, Snodgrass et al. 1999; Bartus, 
Snodgrass et al. 2000; Borlongan and Emerich 2003).  
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Once biopsy tissue has been surgically dissected from its in vivo environment 
therein follows the question of viability. It is fundamental to ascertain the 
viability of cells derived from biopsy tissue so that reliable cytotoxicity testing 
can be performed. The development of a reliable method for chemosensitivity 
testing in vitro has been a longstanding objective in cancer research. Early 
attempts to stratify patients for chemotherapy were based upon clonogenic 
assays, the ability of single cells to clone themselves into a colony. These assays 
were successful only when culturing high-passage cell lines, the plating 
efficiency of primary tumour cells derived from patients was only around 1-2% 
(Salmon 1987).  
 
Toxicity is a complex event in vivo where there may be direct damage to cells by 
a cytotoxic anticancer agent, such as neurotoxicity in the brain, inflammatory 
events and systemic effects. Currently it is not possible to assess the extent of 
any systemic and physiological effects in vitro as available assays generally act 
at the cellular level. The definition of cytotoxicity varies depending on whether 
cells are killed or their metabolism is altered. In the case of anticancer agents the 
focus is on the ability of the test agent to induce cell death, preferably via 
apoptosis.  
 
Cell growth is generally defined as the regenerative potential of cells; this can be 
determined by clonal growth, net change in population size and change in cell 
mass or metabolic activity. It is important, when measuring the effect on cell 
growth, to remember the differences that exist between the in vivo and in vitro 
measurements.  
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Currently there is no in vitro model that takes into account the presence of the B-
BB, and for this reason inhibitory concentrations achieved in vitro cannot be 
directly extrapolated to determine the efficacy of a drug regimen. It is possible to 
measure the plasma concentrations of cytotoxic anticancer agents and even 
though it is tempting to postulate how much of the active metabolite travels 
across the B-BB into the tumour site, it is not currently possible to measure the 
exact perfusion of an agent to the tumour site.  
 
A study is underway currently, however, to determine the concentration of 
Clomipramine at the brain tumour site, using patients who receive the drug 
orally. Through the use of microdialysis electrodes implanted both intra-
tumourally and in the adjacent normal brain it is hoped that levels that cross the 
B-BB and sequester into the tumour and non-neoplastic cells, respectively, can 
be determined (Cruickshank, G; Birmingham, UK). Regional distribution 
concentrations of Clomipramine in the rat brain have been determined via HPLC 
following administration of 15mg/kg; the data showed that the cerebral cortex 
had the highest concentration (2.9 µg/mg), with successively lower 
concentrations in the hypothalamus, striatum, cerebellum, hippocampus and 
brainstem (Aitchison, Datla et al. 2009). 
 
The MTT assay measures continued metabolic activity of cells over a fixed time 
period. The reduction of the tetrazolium salt to formazan (via the succinate 
dehydrogenase enzyme present in cells) is measured to calculate metabolic 
viability or proliferative ability after the removal of a cytotoxic agent.  
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The assay used in this study was adapted from Freshney (Freshney 2005) and is 
relevant for the assessment of cytotoxicity of Clomipramine which exerts its 
effect through the mitochondria. The cells were exposed to Clomipramine and 
then after washing with warm phosphate buffered saline (PBS) the cells were 
allowed to recover for 24 hours.  
 
Washing the plates is essential to allow the recovery of cells, simply removing 
the media and replacing with fresh media is not sufficient to ensure the complete 
elimination of any test agent. Any cell debris is washed away, leaving adhered 
cells attached to the bottom of the plate wells, to allow any cytostatic or 
senescent cells to recover. By including a recovery period the method 
encompasses both the antimetabolic and antiproliferative capabilities of the test 
agent, neither of which can be demonstrated by senescent or cytostatic cells.  
 
Cells require a continual input of free energy for three major purposes: two of 
which are the active transport of molecules and ions and the synthesis of 
macromolecules and other biomolecules from simple precursors. The free energy 
used in these processes, which maintains a cell in a state that is far from 
equilibrium, is derived from the surrounding microenvironment. In most 
processes, the carrier of free energy is ATP. ATP is an energy-rich molecule 
because its triphosphate unit contains two phosphoanhydride bonds. The turnover 
of ATP is very high because motility, active transport, signal amplification, and 
biosynthesis (needed for cell proliferation) can occur only if ATP is continuously 
regenerated from adenosine diphosphates (ADP).  
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Therefore, measurement of ATP can serve as a marker for cell proliferation. The 
determination of ATP using bioluminescence is a well established technique. It 
uses the ATP dependency of the light-emitting, luciferase-catalysed oxidation of 
luciferin for the measurement of extremely low concentrations of ATP (Cree 
1998). 
 
The serum-free growth conditions of the ATP-TCA assay facilitate selective 
growth of malignant cells and the results are reported to give good correlation 
with clinical outcome in ovarian carcinoma (Andreotti, Cree et al. 1995; 
Kurbacher, Bruckner et al. 1997; Kurbacher, Cree et al. 1998), breast carcinoma 
(Cree, Kurbacher et al. 1996; Kurbacher, Cree et al. 1996) and melanoma (Cree, 
Neale et al. 1999).  
 
The test dose concentrations (TDCs) used in both assays are traditionally taken 
from data available through phase I clinical trial, however these levels for use in 
brain tumours (rather than depression) were established from levels measured in 
plasma (see chapter 4) and the concentrations seen in cyst fluid. All tricyclic 
agents for MTT and ATP-TCA assay were deemed to have a TDC (100%) of 
100µM.  Traditional assays utilising extremely homogenous high passage cell 
lines provide little insight into the mechanism of cell kill or the true IC50 or IC90 
as the apoptotic threshold is lowered with increasing passage number (Parker and 
Pilkington 2006). Alongside the viability assay it is important to consider 
whether the agent is causing apoptosis or necrosis and this can be done rapidly 
using the Annexin-V assay with Staurosporine as a control.  
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Clomipramine (50µM) has previously been reported to exert an apoptotic effect  
on human myeloid leukaemia HL-60 cells (Xia, DePierre et al. 1998), C6 glioma 
cells (25µM) on and human Neuroblastoma SH-SY5Y cells (20µM) (Levkovitz, 
Gil-Ad et al. 2005). It has also been demonstrated that synergism can be 
achieved by applying Gleevec and Clomipramine in combination (Bilir, Erguven 
et al. 2008). Significant morphological changes following incubation with 12µM 
Clomipramine, represented by red (Propridium iodide) fluorescence of 
fragmented apoptotic nuclei, were observed by Levkovitz et al. (Levkovitz, Gil-
Ad et al. 2005) when compared to blue (Hoechst) fluorescence of the intact 
nuclei treated with vehicle (saline). Similar morphological findings were 
presented by Daley when human malignant glioma cells were incubated with 
Clomipramine (maximum incubation period of four hours) and subsequently 
stained with ethidium bromide and acridine orange (Daley 2001).  
 
Internucleosomal DNA fragmentation measured by electrophoresis in glioma cell 
lines was also demonstrated by Daley confirming DNA laddering and hence 
condensation of chromatin, the „classic‟ hallmark of apoptosis (Daley 2001). 
These findings, from the literature on Clomipramine, confirm the potent 
apoptotic effect that Clomipramine has on tumour cells. They also observe the 
higher resistance of primary cell cultures (Gil-Ad, Shtaif et al. 2004; Parker and 
Pilkington 2006) which can be accounted for, in part, by the high proportion of 
non-neoplastic cells maintained in these short-term, low passage, cultures but 
may also reflect the presence of particularly resistant sub-populations of 
neoplastic cells in early passage culture, such as cancer stem cells.  
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Apoptosis after Clomipramine treatment is associated with the intrinsic pathway 
of mitochondrial cytochrome C release (Daley, Wilkie et al. 2005; Levkovitz, 
Gil-Ad et al. 2005), following a rapid increase in p-c-Jun (Levkovitz, Gil-Ad et 
al. 2005), and activation of caspase 9 (Ekert, Read et al. 2004).  
 
The two main pathways of apoptosis can be identified in mammalian cells, both 
controlled by caspases and eventually converge on „executioner‟ caspase 3 
(Cohen, Wilson et al. 2004), which is responsible for the cleavage of structural 
cytoplasmic and nuclear proteins, with consequent cell death and collapse 
(Ceruti, Mazzola et al. 2005).  
 
The capabilities of chemosensitivity are far-reaching when screening new agents, 
and by using assays that analyse the activity of the succinate dehydrogenase 
enzyme, or ATP activity, of the electron transport chain, in individual tumours, it 
is possible to correlate an in vitro response with the preclinical effect in vivo and 
tailor the chemotherapy to suit the individual (Blumenthal 2005). 
Chemosensitivity is an ex vivo means of determining the cytotoxic, cytostatic or 
apoptotic potential of anticancer agents. It is imperative that all agents undergo 
rigorous in vitro testing and in vivo animal model testing before being subjected 
to clinical studies in man. In addition to the classic DNA-damaging agents such 
as the PCV chemotherapy triad many new classes of drug exist such as kinase 
and non-kinase enzymes, transcription regulators, agents targeting growth 
factors, chemokines, angiogenic regulators and protein-protein interactions 
(Blumenthal 2005).  
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The difficulty when prescribing a chemotherapeutic regimen is that patients with 
similar tumour histology may display different responses due to differences in 
age, metabolic capacity, liver function, diet (vegetarians have a higher blood pH 
extending the half-life of some compounds), concurrent or prophylactic 
medication such as a corticosteroid or anticonvulsant and differences in the ratio 
of component cell sub-populations within heterogeneous glioma.  
 
The aim of this chapter was to compare efficacy and potency of eight tricyclic 
agents using in vitro chemosensitivity screening, thus demonstrating the potential 
of such agents for glioma therapy. Using a range of cell lines and early passage 
cultures would highlight the differing sensitivities and heterogeneity between cell 
lines and early passage cultures. By contrasting and comparing the three in vitro 
assays the study could go some way towards designing an optimum 
chemosensitivity assay.  
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3.2 Methodology 
 
 
The MTT assay was chosen for its reproducibility as well as for the fact that the 
assay measures mitochondrial activity, this is pertinent for the tricyclics which 
act via complex III of the electron transport chain (see 1.12). The MTT assay was 
carried out as previously described in section 2.3.9 using Clomipramine 
hydrochloride, Norclomipramine hydrochloride, Amitriptyline hydrochloride and 
Nortriptyline hydrochloride on four early passage cell cultures/cell lines and one 
normal human astrocyte early passage culture. All the concentrations were tested 
in triplicate, within one plate and co-efficient of variations calculated. 
 
The ATP-TCA assay was carried out as previously described in section 2.3.10 
using all eight tricyclic agents on five early passage cell cultures/cell lines. In 
addition to those, three „traditional‟ agents, namely BCNU (see 1.7.1 for 
mechanism of action), DTIC (active form of Temozolomide; see 1.8.1 for 
mechanism of action) and AMN107 were tested in parallel on three tumours to 
enable a comparison of the efficacy of DNA-targeting agents to the 
mitochondrially-targeting tricyclics. AMN107, a potential successor to Gleevec, 
is a potent inhibitor of the leukaemia protein Bcr-Abl and, unlike Gleevec, has 
the added advantage of inhibiting both wild-type and mutant forms of the 
chimeric protein (Golemovic, Verstovsek et al. 2005; O'Hare, Walters et al. 
2005; O'Hare, Walters et al. 2005; Weisberg, Manley et al. 2005). All the 
concentrations were tested in triplicate, within one plate and co-efficient of 
variations calculated.  
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The purpose of the Annexin V assay was to ascertain at what relevant 
concentrations apoptosis occurs so the concentrations of Clomipramine used in 
the assay were based upon the data generated from the MTT and ATP-TCA 
assays. The concentrations chosen for use, in this assay, are very low compared 
to the levels seen in plasma. However it has not been fully established what 
levels are achieved at the tumour site, although Clomipramine has been shown to 
be measurable in the cyst fluid from one anecdotal patient (unpublished results).  
 
When designing treatment regimens it is important to cause as little disturbance 
to the CNS as possible, as necrotic cells are not cleared by macrophages in the 
same way that suicidal apoptotic cells are and hence leave caseous (a form of 
coagulative necrosis in which the necrotic cells clump together to form a focus 
within an injured tissue) or even calciferous necrotic debris.  
 
The Annexin V Assay was carried out as previously described in section 2.3.6 
using five cell cultures/cell lines and one normal human astrocyte early passage 
culture. Staurosporine, a protein kinase inhibitor capable of inducing apoptosis 
via the prevention of ATP-binding, was used as a positive control so that the 
quadrants on the flow cytometer could be correctly assigned. In order to identify 
where apoptotic cells fall on the histogram (which differs between cell lines 
according to cell size) a positive control is required for each individual sample.  
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Figure 2.3.24.1 Layout of the 96-well plate used for MTT and ATP-TCA 
chemosensitivity assays 
 
The top row of wells contained the triton-x 100 maximal inhibitor (positive 
control), the bottom row of the plate contained only cells and plain media to act 
as a positive control. Rows B to G contained the test agent, in triplicate, which 
was serially diluted as indicated. Four agents were tested per plate. For the MTT 
assay, flat-bottomed wells were used to allow the cells to adhere whereas u-
bottomed plates were used for the ATP-TCA assays to encourage spheroidal 
growth. The test plate in which the MTT assay was run contains flat-bottomed 
wells to encourage two-dimensional monolayer growth. By propagating an 
adherent culture it was possible to perform „washing‟ steps in the protocol, where 
a buffered saline solution was added to all wells to remove any remaining test 
agent. Fresh media was then be added to allow a 24-hour recovery period. It had 
been reported that following exposure to Clomipramine, some brain tumour cells 
were capable of recovery within twenty-four hours (Daley 2001), hence this 
recovery period was incorporated into the assay both to ensure that the actions of 
the test agent were in fact cytotoxic, not cytostatic, and to allow any viable cells 
to proliferate.  
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Since the cells were not adherent in the ATP-TCA assay the protocol was 
slightly different as the cells needed to be lysed with tumour cell extractant 
reagent before an aliquot of the extract transferred to a white 96-well plate for 
luminometry readings to be taken. White plates were used to measure 
bioluminescence because of their reflective properties and the background 
readings (taken automatically by the luminometer) were subtracted from all 
values.  
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3.3 Results 
 
3.3.1 Calculating MTT & ATP-TCA Results 
 
 
Data from the plate reader/luminometer was transferred automatically to an 
Excel spreadsheet where the results were expressed as a percentage inhibition at 
each of the six TDCs tested. Inhibition was calculated using the equation:  
 
Inhibition = 1 – (test – MI)/(MO–MI)_100 
The maximum inhibition (MI) data is obtained from row A of the test plates, in 
which TCER has been applied to cells to ensure 100% cell kill. The zero 
inhibition (MO) data is obtained from row H of the test plates in which cells have 
been incubated with media only to ensure maximum viability. The results are 
interpreted and compared using four parameters. The drug concentrations that 
achieve 50 and/or 90 % growth inhibition (IC50 and IC90 respectively) are 
calculated by interpolation using Excel and a macro in appendix 9.2 which 
compares each inhibitory value to the ones either side of it. The „area under the 
concentration–inhibition curve‟ (IndexAUC) values were calculated from the 
data using the trapezoidal rule, and represent the total amount of drug uptake by 
the tumour cells in the assay. In simple terms; the higher the AUC value, the 
higher the sensitivity of the tumour. A sensitivity index (Index SUM) is 
calculated as the sum of the percentage inhibition at each concentration tested (SI 
= 600 - Σ %Inhibition at 200,100,50,25,12.5 and 6.25% TDC). Previous ATP-
TCA studies have found that this natural logarithmic Index SUM calculated by 
direct addition of the percentage survival at each concentration tested provides a 
better indication of sensitivity or resistance to different drugs in different tumour 
types (Hunter, Sutherland et al. 1993; Konecny, Crohns et al. 2000).  
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The total inhibition of growth resulted in an index of 0 and no inhibition of 
growth at any concentrations produces an index of 600. Any Index SUM value 
falling between 0 and 300 is deemed as „sensitive‟ to the test agent, between 300 
and 350 is deemed as „equivocal‟ and 350 – 600 is deemed „resistant‟.  Statistical 
tests, specifically coefficient of variation, were performed using non-parametric 
methods which did not rely on Gaussian distribution. 
 
Although there is no distinct pattern between tumour grade or passage number of 
cells and the sensitivity of cells to Clomipramine hydrochloride, the results are 
promising and further investigation is warranted. It is interesting to note that 
UPMC, the cells with least sensitivity, appears to be an aggressive tumour that 
presented in accident and emergency and the acutely ill patient did not survive 
surgery. 
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 Clomipramine Norclomipramine Amitriptyline Nortriptyline 
AUC IC 90 IC 50 Index AUC IC 90 IC 50 Index AUC IC 90 IC 50 Index AUC IC 90 IC 50 Index 
UPAB 20357 40.18 26.12 205 7244 12.26 9.57 229 17745 37.55 21.57 204 17895 49.50 20.59 225 
SNB-19 19645 40.06 22.40 162 19192 20.99 3.47 38 16590 45.30 24.72 302 15616 54.67 20.53 283 
DK-MG 14197 23.07 12.05 207 23599 18.11 11.50 2 14685 41.65 21.93 305 3404 43.77 19.63 297 
UPMC 15391 93.79 54.62 270 14069 152.96 58.97 242 12167 194.61 67.40 304 13436 203.76 49.85 314 
UPJM  -  - 17.40 - - - - - - - - - - - - - 
CC-2565 -1290 3628.65 1266.07 736 -1671 5533.10 3073.95 755 -2791 8986.03 4992.24 807 -2685 3047.92 1693.29 821 
Table 3.3.1 A summary tableof AUC, IC90, IC50 and INDEXSUM values for four tricyclic antidepressants analysed using the MTT assay in glioma 
cells 
The data emboldened in grey are values <300 indicating sensitivity in the four tumours tested. Four cell cultures (UPAB, SNB-19, DK-MG and 
UPMC) are sensitive to Clomipramine and Norclomipramine. UPAB is sensitive to Amitriptyline and UPAB, SNB-19 and DK-MG are sensitive 
to Nortriptyline. CC-2565 is not sensitive to any of the four antidepressants tested. UPJM senesced after completing a proportion of experiments 
and so data is not available for all agents tested using the MTT assay, however a prelimary MTT was carried out on UPJM cells using 
Clomipramine Hydrochloride and the IC50 has been included in the table. The data demonstrates the potential for using tricyclic antidepressants 
against malignant glioma and also the variability in IC50 values. The range and standard deviation for Clomipramine in five cell cultures is 42.57 
± 16.58 µM, the range and standard deviation for Norclomipramine in four cell cultures is 55.5 ± 25.62 µM, the range and standard deviation for 
Amitriptyline in four cell cultures is 45.83 ± 22.37 µM and the range and standard deviation for Nortriptyline in four cell cultures is 30.22 ± 
14.81 µM. The IC50 values included for CC-2565 are not „true‟ values as 50% cell kill was not achieved in the assay, they are forecasted values 
given the response that was seen at the concentrations tested. 
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 Clomipramine Norclomipramine Amitriptyline Nortriptyline 
AUC IC 90 IC 50 Index AUC IC 90 IC 50 Index AUC IC 90 IC 50 Index AUC IC 90 IC 50 Index 
UPAB 15245 90.72 52.92 264 19021 12.19 9.19 96 10476 174.67 86.00 415 18660 22.11 11.56 137 
SNB-19 15410 97.32 35.09 228 19301 9.20 3.85 19 12284 171.69 66.32 337 18982 20.19 5.77 72 
DK-MG 13460 163.91 48.48 274 18404 40.81 10.89 115 6671 192.26 130.65 584 16192 47.67 38.92 288 
UPMC 14681 86.53 45.15 356 19327 5.83 3.24 5 15836 80.51 38.86 274 18965 15.30 5.92 62 
UPJM 11386 171.96 85.60 349 18938 16.61 9.54 105   10318 173.07 83.12 444 18281 24.44 17.47 142 
 
Table 3.3.2  A summary table of AUC, IC90, IC50 and INDEXSUM values for four tricyclic antidepressants analysed using the  ATP-TCAin 
glioma cells 
 
The data emboldened in grey are values <300 indicating sensitivity in the five tumours tested. Two of the cell cultures are sensitive to 
Clomipramine, all cell cultures are sensitive to Norclomipramine, one cell culture is sensitive to Amitriptyline and all cell cultures are sensitive 
to Nortriptyline. The data for Norclomipramine agrees with that of the MTT (see Table 3.3.1) and all cell cultures are sensitive, whereas here 
UPMC and UPJM are shown to have equivocal values for Clomipramine. The data for Amitriptyline does not agree with that of MTT, here 
UPMC is sensitive. The MTT assay suggested UPMC was not sensitive to Nortriptyline whereas the ATP-TCA assay shows it has the lowest 
sensitivity index. CC-2565 was not included in the panel of established cell lines/early passage cultures assayed using the ATP-TCA due to the 
length of incubation period being 6 days. The very nature of the assay is that under serum-free conditions only neoplastic tumour cells are viable 
after six days (which means normal brain cells would not survive) and normal human astrocytes require the presence of serum to establish 
themselves as reactive astrocytes in culture. The data again demonstrates variability across the IC50 values; the range and standard deviation for 
Clomipramine was 50.51 ± 19.13 µM, the range and standard deviation for Norclomipramine was 7.65 ± 3.53 µM, the range and standard 
deviation for Amitriptyline was 91.79 ± 33.48 µM and the range and standard deviation for Nortriptyline was 33.15 ± 13.72 µM.  
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 Imipramine Promethazine Chlorpromazine Doxepin 
AUC IC 90 IC 50 Index AUC IC 90 IC 50 Index AUC IC 90 IC 50 Index AUC IC 90 IC 50 Index 
UPAB 10067 179.79 97.44 393 13324 159.18 55.53 311 13249 97.66 70.09 352 12696 96.98 62.95 434 
SNB-19 15291 93.49 37.02 279 15319 89.42 44.81 281 14066 98.66 59.63 316 14768 89.91 46.54 330 
DK-MG 12612 213.41 4.92 209 10921 181.91 18.285 262 4916 196.17 146.61 586 2082 192.04 158.40 599 
UPMC 8565 181.38 106.39 467 15269 86.83 42.75 312 16683 82.04 21.75 206 16726 62.04 32.08 234 
UPJM 13715 96.94 56.42 357 13748 170.93 27.39 262 15121 100.22 22.75 271 16403 89.16 20.43 194 
 
 
Table 3.3.3 A summary table of AUC, IC90, IC50 and INDEXSUM values for four additional tricyclic agents analysed using the  ATP-TCA in 
glioma cells 
 
The data emboldened in grey are values <300 indicating sensitivity in the five cell cultures tested. According to the index values SNB-19 is 
sensitive to Imipramine, and Promethazine, UPMC is sensitive to Chlorpromazine and Doxepin and UPJM is sensitive to Promethazine, 
Chlorpromazine and Doxepin. This demonstrates both the potential for use of other compounds with tricyclic structure (two are antidepressants, 
one a sedating antihistamine and one an anti-psychotic) against malignant glioma and also the variability in sensitivities displayed across 
tumours. This data is interesting and warrants further investigation. The area under the curve values represent the amount of drug taken up by the 
cells during the assay, and the lowest AUC values for all assays are seen here for DK-MG exposed to Chlorpromazine and Doxepin.  
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The index SUM values indicate sensitivity of an early passage or established 
culture to a test agent, whereas the IC50 value gives evidence of the degree of cell 
kill when cells are exposed to 50% of the test concentration. In some cases, for 
example UPMC tested via MTT assay, the sensitivity indices show that this early 
passage culture is most sensitive to Norclomipramine, however it is interesting to 
note that the IC50 value for Norclomipramine is higher than the IC50 values 
achieved by Clomipramine and Nortriptyline exposure. The index SUM values 
are based upon area under the curve (test concentration vs. Inhibition) and take 
into account the slope of the inhibitory curve, therefore are more accurate at 
predicting clinical response in patients than referring to a single IC50 value 
(Andreotti, Cree et al. 1995). An IC50 value would be a useful reference marker if 
there was evidence to show what concentration of test agent is present at the 
tumour site. It is difficult to compare the results from the MTT assay (Table 
3.3.1) with those from the ATP-TCA assay (Table 3.3.2) because the MTT assay 
media contains serum and the ATP-TCA media is serum-free. The other main 
differences in the set up of the assays are the adherent growth of cells in the MTT 
assay and spheroidal growth that is encouraged in the ATP-TCA assay and the 
incubation times (2 days for MTT, 6 days for ATP-TCA). One interesting feature 
of the results of the two assays are that the parent drugs have higher IC50 values 
than the metabolites in the ATP-TCA assay and the reverse is seen in the MTT 
assay. This may be due, in part, to the half life of the compounds. The half-lives 
of Clomipramine and Amitriptyline are 21 and 15 hours (on average) 
respectively, whereas those for Norclomipramine and Nortriptyline can be up to 
50 and 90 hours respectively (Nagy and Johansson 1977; Westenberg, De Zeeuw 
et al. 1977; Nagy 1980; Burch, Shaw et al. 1982).  
 157 
Therefore the metabolites retain activity for a longer, and assays that last more 
than 48 hours would show them to be more potent. To accurately compare the 
assays, they would both need to be run over the same number of days. Although 
no discernable pattern of tumour sensitivity (according to tumour grade or type) 
was detected in these samples analysed using the MTT and ATP-TCA assays, the 
diversity of tumour types was small. Further investigation using a diverse range 
of tumour types may yield relevant information.  
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Figure 3.3.1.1 The ATP-TCA results for early passage culture UPMC 
 
To illustrate the data obtained in Table 3.3.2 the results for four test agents have 
been plotted to demonstrate the dose-response curve. Clomipramine is the parent 
drug and Norclomipramine is the active metabolite of Clomipramine. 
Amitriptyline is the parent drug and Nortriptyline is the active metabolite. This 
graph represents one 96-well plate, in which each test drug concentration has 
been tested in triplicate. Error bars are smaller than the symbols and have been 
omitted; they do however demonstrate the reproducibility of the method. The 
coefficient of variation (CV) for this test plate was 10.59%. This value was 
calculated using the negative control wells and demonstrates the accuracy and 
reproducibility of the method. Any plates with CV‟s greater than 20% were 
discarded and repeated. Because the CV values would be adversely affected by 
clumping of cells or infection of primary cultures this is an accurate calculation 
of accuracy and a method of quality control. The most active tested was 
Norclomipramine, according to the Index SUM values. All tumours were 
sensitive to this agent. The values were the lowest of all the drugs tested. The 
agents with least efficacy across all cells tested were Imipramine and 
Amitriptyline, with only one cell culture demonstrating sensitivity in each case. 
There is no pattern of which cells will be sensitive to which agent; this further 
demonstrates the need for treating patients on an individual basis.
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 SNB-19 UPAB UPMC DK-MG 
AUC IC 90 IC 50 Index AUC IC 90 IC 50 Index AUC IC 90 IC 50 Index AUC IC 90 IC 50 Index 
AMN107 10580.99 199.97 80.82 403.99 11182.46 252.70 71.41 364.15 11384.20 138.28 78.71 418.96 9933 1518.16 13.61 303 
BCNU 8038.34 216.74 114.37 428.29 1426.18 5272.39 2929.11 542.78 4658.61 456.03 253.35 476.23 9070 284.19 87.94 369 
DTIC 1369.09 985.93 547.74 588.83 3398.34 848.02 471.12 512.59 5357.35 739.08 410.60 415.40 2184 725.66 405.14 583 
Table 3.3.4  A summary table of AUC, IC90, IC50 and INDEXSUM values for the data obtained via ATP-TCA for AMN107, BCNU and DTIC in 
four malignant glioma  
 
Established cell lines SNB-19, DK-MG and early passage cultures UPAB and UPMC were plated individually for ATP-TCA analysis, each with 
three test agents AMN107, BCNU and DTIC. Two of these are the „standard‟ chemotherapy agents administered for GBMs under NICE 
guidelines, namely BCNU (in the form of a Gliadel wafer, see 1.8.3) and DTIC (the active form of Temozolomide, see 1.8.1). AMN107 is a 
potential successor to Gleevec which has previously been tested in clinical trial for brain tumours (see 1.8.2). The reason for choosing these 
agents are that the TDCs have been calculated and tested for routine chemosensitivity testing in other types of tumour. None of the cells are 
sensitive to these agents. When compared to data from ATP-TCA analysis of the tricyclic agents it would appear, according the Index SUM 
values that the three cell cultures tested are sensitive to novel tricyclic agents and resistant to standard chemotherapy.  
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 SNB-19 DK-MG UPAB UPMC UPJM CC-2565 
Apoptosis (%) 
Control Sample 1.25 2.05 2.27 10.77 3.03 0.36 
Staurosporine (6hr 1 µM 
control) 
21.47 71.56 5.04 47.43 38.94 1.94 
 
 
20µM 
6h 1.25 1.87 2.35 9.96 1.01 0.29 
5h 0.92 1.50 3.21 10.81 3.20 4.68 
4h 0.95 1.38 2.11 12.74 0.50 3.21 
3h 1.29 1.18 3.00 11.72 0.88 2.51 
2h 0.71 1.40 1.87 10.99 0.24 4.12 
1h 1.45 1.03 1.46 10.13 1.31 2.98 
 
 
40µM 
6h 3.67 1.95 2.84 11.67 N/D 3.62 
5h 2.69 2.64 3.45 13.32 N/D 3.28 
4h 2.13 1.30 4.19 14.11 N/D 2.92 
3h 2.11 5.39 2.93 12.41 N/D 1.55 
2h 2.64 4.26 3.00 12.31 N/D 3.74 
1h 2.72 3.14 4.01 14.03 N/D 3.32 
 
 
60µM 
6h 4.84 23.27 3.86 14.26 N/D 2.86 
5h 5.14 21.44 3.40 12.16 N/D 0.03 
4h 11.50 51.25 2.99 12.80 N/D 5.65 
3h 10.98 18.75 3.71 13.62 N/D 0.32 
2h 5.9 26.53 3.66 12.33 N/D 4.49 
1h 5.31 19.75 3.08 13.47 N/D 3.52 
 
 
80µM 
6h 5.89 27.13 3.00 14.22 12.32 0.23 
5h 15.91 20.86 4.36 14.02 10.00 1.65 
4h 10.55 38.92 3.18 15.88 10.47 0.15 
3h 4.98 42.25 3.31 15.82 N/D 0.05 
2h 9.18 23.76 2.51 13.19 N/D 0.02 
1h 10.27 23.41 3.71 14.59 N/D 0.00 
 
 
100µM 
6h 11.03 49.16 3.91 10.97 10.73 0.36 
5h 2.57 23.18 2.77 12.91 8.64 0.01 
4h 10.91 22.81 2.97 11.64 5.99 3.21 
3h 12.58 17.74 4.98 11.94 10.28 0.04 
2h 17.13 20.66 4.68 10.76 6.50 0.05 
1h 11.00 30.84 2.79 9.41 N/D 0.38 
Table 3.3.5 A summary of the apoptosis data obtained by Annexin V flow 
cytometry for Clomipramine 
Highlighted in bold are the samples at which apoptosis (defined as a sample with greater 
apoptosis than the negative control) was achieved when compared to the negative and 
staurosporine controls, which were cells with no drug and cells with staurosporine added 
respectively. Results are expressed as a percentage of the total cell population analysed 
by flow cytometry. The aim was to examine which of the cell cultures were most 
sensitive to undergoing apoptosis and this table illustrates the differences between the 
cell cultures; with DK-MG being the most responsive when compared to the control 
values. In addition to the results seen in DK-MG there was some apoptosis observed in 
cell line SNB-19 at 60 µM and above, and in UPJM where data is available from 60 µM 
upwards (N/D indicates that there were not enough viable cells present, UPJM was an 
extremely slow-growing diffuse grade II/III astrocytoma that spontaneously senesced 
and so was difficult to propagate: the reason why established cell lines are easier to grow 
and the cells of choice for many researchers).  
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Cells undergoing apoptotic cell death expose their phosphatidyl serine residues 
and are detected by calcium-dependent binding of the Annexin-V reporter probe. 
By using a propridium iodide counter stain it is possible to further distinguish 
cells that are necrotic (or deemed „dead‟ in this case) by virtue of their leaky 
membrane. Cells undergoing apoptotic cell death when exposed to the test agent 
bound to the Annexin-V probe in a non time-dependent manner, however 
without also measuring a marker of the end stages of apoptosis such as 
cytochrome C release it is not possible to determine if the suicide process was 
complete within the six hour experiment. Further work to design a multiplex 
assay, using a second phycoerythrin (PE) laser (in addition to the FITC one used 
for Annexin V) and a cytochrome C marker with a fluorescent PE tag might 
provide useful data.  
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3.4 Annexin-V Results 
 
The MTT data indicates that there is considerable heterogeneity in the sensitivity 
of the cells tested to Clomipramine. The DK-MG cell line was the most sensitive 
to Clomipramine with an IC50 value of 12.05µM.  This correlates with the data 
obtained by Annexin-V which also showed DK-MG to be the most sensitive to 
Clomipramine as determined by percentage of cells dying via apoptosis. The 
least sensitive neoplastic cell culture tested via MTT was UPMC with an IC50 of 
54.62µM. This also correlates well with the Annexin-V data which would 
suggest that, at the concentrations tested, there was no apoptosis occurring when 
compared to apoptosis occurring in the untreated control sample. The results for 
UPMC obtained via the ATP-TCA assay would agree with the MTT and 
Annexin V results, indicating via the Index SUM that UPMC is not sensitive to 
Clomipramine, and that the IC50 is 45.15µM.  
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Figure 3.3.1.1 The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour SNB-19 incubated with 100µM clomipramine 
 
The flow cytometry plot consists of FL-1 data on the horizontal axis: the FL-1 
detector shows cells that have the FITC fluorochrome attached and are 
undergoing apoptosis, against the FL-3 detector which represents leaky (dying 
cells) that have taken up propidium iodide. The graphs show that compared to the 
negative control (A) and the positive control (B) there is apoptosis in all samples 
(C-H respectively. The negative control histogram was divided into three 
sections, live, dead and apoptotic ensuring that <2% cells were contained within 
the apoptotic area and then the template grid was pasted onto all test histograms 
to obtain percentage values for apoptosis.  
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3.5 Discussion 
 
Measuring the potency of chemotherapeutic drugs requires precise and accurate 
laboratory tests, with awareness of the limitations of the assay (Hanauske 1993). 
It is also important to choose a cytotoxicity assay suitable for the proposed cell 
death mechanism (Weyermann, Lochmann et al. 2005). Cytotoxicity assays 
possess some viability-related features, such as dehydrogenase activity or ATP 
amount, and they can be used to indirectly measure the metabolic activity. 
Amongst these, two of them are of highest importance. The MTT and ATP-TCA 
assays have been used to determine in vitro resistance and sensitivity (Wilson, 
Sargent et al. 1990; Sevin, Perras et al. 1993; Cree, Kurbacher et al. 1996; 
Kurbacher, Cree et al. 1998; Taylor, Sargent et al. 2001; Furukawa 2004; 
Nakamura, Saikawa et al. 2006).  
 
Tetrazolium salts have become some of the most widely used tools in cell 
biology for measuring the metabolic activity of cells ranging from mammalian to 
microbial origin. With mammalian cells, fractionation studies indicate that the 
reduced pyridine nucleotide cofactor, NADH, is responsible for most MTT 
reduction and this is supported by studies with whole cells. MTT reduction is 
associated not only with mitochondria, but also with the cytoplasm and with non-
mitochondrial membranes including the endosome/lysosome compartment and 
the plasma membrane. The net positive charge on tetrazolium salts like MTT 
appears to be the predominant factor involved in their cellular uptake via the 
plasma membrane potential.  
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However, second generation tetrazolium dyes that form water-soluble formazans 
and require an intermediate electron acceptor for reduction, are characterised by 
a net negative charge and are therefore largely cell-impermeable. Considerable 
evidence indicates that their reduction occurs at the cell surface, or at the level of 
the plasma membrane via trans-plasma membrane electron transport. The 
implications of these new findings are discussed in terms of the use of 
tetrazolium dyes as indicators of cell metabolism and their applications in cell 
biology (Berridge, Herst et al. 2005). 
 
Cell lines DK-MG and SNB-19 cell lines appeared extremely homogeneous 
(based on cell size and shape) under phase contrast microscopy (see 2.3.2). A 
growing body of literature suggests that high passage cell lines and over sub-
culturing of cells causes alterations in morphology, response to stimuli, growth 
rates, protein expression, transfection and signalling (Briske-Anderson, Finley et 
al. 1997; Chang-Liu and Woloschak 1997; Esquenet, Swinnen et al. 1997; Yu, 
Cook et al. 1997; Wenger, Senft et al. 2004; Sambuy, De Angelis et al. 2005).  It 
has been proposed that cells in culture are stressed, because of the foreign 
environment, and immortalisation causes extra stress because artificially forcing 
cells to express a genetically engineered (possibly non-native) protein such as 
hTERT or SV40 equals extra energy expenditure and finite energy sources 
usually used for growth are depleted (resulting in a slower than normal growth 
rate) (Ryan 2007). Because of the lack of contact with the extra cellular matrix 
(ECM) vital characteristics such as the α5/β1-integrin and fibronectin 
interactions are lost (Schiller and Bittner 1995). Therefore it is very difficult to 
reflect the true in vivo conditions in an in vitro chemosensitivity assay.  
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In the MTT assay it was necessary to remove any residual test agent from the 
cells after the initial 48-hour incubation period and so, as such, there is the 
potential for removing any necrotic cells that have detached from the monolayer.  
 
3.5.1 The importance of the concentration values depend on the levels of 
Clomipramine that can be achieved in vivo 
 
Data from Weigmann et al. indicates that Clomipramine and its metabolite 
(Norclomipramine) are rapidly exchanged between blood and the brain. In a 
study carried out on Sprague-Dawley rats the mean brain concentrations were 
12.5-fold higher for Clomipramine and 7.4-fold higher for Norclomipramine than 
in serum (brain Clomipramine and Norclomipramine levels were 5,593 ng/ml x h 
and 16,622 ng/ml x h respectively whereas serum Clomipramine and 
Norclomipramine levels were 447 ng/ml x h and 2,171 ng/ml x h respectively) 
(Weigmann, Hartter et al. 2000). This study highlighted the need for 
determination of a steady-state Clomipramine concentration rather than after a 
single dose, which could be misleading, and would involve administering 
Clomipramine each day at the same time over a number of days to weeks.  
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3.5.2 Application of the MTT assay in screening mitochondrially-acting 
drugs 
 
The principle of the MTT dye is ideally suited when testing a drug such as 
Clomipramine, which exerts its effect via the mitochondria. However it may be 
useful with future studies to redesign the assay omitting as many washing stages 
as possible, because some of the cells which have not adhered may still be viable, 
but it is vital that the 24 hour recovery period is retained (to ensure that the anti-
proliferative effect of the test agent can be determined). This stage also ensures 
that the test agent has had a true cytotoxic effect, and is not simply acting as a 
cytostatic agent.  
3.5.3 Analysing the Index SUM values 
 
The Index SUM is a natural logarithmic index, ranging from 0 – 600 for 
inhibition, with zero corresponding to complete cell kill, and 600 equating to no 
effect. Examination of the frequency histograms for each of the drugs tested 
shows considerable heterogeneity of chemosensitivity between individual 
tumours for all drugs tested, with the greatest activity (i.e. lowest Index SUM) 
seen for Norclomipramine, while the other test agents showed weaker but more 
variable activity.  The ATP-TCA assay relates to cell proliferation via the 
amount of residual ATP that is quantified by luminescence following detergent 
lysis of the cells. Because ATP degrades rapidly it will not be detected in any 
dead cells, thus the measurements taken represent the degree of cell proliferation 
relative to the negative controls. Stable light-emitting reagents are the best 
reagents suitable for measuring ATP-converting reactions i.e. assays of 
metabolites or oxidative phosphorylation. Using ATP as an endpoint is extremely 
sensitive because measurements can be made down to 1 amol (Lundin 2000).  
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3.5.4 Comparative activity of agents in glioma cell preparations 
 
Norclomipramine was universally the best test agent when assayed via ATP-
TCA and MTT assays. It is the metabolite of Clomipramine; however it is not 
marketed or sold as a drug in its own right. Nortriptyline, which also showed 
considerable anti-tumour activity is manufactured and sold as Allegron® and, as 
such, could be considered as a putative chemotherapeutic option. UPMC was the 
most sensitive to Norclomipramine (Index SUM 5; IC50 3.24µM) in the ATP-
TCA assay which indicates considerable anti-tumour activity. However this 
tumour had an IC50 of 58.97 µM (Index SUM 242) when measured using the 
MTT assay, again this demonstrates the limits of the IC50 value in contrasting 
and comparing sensitivities.  
 
The cell culture UPMC was derived from a biopsy, taken from a 68-year old 
female who presented in accident and emergency with left-sided hemi-plegia. 
The patient died twelve hours after an emergency craniotomy to remove a right 
front-parietal enhancing tumour. This would suggest an extremely aggressive 
tumour that suddenly presented. This may explain the lower sensitivity seen in 
the MTT assay which allows the recovery and proliferation of cells over a 24-
hour period, an aggressive tumour such as this would rapidly proliferate within 
the test wells, and the sensitivity seen in ATP-TCA where cells are not allowed 
to recover before lysing the cells.  
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Amitriptyline was only observed to have anti-tumour activity in UPMC (Index 
SUM 274; IC50 38.86) via ATP-TCA and UPAB (Index SUM 204; IC50 21.57) 
via MTT assay. Again it is interesting to note that a high grade GBM is sensitive 
to agents. All other agents tested (Imipramine, Promethazine, Chlorpromazine 
and Doxepin) showed anti-tumour activity in some of the cell cultures with no 
pattern observed relating to passage number or histological classification. The 
data shows them not to be as effective as Norclomipramine and Nortriptyline at 
the concentrations tested, but Clomipramine, Amitriptyline, Promethazine, 
Chlorpromazine and Doxepin are parent drugs and as it will be predominantly 
the parent drug‟s metabolic product which will act in situ on the brain (as it does 
at a direct cellular level in the in vitro situation) it is more important to study the 
metabolic products. In no cell cultures did these drugs have no observed effect at 
all. This data shows the potential of all eight tricyclic test agents for use in the 
malignant glioma. In a clinical setting it would be clinically useful to test the 
patients‟ tumour cells with the panel of all eight drugs to ensure that the most 
effective agent is selected.  
 
Of the five malignant glioma tested, the two established cell lines (SNB-19 and 
DK-MG) had the lower apoptotic threshold, with a significantly higher 
percentage of apoptotic cells present at 60µM Clomipramine and above. The 
three early passage cultures, developed „in-house‟ from biopsy, had higher 
apoptotic thresholds, withstanding up to 100µM Clomipramine incubation for six 
hours.  
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The normal human astrocytes, tested in parallel, demonstrated that Clomipramine 
did not cause cell death at the concentrations tested. The neoplastic cells at the 
highest passage number (DK-MG) were responsive to Clomipramine in both the 
MTT and ATP-TCA assays; this could be due, in part, to the homogeneity of the 
sample population. Also, it is of interest to note that the Clomipramine was less 
effective at causing apoptosis in the CC-2565 non-neoplastic astrocyte cell line 
than Staurosporine (Table 3.3.5).  
 
3.5.5 Results obtained for Amitriptyline Hydrochloride and Nortriptyline 
Hydrochloride by a supervised project student 
 
 
During the course of the project, a Pharmacy Masters student (Ahmed, T: “The 
effect of Amitriptyline Hydrochloride on glioma cell line IPSB-18” 2005) was 
supervised in performing MTT assays on Glioblastoma multiforme (established) 
cell line IPSB-18. The results show that the IC50 for Amitriptyline was 71.04 µM 
and the IC50 for Nortriptyline was 61.25 µM. The values obtained by the student 
are higher than those obtained in this study on eatablished cell lines DK-MG and 
SNB-19, however IPSB-18 was serially passaged over two hundred times and 
this may influence the ability to undergo apoptosis. The values also agree that a 
GBM (IPSB-18) was sensitive to tricyclic antidepressants and show promise for 
the use of tricyclic antidepressants in glioma therapy. The drawbacks of this 
study were few repetitions of the drug concentrations (although they were 
assayed in triplicate) and different concentrations were used to those in this study 
(0.5 – 1000 µM). The results are extremely limited, however they do support the 
findings of this thesis.  
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3.5.6 Technical considerations and future directions of chemosensitivity 
testing 
 
When designing an in vitro assay it is vital to ensure that the microenvironment 
replicates that of the tumour in situ as closely as possible. The principle behind 
the ATP-TCA assay is that by using a serum-free complete assay media only the 
growth of tumour cells, rather than non-neoplastic cells, will be supported after 
six days in culture. Normal human astrocyte growth is supported by the presence 
of serum (Freshney 2005), as is the growth of microglia when propagating early 
passage cultures or cell lines. When subsequently transferred to serum-free 
conditions both these cell types can survive for only a matter of days. Moreover, 
the use of human serum supplementation (rather than foetal bovine serum or 
foetal calf serum) not only alters growth rate but also changes the adhesive 
properties and antigenic expression of neoplastic cells (Vierck and Dodson 
2000).  
 
 
The TNF family of inflammatory mediators, in particular, can induce caspase-
independent and caspase-dependent pathways to programmed cell death (Lange, 
Thon et al. 2005). The presence of inflammatory mediators in culture could 
potentially have a pro-apoptotic effect. It is for this reason that the ATP-TCA 
assay could be further developed with the addition of M-CSF to the serum-free 
culture media. This would support the survival of microglia and give a more 
accurate representation of induction of apoptosis in vivo.  
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Standard brain tumour cell culture conditions are not ideal (pH and D-glucose 
concentration in the culture medium) and the MTT response may vary greatly in 
viable cells due to the metabolic state of the cells (and the cellular concentration 
of the pyridine nucleotides). Furthermore it has been found that certain drugs, 
such as genistein, inhibit tumour cell growth but increase the production of 
formazan, giving false negative results so care must be taken when assaying new 
agents (Hanauske 1993; Pagliacci, Spinozzi et al. 1993).  
 
Developing a „gold standard‟ chemosensitivity assay for use in brain tumours 
needs to assess the effect on both metabolic activity and proliferation because of 
the ability of neoplastic glial cells to „switch‟ phenotype from proliferative to 
invasive cell. A test agent that appears effective via ATP-TCA assay may have 
the ability to initiate cell death in an experimental plate but in vivo may in fact 
signal tumour cells to switch to an invasive phenotype and migrate away from 
the area of chemotherapeutic assault. Since it is impossible to determine the 
cellular proliferation of primary human tumour cells in vivo an appropriate 
biomarker would need to be employed.  
 
Measuring the effect of a drug on cells in vitro is a tenuous issue due the number 
of events that take place. Traditional assays monitor one aspect of cellular 
function whereas the true picture in vivo encompasses many events taking place 
at the same time. The MTT and ATP assays are metabolic assays and do not 
reflect the ability of cells to proliferate, but it is possible to use a proliferative 
marker. By monitoring the metabolic status of cells, via ATP levels or succinate 
dehydrogenase activity, it is possible to determine cell viability.  
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Whilst ATP is a highly sensitive endpoint it does not reveal the degree of 
proliferation subsequent to drug exposure and a huge drawback is that dead cells 
and cell extracts can be metabolically active. This may explain, in part, the 
results from the MTT and ATP-TCA assays showing that the parent drugs were 
more potent than their metabolites in the MTT assay whereas the reverse was 
observed in the ATP-TCA assay. In contrast, by measuring a proliferative marker 
such as Ornithine decarboxylase (ODC) it is assumed that viable cells are 
actively proliferating which both in vitro and in vivo is not necessarily the case. 
Neoplastic glial cells are capable of senescing or even switching phenotype to 
that of an invading cell, in response to an external insult (Gratsa, Rooprai et al. 
1997). Indeed this is one of the main reasons for the failure of chemotherapy in 
brain tumour patients, single cells are capable of migrating away from the main 
tumour site and establishing themselves in an area of intact B-BB. Many patients 
are treated with ineffective agents, exposed to unnecessary side-effects and 
confer no actual benefit because the resistance to chemotherapeutic agents poorly 
characterised (Jackson 2007). ODC is a universal marker expressed early in the 
cell cycle, with a short half-life that can be used to detect cell proliferation and 
would be useful as a supplementary marker in the MTT and ATP-TCA assays. 
This enzyme catalyses the conversion of Ornithine into the diamine putrescine, 
which is the precursor for the synthesis of the naturally-occurring polyamines 
(Russell 1985; Cohen 1998). Because of the ATP-TCA assay protocol, which 
lyses cells within the test plate and then takes an aliquot for analysis it is possible 
that the remaining cell lysate could be used to measure the levels of ODC. 
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The MTT and ATP-TCA assays were found to be significantly correlated by two 
groups (Hazary, Chaudhuri et al. 2001; Ulukaya, Ozdikicioglu et al. 2008) and 
conversely were reported to show no correlation (Kerokoski, Soininen et al. 
2001). Moreover, it was reported that whilst ATP increased in the first three 
hours of analysis, the reduction of MTT decreased immediately (Liu, Song et al. 
2003). Both assays reflect different aspects of the metabolic status of the cells but 
they can still report different outcomes depending on the time point because of 
the possibility of drug targets (energy sources, signalling molecules and DNA). 
According to the results of Ulukaya et al. cells are able to lose their ATP content 
but still retain some dehydrogenase activity (Ulukaya, Ozdikicioglu et al. 2008). 
This might further explain the observation that the parent drugs were more potent 
than their metabolites in the MTT assay. The ATP assay was found to be able to 
detect lower numbers of cells compared to the MTT assay (Petty, Sutherland et 
al. 1995; Eirheim, Bundgaard et al. 2004). The next steps in this research are to 
combine Clomipramine with other potentially synergistic agents to enhance the 
apoptotic effect. Indeed the relationship between Clomipramine and 
Dexamethasone in a dose-dependent manner have recently been reported in 
neoplastic glia (Higgins and Pilkington 2010).Moreover, it may also be possible 
to isolate cancer stem cells and/or other „clones‟ from heterogeneous primary 
glioma to test the resistance of such subpopulations as well as to investigate the 
influence of hypoxia on drug activity.The difference in sensitivities between 
glioma, in this small study, indicates the importance of analysing early passage 
cultures, which retain original morphology and characteristics to a greater extent, 
alongside cell lines transformed for survival (Baguley and Marshall 2004). 
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4 The influence of cytochrome P450 genotype on 
chemosensitivity of glioma 
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4.1 Introduction 
 
 
Individualising therapy for patients being treated with chemotherapeutic agents is 
now regarded as the most critical goal in cancer chemotherapy. Being able to 
stratify patients as to which agents will work to best effect in each individual will 
reduce the needless administration of broad-spectrum, highly toxic and 
debilitating drug regimens. The planning of treatment modalities for patients 
with high-grade glioma is a challenge harder than that of any other cancer due to 
the extreme vulnerability of the CNS.  
 
Many sources of inter-individual differences exist in drug toxicity and efficacy, 
both pharmacokinetic and pharmacodynamic, as highlighted in Figure 3.5.6.1. 
These differences include body mass and composition, age, ethnicity and sex as 
well as disease state and organ function. Environmental factors include 
interactions with food, drinks, environmental toxins, other drugs (prescription, 
over the counter and herbal formulations), as well as interactions with drug 
formulation components (Deeken, Figg et al. 2007). 
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Figure 3.5.6.1 Sources of inter-individual variability in brain tumour patients 
There are six main areas of variability in brain tumour patients which can affect 
the outcome of a treatment regimen. The factors involved in genetic variation, 
drug metabolism and drug transporters, are investigated in this chapter and 
chapter 6.  
 
There are many factors affecting the efficacy of drug therapies, see Figure 3.5.6.1 
Sources of inter-individual variability in brain tumour patients, however of 
particular relevance to this study are the genetic factors involved in 
heterogeneity, both drug metabolism (in particular the cytochrome p450 family 
of enzymes) and drug transporters (the SLC6A2 norepinephrine transporter; 
NET, see chapter 5). It is possible to examine specific mutations in the genes 
encoding the CYP enzymes that degrade tricyclic antidepressants, to see if there 
is loss or alteration in the drug metabolising capacity of a patient. Drug 
metabolising enzyme (DME) mutations in the genome can determine how well 
an individual patient will tolerate tricyclic antidepressant chemotherapy.  
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4.1.1 Genotyping CYP family enzymes responsible for tricyclic 
antidepressant metabolism in glioma patients 
 
The Cytochrome P450 (CYP450) family of enzymes is expressed in many 
tissues, with the largest activities found in the liver. By conducting oxidative 
metabolism on many endogenous substrates and over ninety percent of drugs, 
their function is of vast clinical relevance and they have therefore been the focus 
of much research over the past decade (Deeken, Figg et al. 2007).  Genetic 
variants, SNPs, exist in these enzymes, and significant alterations in drug 
metabolism, efficacy and toxicity can occur owing to these differences. The CYP 
superfamily consists of more than sixty enzymes that have been grouped into 
several families and subfamilies. Of interest to this particular study are the 
enzymes CYP2D6 and CYP2C19.  
 
The isoenzymes which catalyse the polymorphic hydroxylations of debrisoquine 
and S-mephenytoin are cytochromes P450 2D6 and P450 2C19 (CYP2D6 and 
CYP2C19), respectively (Daly, Cholerton et al. 1993; Bertilsson 1995).  
 
Figure 4.1.1.1 Debrisoquine (specific for CYP2D6) and S-mephenytoin (specific 
for CYP2C19) are reference compounds that define P450 active site specificity 
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CYP2D6 is involved in the stereospecific metabolism of several important 
groups of drugs, including the tricyclic antidepressants Clomipramine and 
Amitriptyline (Scordo, Caputi et al. 2004). CYP2D6 has a significant role in the 
metabolism of many lipophilic agents such as the common antidepressants 
(Clomipramine, Amitriptyline, Desipramine, Paroxetine and Fluoxetine) the 
antipsychotics (Haloperidol, Risperidone and Thioradazin), beta blockers 
(Carvedilol, s-Metaprolol, Propafenone and Timolol), antiarrhythmics 
(Flecainide, Lidocaine) as well as some antiemetics (such as Ondansetron).  
 
Known inhibitors of CYP2D6 include Cimetidine, Fluoxetine, Haloperidone, 
Paroxetine, Methadone and Quinidine (Finn, Purnell et al. 1996). It is pertinent 
that Dexamethasone, which is used to treat oedema in patients with glioma, and 
Rifampin can induce enzymatic activity (Ingelman-Sundberg 2005). The gene 
encoding CYP2D6 is located on 22q13, thus far there have been fifty-eight 
allelic variants described. Including allelic subtypes there are over one hundred 
known variants, including twenty-two null alleles. Approximately 71% of the 
CYP2D6 alleles are functional in Caucasians, whereas 26% are non-functional. 
This is compared with Asians where only 50% of the alleles are functional. This 
may be due to the close proximity of the gene to two pseudogenes (CYP2D7 and 
CYP2D8), as well as the increase in relative activity of the locus with other CYP 
genes (Ingelman-Sundberg 2005). In addition to these variants CYP2D6 gene 
duplication, which results in ultra rapid metabolism, has been identified in 
different ethnic groups at high frequencies (Swedish 2%; German 3.6%; Spanish 
7-10%; Italian 10%; Saudi Arabians 20% and Ethiopians 29%) (Smith 2004).  
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CYP2C19 is involved in the metabolism of some antidepressant and anti-
anxiolytic drugs. The metabolism of Amitriptyline, Citalopram, Clomipramine, 
Diazepam, Imipramine and Moclobemide is catalysed by CYP2C19 (Carrillo, 
Dahl et al. 1996). CYP2C19 is expressed exclusively in the liver and duodenum 
(Totah and Rettie 2005). Commonly used acidic drugs that are metabolised by 
this enzyme include the proton pump inhibitors (Propranolol, Lansoprazole, 
Omeprazole and Pantoprazole), the antiseizure medications (s-mephenytoin and 
Diazepam) as well as Amitriptyline, Citalopram, Proguanil, Propranolol and 
Teniposide. Drugs known to inhibit enzymatic activity include Fluoxetine, 
Lansoprazole, Omeprazole and Ticlopidine (Flockhart 2007). When selecting 
agents such as the tricyclics to target the mitochondria of glioma cells, it is 
important to consider the interactions of any prophylactic agents that a person 
with a brain tumour may already be prescribed, such as Propranolol. Propranolol 
acts via the mitochondrial membrane, is an antagonist of norepinephrine and is 
metabolised via the same enzyme as Amitriptyline so, for example, should these 
two such agents be taken together might have reduced efficacy due to 
competition (Yoshimoto, Echizen et al. 1995; Naritomi, Teramura et al. 2004). 
 
The gene encoding CYP2C19 is located on 10q24, combinations of twenty-three 
different single nucleotide polymorphisms (SNPs) in exon encoding regions 
comprise twenty-five allelic variants (Desta, Zhao et al. 2002). The CYP2C19*2 
and *3 variants both notable for leading to premature stop codons and premature 
truncations of the protein, resulting in a completely inactive enzyme.  
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There is a high frequency of the CYP2C19*2 variant in African-Americans, 
Caucasians and Asians, whereas the CYP2C19*3 is less frequently observed. It 
is estimated that the CYP2C19*2 accounts for approximately seventy-five to 
eighty-five percent of poor metabolisers in Asians and Caucasians.  
 
The CYP2C19*5 and CYP2C19*7 variants lead to translation of inactive 
enzymes, whereas the CYP2C19*6 and CYP2C19*8 variants have two and nine 
percent of the wild-type version, respectively (Goldstein 2001).  The mutations 
seen in a population cause it to be polymorphic; the site on a chromosome at 
which an individual base differs is termed a SNP.  
 
Plasma metabolite/drug ratios differ extensively according to metabolic 
phenotype and administration route. An example of this phenomenon is with the 
drug Risperidone where the plasma metabolite to drug ratio is thirty-fold lower in 
CYP2D6 poor metabolisers, compared to ultra rapid metabolisers, and four-fold 
lower after intramuscular compared to oral administration (Hendset, Haslemo et 
al. 2006). The major route of biotransformation of the parent drug Clomipramine 
is demethylation via the cytochrome P450 liver enzymes to active metabolite 
Norclomipramine (Desmethylclomipramine). Norclomipramine is then further 
hydroxylated to 8- hydroxyl Desmethylclomipramine and Di-
desmethylclomipramine. Clomipramine is also hydroxylated to 8-hydroxy-
clomipramine, via CYP2D6 (Yokono, Morita et al. 2001). The hydroxylation of 
secondary amine TCAs is catalysed by CYP2D6 (Sjoqvist and Bertilsson 1986) 
and the n-demethylation of Clomipramine is catalysed by several enzymes 
including CYP2C19 (Nielsen, Brosen et al. 1994).  
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4.1.1.2 The metabolism of clomipramine hydrochloride and CYP gene 
involvement 
 
The parent drug, Clomipramine hydrochloride, is metabolised into three 
secondary amine structures. Norclomipramine is the most abundant of these and 
is further metabolised into two tertiary structures. Clomipramine is metabolised 
preferentially, but not exclusively by, CYP genes 2D6 and 2C19.  
 
 
 
 
 
 
 
CYP2D6 
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It may be possible to predict the capability to metabolise Clomipramine, and its 
more active metabolite Norclomipramine (because of the higher binding affinity 
for the norepinephrine transporter), via genotypic screening of the two CYP 
genes, CYP2D6 and 2C19. Whilst many studies have been carried out on 
screening the allele and genotype frequencies of the CYP2D6 and CYP2C19 
genes in various populations (Wanwimolruk, Bhawan et al. 1998; Yamada, Dahl 
et al. 1998; Bathum, Skjelbo et al. 1999; Britzi, Bialer et al. 2000; Dandara, 
Masimirembwa et al. 2001; Tamminga, Wemer et al. 2001; Yokono, Morita et al. 
2001; Bozina, Granic et al. 2003; Herrlin, Yasui-Furukori et al. 2003; Luo, 
Aloumanis et al. 2004; Scordo, Caputi et al. 2004; Halling, Petersen et al. 2005) 
only one study by Norguchi et al. (1993) reports that higher plasma 
concentrations of Clomipramine and lower plasma concentrations of 
Norclomipramine predict better clinical outcome in Japanese patients with 
depression despite the fact that Norclomipramine is the active metabolite of 
Clomipramine. This variation could be due to the Japanese diet which is richer in 
fish than red meats (possibly causing a more alkaline pH) and significantly 
differs from that of the Western continents.  
 
Yokono et al. have also studied the metabolism of Clomipramine in a population 
of Japanese psychiatric patients (Yokono, Morita et al. 2001) but to date no 
studies have been performed on the correlation of CYP2D6, CYP2C19 and 
clinical effect of tricyclic antidepressants in cancer patients. 
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By screening a small group of glioma patients already taking Clomipramine and 
genotyping them for expression of the CYP2D6 and CYP2C19 alleles and 
pairing the data with that for concentration of Clomipramine (and its metabolite) 
in their plasma, it may be possible to see if genotype determines ability to 
metabolise Clomipramine. If the results show that genotype does correlate with 
the extent of parent drug metabolised then it might be possible, in brain tumour 
patients who would like to start taking Clomipramine,  to predict how they will 
tolerate Clomipramine before it is prescribed and adjust the dose accordingly to 
minimise side effects. The side effects listed in the British National Formulary 
(BNF) are: arrhythmias and heart blockade, convulsions, hepatic and 
haematological reactions, drowsiness, dry mouth, blurred vision, constipation, 
urinary retention, hyponatraemia and neuroleptic malignant syndrome.  
 
After oral administration some 50% of a dose of Clomipramine undergoes pre-
systemic metabolism to Norclomipramine (Desmethylclomipramine) and secondary 
metabolite 8-hydroxy Desmethylclomipramine (see figure 4.1.1.2). The mean 
plasma elimination half-life of Clomipramine is twenty-five hours (range 20 – 40 
hours). The half-life of Norclomipramine is somewhat longer (as discussed 
previously in 3.3.1) and thus this latter compound accumulates in plasma during 
chronic therapy.  
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When designing drugs for use in brain tumour patients, the primary consideration 
should be the pharmacokinetic profile because ultimately this contributes to the 
success or failure of a compound. As previously indicated in Figure 1.7.5.1, 
newer agents developed for use in glioma are interactive but the high specificity 
achieved by such compounds results in a lower efficacy. Thus, many drug 
companies are carrying out rational high-throughput drug metabolism and drug 
transport screening. Attention is now being focussed on optimising the 
pharmacokinetic profiles of drug candidates using transporter function (Ayrton 
and Morgan 2001; Mizuno and Sugiyama 2002).  
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4.2 Methodology 
 
4.2.1 Clomipramine Questionnaire (LREC04-066) 
 
 
This questionnaire was designed to obtain information on potential variations in 
chemotherapy, prophylactic medication, herbal supplements and lifestyle from 
the patients taking part in the study. It was important to know the body mass of 
the patient and the daily dose of Clomipramine in order to be able to correct the 
plasma concentrations of the antidepressant to a universal unit that can be 
compared between patients.  
 
Other factors can affect the half-life and metabolism of an antidepressant, so 
information on age, other medication (anticonvulsants, steroids) and if they 
smoke or not was relevant to the study.  
 
The patients were asked if they experienced any side effects, however this is a 
difficult factor to assess since something that is perceived as a side-effect by one 
person goes unnoticed in another. The other point to note is that in brain tumour 
patients the side effects could be due to any number of things (location of the 
tumour, other medication) and not a result of taking Clomipramine. 
Clomipramine, as recommended in the BNF, is taken via a dose escalation 
starting at 25mg/day. The recommended daily dose for depression is 30-250 
mg/day (British National Formulary. Higher levels can be tolerated but 
Clomipramine has a narrow therapeutic range and when tested in 151 patients (at 
25, 50, 75, 125, and 200 mg/day) the dose-effect curves were flattened, which 
suggests a disproportionate increase with dose (Gram 1999). 
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Please answer as many of the questions as you can, we want to account for all the 
differences between individuals. 
 
Surname: First Name: 
 
DOB: Approx. Weight: 
 
Approx. Height: Smoker?:               YES/NO 
Ethnic Origin: 
Units of alcohol per week:  
(1 unit = half a pint of beer, 125mls wine, 25mls spirit) 
 
How long have you been taking Clomipramine? 
 
 
What dose are you currently on? 
 
 
Have you always been on this dose?    YES/NO 
 
If no, please detail (if possible) when you last changed it, who recommended the change and why 
e.g. Changed dose from 150mg/day to 100mg/day in July 2004 because of increase in seizures, 
recommended by GP 
 
 
Are you taking an anticonvulsant? If yes, please give details below 
 
 
 
 
Are you taking any other medication? E.g. Dexamethasone 
  
 
 
 
Do you currently experience any side effects? If yes, please give details below 
 
Signature:                     
 
 
Date: 
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4.2.2 High Pressure Liquid Chromatography – Mass Spectrometry 
(HPLC-MS.MS) analysis of the plasma concentration of 
Clomipramine and Norclomipramine 
 
Plasma was obtained from whole blood collected into Lithium/Heparin sample 
tubes. Samples were stored at 4°C prior to analysis. If analysis was delayed then the 
plasma samples were stored at –20°C. Prior to analysis the plasma samples were 
defrosted and gently mixed before a 100µl aliquot was pipetted into an 
appropriately labelled microcentrifuge tube. Calibrators (Chromsystems calibrator 
standard for TCAs), quality controls (Chromsystems control for TCAs) and a blank 
(fresh frozen plasma) were prepared in the same manner. After adding 200µl 
working diluent/internal standard to each sample the tubes were vortexed, flicked to 
break up any clumps and then vortexed once again. All samples were then 
microcentrifuged for five minutes at 10,000 rpm. Subsequently 100µl supernatant 
was pipetted into appropriately labelled analysis vials with crimp caps. The samples 
were loaded onto the autosampler of a Waters Symmetry 300 C18 5µm 2.1 x 
150mm column (WAT106172) with guard column (Phenomenex C18 Security 
Guard KJO-4282). The „blank‟ was loaded into position one followed by the 
calibrant, controls and then patient samples. The analysis consisted of reverse-phase 
liquid chromatography, with detection by triple-quadrupole mass spectrometry. 
This is highly specific with the first quadrupole selecting ion masses equal to that of 
the ammoniated analyte ion (M + NH4
+
). Nitrogen as a collision gas produces 
daughter ions, which are selected in the second quadrupole. A third quadrupole 
selects only ions of the mass of a significant fragment of the analyte. Internal 
quality controls were analysed using QCPlus and deemed acceptable before the 
results were reported. The concentrations were reported to the nearest whole 
number.  
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4.2.3 Calibrating the BioRad iQ Real Time Detection System to detect a 
drug metabolism genotyping assay 
 
To enable the detection of more than one fluorophore it was necessary to 
calibrate the i-Cycler using a standard kit, the calibration kit was used according 
to the manufacturer‟s instructions.  
 
In brief, an external well factor plate was run (to calculate background) using the 
pure dye calibration protocol followed by a 96-well plate loaded with ten wells 
(B2-B11; C2-C11) of each of the two dyes (FAM™ and VIC™). The 
Genotyping Assay, for which this calibration was carried out, required multiplex 
PCR for two CYP genes using the fluorophore FAM™ (Excitation 490/20X; 
Emission 530/30M) and VIC™ (Excitation 530/30X; Emission 575/20M), 
however since a VIC™ calibrator solution was not available from the 
manufacturer it was recommended to use a fluorophore on the same excitation 
and emission spectra, in this instance JOE™.  
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4.2.4 A Taqman Drug Metabolism Genotyping Assay to detect mutations 
in the CYP2D6 and 2C19 alleles responsible for the metabolism of 
Clomipramine hydrochloride 
 
The Taqman 5‟ nuclease assay from Applied Biosystems is a SNP genotyping 
system that enables rapid screening of patient samples via qRT-PCR. PCR 
amplification of genomic DNA with allele-specific primers enables rapid 
prediction of patient drug metabolising genotype and may lead to the adjustment 
of chemotherapeutic dose in the individual patient. Allelic discrimination using 
this method is based on the design of two TaqMan probes, specific for the 
wildtype allele and the mutant allele in a two-allele system. Each of the two 
probes is labelled with a different fluorescent reporter (in this case FAM™ and 
VIC™), and each is designed with the gene mutation affecting the middle part of 
the probe sequence. FAM™ is a green emitting fluorescent reporter tag that has 
an excitatory wavelength of 490nm and emission wavelength of 530nm, VIC™ 
is a yellow emitting fluorescent reporter tag that has an excitatory wavelength of 
530nm and an emission wavelength of 575nm. When using two reporter tags it is 
important to choose two that emit at different wavelengths, so that they can be 
discriminated from each other. Well factors were collected before each run using 
iCycler iQ external well factor solution (Bio Rad) because collection of well 
factor data optimises fluorescent data quality and analysis in multiplex PCR.  
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The finger-prick blood samples of seventeen brain tumour patients (see Table 
4.2.2 for tumour types and grades), who had been taking clomipramine for a 
minimum of two weeks, were processed as described in section 2.3.13 and the 
genomic DNA (gDNA) quantified as described in section 2.3.14. After vortexing 
all samples, the DNA was plated at a concentration of 40ng complementary 
DNA (cDNA) per well according to the worksheet and analysed via quantitative 
Real Time PCR qRT-PCR) (section 2.3.23).  
 
Each PCR reaction had a final volume of 25µl comprising of 11.25µl of gDNA 
(diluted with the appropriate volume of nuclease-free water) and 13.75µl of the 
Applied Biosystems Taqman Drug Metabolism Genotyping Assay 
(CYP2D6*2X3 C_27102414_10; CYP2C19*2A C_1329163_10) to detect the 
SNPs involved with alleles 2X3 and 2A, respectively, which had been diluted 
tenfold with Taqman Universal Master Mix (without Amperase UNG). 
 
The two assays chosen for preliminary analysis were for alleles CYP2D6*2X3 
and CYP2C19*2A with minor allele frequencies in Caucasians of 0.46 and 0.15 
respectively. Because readymade SNP assays are only recently available from 
Applied Biosystems there are a limited number of assays available, especially for 
2C19. Because of the high cost involved these two were chosen to be the most 
relevant in this study. In a clinical setting, genotyping for one allele only would 
be of limited use. Instead one would need to screen patients for all alleles related 
to the CYP gene in question, taking into account ethnicity and minor allele 
frequencies. 
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The context sequence representation for the mis-sense mutation seen on allele 
CYP2D6*2X3 was AGCACAAAGCTCATAGGGGGATGGG[C/G]TCACCAG 
GAAAGCAAAGACACCATG and for the silent mutation on allele 
CYP2C19*2A was GGAGAGGAAAACTCCCTCCTGGCCC[C/T]ACTCCTCT 
CCCAGTGATTGGAAATA. This means that for CYP2D6 the SNP [C/G] can 
be read as C = wildtype allele 1 (VIC) and G = mutant allele 2 (FAM). For 
CYP2C19 the SNP [C/T] can be read as C = wildtype allele 1 (VIC) and T = 
mutant allele 2 (FAM). Forward and reverse primers were designed around the 
context sequence (the primer design information is not available to end-user), the 
forward primer meant that the probe bound to the same strand as the forward 
primer and the reverse primer caused the probe to bind to the same strand as the 
reverse primer.  
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Figure 4.2.4.1 The principle behind the Taqman genotyping results for 
identifying mutations in the alleles of CYP2D6 and 2C19 
 
The figure above shows results from matches and mismatches between target and 
probe sequences in TaqMan Drug Metabolism Genotyping Assays. In this case 
the target is mutations in CYPs 2D6 and 2C19. The major groove binder binds to 
its complementary sequence between forward and reverse primer sites. When the 
oligonucleotide probe is intact, the proximity of reporter dye to quencher dye 
results in quenching of reporter fluorescence by Forster-type energy transfer 
(FRET). The AmplitaqGold DNA Polymerase extends the primers bound to the 
genomic DNA template and cleaves only probes that are hybridised to the target. 
Cleavage separates the reporter from the quencher and results in a fluorescence 
increase;, this means the allele is present. Even a single nucleotide mismatch 
between the probe and target can reduce the efficiency enough to reduce the 
degree of reporter dye cleavage, and in turn the fluorescence.  
 
The major groove binder increases the melting temperature (Tm) for a given 
probe length which allows the design of shorter probes. The greater difference in 
Tm values between matched and mismatched probes provides extremely robust 
allelic discrimination. Product amplification was performed up to forty cycles on 
a Biorad i-Cycler instrument (Biorad Laboratories, UK) after polymerase 
activation (10 minutes at 95
o
C). 
Amplitaq Gold DNA Polymerase       Reporter Dye
  
  Non-fluorescent Quencher   Minor Groove Binder 
 
 
 
 
  
MATCH 
MISMATCH 
 194 
 
Table 4.2.1 Calculation of the cDNA/nuclease free water dilution to ensure that all test wells had 40ng of template 
The template was calculated for six wells plus one extra well to take into account any pipetting error. Samples were plated inside a dedicated 
class II laminar flow cabinet using DNAse/RNAse free consumables to ensure no genomic contamination occurred and a no-template control 
(mastermix, probe and nuclease-free water only) was used to double check that no contamination was present.
  Sample 
cDNA ng/ µL                      
[nano-drop] cDNA ul/well Total Vol µL / plate (a) Promega water (b) 
Control Control 13.14 3.0 21.3 57.4 
S1 ANEC001 9.37 4.3 30.1 48.6 
S2 ANEC010 20.65 1.9 13.6 65.2 
S3 ANEC011 7.84 5.1 35.7 43.0 
S4 ANEC012 8.61 4.6 32.5 46.2 
S5 ANEC013 28.57 1.4 9.8 68.9 
S6 ANEC014 8.72 4.6 32.1 46.6 
NTC CONTROL   0 0.0 0.0 78.8 
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  Tumour Type Age Sex 
Mass 
(kg) 
Dose of Clom 
(mg/day) Time on Clom Other medication Perceived Side Effects Smoker Ethnic Origin 
ANEC001 Oligodendroglioma Grade II 39 M 78.00 150.00 2 years Keppra, Tegretol Lethargy, insomnia, weight gain No White British 
ANEC004 
Glioblastoma multiforme 
Grade IV 42 F 62.00 25.00 6 months Keppra, Tegretol, PCV Lethargy  No White British 
ANEC008 Oligodendroglioma Grade III 41 F 57.15 150.00 5 years Tegretol Dry mouth, hot flushes, low libido Yes White British 
ANEC010 Oligodendroglioma Grade II 41 F 63.50 100.00 3.5 years Tegretol, Keppra Increase in partial seizures No White British 
ANEC011 
Glioblastoma multiforme 
Grade IV 54 F 55.00 150.00 4 years Phenytoin Low libido No White British 
ANEC012 
Metastatic breast 
adenocarcinoma 63 F 60.30 100.00 1.5 years 
Epanutin, Dexamethasone, 
Ranitidine Mild seizures No White British 
ANEC013 
Glioblastoma multiforme 
Grade IV 30 M 103.00 150.00 18 months 
Dexamethasone, Phenytoin, 
Omeprazole Shaking hand No White British 
ANEC014 Astrocytoma Grade II 60 M 92.00 150.00 15 months 
Epanutin, Dexamethasone, 
Simvastin, Ramipril None No White British 
ANEC015 
Glioblastoma multiforme 
Grade IV 54 M 80.20 150.00 23 months Phenytoin Dry mouth, lethargy No White British 
ANEC016 
Glioblastoma multiforme 
Grade IV 45 F 45.00 100.00 3 weeks 
Tegretol, Dexamethasone, 
Zoton, Domperidone Dry mouth, constipation No White British 
ANEC018 Oligoastrocytoma Grade III 36 M 82.50 150.00 8 months Celebrex, Tamoxifen None No White British 
ANEC019 
Glioblastoma multiforme 
Grade IV 59 F 60.00 75.00 18 months Epilim Shaking hands, impaired speech No White British 
ANEC020 
Gemistocystic Astrocytoma 
Grade IV 37 F 65.00 150.00 18 months 
Tegretol, Iscador, 
Multivitamins Dry mouth, lethargy No White British 
ANEC021 
Brain Stem Glioma 
Grade IV 40 M 76.20 75.00 18 months None None No White British 
ANEC022 Gliomatosis cerebri 33 M 97.00 100.00 2.5 years 
Tegretol, Dexamethasone, 
Glidazide, Pantoprazole Slight twitching, weight gain No White British 
ANEC024 
Glioblastoma multiforme 
Grade IV 37 M 72.00 150.00 3.5 months 
Phenytoin, Keppra, 
Dexamethasone, 
Temozolomide Dry mouth, excessive sweating No White British 
ANEC028 
Glioblastoma multiforme 
Grade IV 73 M 80.00 150.00 4 weeks 
Dexamethasone, Ranitidine, 
Simvastatin None No White British 
Table 4.2.2 Patient variability data obtained by questionnaire
 196 
 
4.3 Results 
 
4.3.1 HPLC & CYP Genes in glioma patient plasma samples 
 
 
The relationship between plasma Clomipramine and Norclomipramine 
concentrations and therapeutic effect have not previously been clearly defined, 
although for chronic antidepressant therapy a target range (Clomipramine + 
Norclomipramine) of 150 – 450ng/ml is used. After acute over dosage, plasma 
Clomipramine above 1000ng/ml (Norclomipramine 2000ng/ml) may be associated 
with serious toxicity in individual patients (Westenberg, De Zeeuw et al. 1977). The 
results in Table 4.3.1   below are the mean plasma concentrations calculated from 
four individual blood samples taken from each patient, once a month for four 
months expressed in ng/ml. The results show fluctuations in plasma levels of both 
parent drug and metabolite, and the degree of variation is represented by standard 
deviation values. Using ANEC008 and ANEC013 as an example, as they have 
particularly high standard deviation values for both Clomipramine and 
Norclomipramine, it is interesting to note that ANEC008 is taking Tegretol 
(Carbemazepine) and ANEC013 is taking a proton-pump inhibitor (Omeprazole). 
Carbemazepine and Omeprazole are both metabolised via CYP2C19 (also 
responsible for the major demethylation route of Clomipramine) and it might be 
possible that they are competing at the microsomal CYP enzyme level.  
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  Clomipramine 
(ng/ml) 
Norclomipramine 
(ng/ml) 
Total 
(ng/ml; 
150-
450ng/ml) 
Total 
(µM) 
ANEC001 67.84 ± 12.47 150.80 ± 30.78 218.64 0.64 
ANEC004 155.00 ± 25.52 239.50 ± 97.66 394.50 1.12 
ANEC008 111.83 ± 45.23 290.25 ± 122.97 402.08 1.14 
ANEC010 26.00 ± 3.40 67.50 ± 9.65 93.50 0.27 
ANEC011 104.00 ± 38.70 229.00 ± 88.40 333.00 0.95 
ANEC012 129.33 ± 16.29 57.63 ± 10.19 186.97 0.53 
ANEC013 77.40 ± 46.48 43.70 ± 28.86 121.10 0.25 
ANEC014 127.98 ± 26.02 206.00 ± 44.65 333.98 0.95 
ANEC015 54.48 ± 17.95 154.75 ± 50.05 209.23 0.60 
ANEC016 69.00 ± 21.64 235.25 ± 69.47 304.25 0.87 
ANEC018 96.10 ± 30.14 241.33 ± 70.22 337.43 0.96 
ANEC019 22.67 ± 2.50 135.00 ± 26.85 157.67 0.45 
ANEC020 60.78 ± 32.12 212.25 ± 31.70 273.03 0.78 
ANEC021 87.57 ± 21.60 77.17 ± 13.12 164.73 0.47 
ANEC022 205.67 ± 78.08 119.33 ± 30.09 325.00 0.93 
ANEC024 25.60 ± 11.90 39.53 ± 6.67 65.13 0.19 
ANEC028 165.00 ± 18.50 199.00 ± 38.70 364.00 1.04 
Table 4.3.1 The plasma concentrations of Clomipramine and its metabolite in 
glioma patients as determined via HPLC-MS/MS please refer to Table 4.2.2 for 
daily dose 
 
The data shows variability in the plasma concentrations achieved by the patients 
included in the study. It was necessary to correct these values for body weight 
and daily dose in order to carry out a comparative study because the patients 
were on different doses – the universal unit to which all patient samples are 
corrected is nanograms per millilitre, per milligram of Clomipramine taken each 
day, per kilogram body weight and these values can be seen in table Table 4.3.2. 
This allows comparison of all patients against each irrespective of weight or 
daily dose of Clomipramine. The values shown in µM are similar than those 
tested using the MTT and ATP-TCA (the lowest concentration was 6.25 µM). 
Without knowing the amount of Clomipramine and Norclomipramine that is able 
to effectively cross the B-BB it is difficult to suggest a daily dose for brain 
tumour patients. 
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Before carrying out the analysis of the qRT-PCR human CYP450 gene results 
the amplification plots were checked to confirm that the positive control had 
appeared as expected, and that the no-template controls had not appeared. The 
melt curves were checked to ensure that there was no non-specific amplification. 
The results produced by the Biorad i-cycler were copied into an Excel 
spreadsheet that had been set up to calculate the mean, standard deviation and 
coefficient of variation (CV) in the triplicate values. These values were reported 
if the CV was acceptable. The samples were then assigned to the homozygous or 
heterozygous categories depending on the presence of one or more fluorophore. 
The fluorophore JOE was always assigned to allele *1 (the major/wildtype allele) 
and fluorophore FAM was always assigned to allele *2 (minor/mutant allele). It 
is important to select two fluorophores, such as these, with differing excitation 
and emission wavelengths so that the alleles can easily be distinguished via PCR 
and there is no overlapping of wavelengths.  
 
4.3.2 Analytical strategy of CYP450 analysis in glioma patient plasma 
samples 
 
The significance of these alleles is that the presence of a mutated allele decreases 
the metabolism and distribution (biotransformation) of the drug, in this case 
Clomipramine. The results were then grouped into four categories, 
Clomipramine and 2D6, Clomipramine and 2C19, Norclomipramine and 2D6 
and finally Norclomipramine and 2C19. Statistical analyses were performed 
using ANOVA to determine if there was any statistical relationship between 
either of the CYP genes and plasma levels of Clomipramine or its metabolite.  
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Figure 4.3.2.1 An example of qRT-PCR amplification vs. cycle data for VIC 
reporter dye in plate 1 using primers for mutations in CYP genes 2D6 and 2C19 
 
On this logarithmic PCR trace the cycle number is shown along the X-axis and 
arbitrary fluorescence units are shown on the Y-axis. The different coloured lines 
represent each individual sample (see Table 4.3.1). The traces were checked to 
ensure that the fluorescence values were coming up and that there were no 
erroneous results, on this run the samples began to fluoresce around cycle 
threshold (Ct) 28 which shows that the concentration of template used the assay 
was correct. Any sample with a Ct value of 35 and upwards was regarded as 
negative when compared to the positive control and results are shown in Table 
4.3.2.  
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There were pronounced inter-individual variations in the steady-state plasma 
concentrations of Clomipramine and its metabolites. The range of parent drug 
concentrations after correction with daily dose and body weight was 12.3 – 384.0 
(75 ± 91) ng/ml mg
-
1 kg 
-
1  and the range of metabolites was 19.0 – 594.0 (60 ± 
128) ng/ml mg
-
1 kg 
-
1. The seventeen subjects were divided into three groups for 
each of the parent drug and metabolite. These groups, determined by the reporter 
dye assignment to the alleles (i.e. JOE = wildtype major allele, FAM = mutant 
minor allele), were deemed homozygous major allele (Homo V), heterozygous 
(Hetero) or homozygous minor allele (Homo FAM). These groups were then 
numbered 1, 2 and 3 respectively. The table below shows the results for both 
corrected plasma concentration and genotype. 
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Case CLOM 
 
NOR 
CLOM 
C/NC 
Ratio 
Genotype CYP 
2D6*2X3 
Genotype CYP 
2C19*2A 
ANEC001 35.2768 78.416 0.45 Hetero 2 Hetero 2 
ANEC004 384.4 593.96 0.65 Homo FAM 3 Hetero 2 
ANEC008 42.60533 110.5853 0.39 Hetero 2 Homo FAM 3 
ANEC010 16.51 42.8625 0.39 Homo V 1 Hetero 2 
ANEC011 38.13333 83.96667 0.45 Homo V 1 Homo V 1 
ANEC012 77.988 34.7529 2.24 Homo V 1 Homo V 1 
ANEC013 53.148 30.00733 1.77 Homo V 1 Homo V 1 
ANEC014 78.49133 126.3467 0.62 Homo V 1 Homo V 1 
ANEC015 29.12597 82.73967 0.35 Homo V 1 Homo V 1 
ANEC016 31.05 105.8625 0.29 Homo V 1 Homo V 1 
ANEC018 52.855 132.7333 0.40 Homo FAM 3 Homo FAM 3 
ANEC019 18.13333 108 0.17 Homo FAM 3 Homo FAM 3 
ANEC020 26.33583 91.975 0.29 Homo V 1 Homo V 1 
ANEC021 88.96773 78.40133 1.13 Hetero 2 Homo FAM 3 
ANEC022 199.4967 115.7533 1.72 Homo V 1 Homo V 1 
ANEC024 12.288 18.972 0.65 Homo V 1 Homo V 1 
ANEC028 88 106.1333 0.83 Homo V 1 Homo V 1 
 
Table 4.3.2 HPLC-MS/MS results corrected for clomipramine and 
norclomipramine dose (ng/ml mg
-1
 kg
-1
) against genotype 
 
The alleles selected for analysis were suitable for the group of patients selected 
for this study (see Table 4.3.1), with all three genotypes present. There were no 
patients with rare duplicated alleles; this is to be expected with only a small 
number of volunteers. The lower the Clomipramine/Norclomipramine (C/NC) 
ratio: the greater the ability of the patient to metabolise Clomipramine.  
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The results (Table 4.3.1) were then analysed by one way - Analysis of Variance 
(ANOVA) to determine the variance between plasma concentrations of 
Clomipramine and Norclomipramine when separated into three genotypes. This 
is a statistical analysis of individual parameters in one test, as a whole. It 
removes the need for single t-tests for each group to be carried out. The 
underlying assumption of the test is that there is equal variance. The mean, 
standard deviation and standard error of plasma levels of Clomipramine and 
Norclomipramine were calculated for each allelic group i.e. homozygous 
wildtype (Homo V), heterozygous (Hetero) and homozygous mutant (Homo 
FAM). From this source of variance could be determined via the sum of squares 
(SSq), degrees of freedom (DF) and mean of squares (MSq; SSq/DF). The 
variance ratio test provides an F value which, when applied to an „F‟ table gives 
the significance value.    
 
There is variation present in the C/NC ratios between patients in the study, this 
could possibly be attributed to the other prescription medicines that the patients 
are taking. For example, ANEC013 and ANEC022 both have the highest C/NC 
ratios and both take proton-pump inhibitors (Omeprazole and Pantoprazole). 
Regardless of the genotype of these patients and their genomic ability to 
metabolise Clomipramine, proton-pump inhibitors competitively inhibit 
CYP2C19 and can cause increased levels of Clomipramine. It might be 
advisable, in patients such as these two, to switch to an alternative gastric reflux 
medication such as ranitidine, which has no known CYP interactions (and is an 
H2-receptor antagonist).  
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Table 4.3.3 1-way ANOVA analysis of the effect on Clomipramine metabolism 
by a mutation in one or more alleles of the CYP2D6*2X3 gene 
 
Of the seventeen patients in this study, three have two mutated alleles (Homo 
FAM), three have two mutated alleles (hetero) and eleven have no mutations 
(Homo V) and patients have been divided into three groups of the basis of how 
many mutated alleles they carry for the *2X3 in the CYP2D6 gene. The results 
show that for the group of patients selected for study there is no significant 
(p>0.05) differences between number of mutated alleles and plasma 
concentrations of Clomipramine. In this group of patients, the genotype for 
CYP2D6*2X3 does not significantly affect the ability to metabolise 
Clomipramine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Test  1-way between subjects ANOVA     
            
Comparison  Clom by CYP 2D6 Group: Hetero, Homo FAM, Homo V 
  
            
      
n  17      
      
Clom by CYP 2D6 Group  n Mean SD SE  
Hetero  3 55.617 29.114 16.8092  
Homo FAM  3 151.796 202.188 116.7331  
Homo V  11 59.142 53.402 16.1014  
      
Source of variation  SSq DF MSq F p 
CYP 2D6 Group  21585.866 2 10792.933 1.35 0.2911 
Within cells  111973.179 14 7998.084   
Total  133559.045 16    
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Table 4.3.4 1-way ANOVA analysis of the effect on Clomipramine metabolism 
by a mutation in one or more alleles of the CYP2C19*2A gene 
 
Of the seventeen patients ten had no mutated alleles (Homo V), four had two 
mutated alleles (Homo FAM) and three had one mutated allele (hetero) and so 
have been grouped according to number of mutated alleles. The results show that 
for the group of patients selected for study there is no significant (p>0.05) 
difference between number of mutated alleles and plasma concentrations of 
Clomipramine. For this group of patients, a mutation in CYP2C19 does not affect 
ability to metabolise Clomipramine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Test   1-way between subjects ANOVA     
            
Comparison   Clom by CYP 2C19 Group: Hetero, Homo FAM, Homo V 
  
            
      
n  17      
      
Clom by CYP 2C19 
Group  
n Mean SD SE  
Hetero  3 145.396 207.196 119.6249  
Homo FAM  4 50.640 29.412 14.7059  
Homo V  10 63.406 54.282 17.1655  
      
Source of variation  SSq DF MSq F p 
CYP 2C19 Group  18584.184 2 9292.092 1.13 0.350
4 
Within cells  114974.861 14 8212.490   
Total  133559.045 16    
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Test   1-way between subjects ANOVA     
            
Comparison   NC by CYP 2D6 Group: Hetero, Homo FAM, 
Homo V 
  
            
      
n  17      
      
NC by CYP 2D6 Group  n Mean SD SE  
Hetero  3 89.134 18.577 10.7255  
Homo FAM  3 278.231 273.709 158.0258  
Homo V  11 76.307 38.006 11.4594  
      
Source of variation  SSq DF MSq F p 
CYP 2D6 Group  98398.560 2 49199.280 4.18 0.0378 
Within cells  164968.082 14 11783.434   
Total  263366.642 16    
 
Table 4.3.5 1-way ANOVA analysis of the effect on Norclomipramine 
metabolism by a mutation in one or more alleles of the CYP2D6*2X3 gene 
 
Of the seventeen patients in this study, three have one mutated allele (hetero), 
three have two mutated alleles (Homo FAM) and eleven carry no mutated alleles 
(Homo V). The results show that for the group of patients selected for this study 
there is a significant (p<0.05) difference between number of mutated alleles and 
plasma concentration of Norclomipramine. The presence of two mutated alleles 
(Homo FAM) increases the metabolism of Norclomipramine, when you would 
expect a mutation to decrease the metabolism of Norclomipramine.  
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Test   1-way between subjects ANOVA     
            
Comparison   NC by CYP 2C19 Group: Hetero, Homo FAM, 
Homo V 
  
            
      
n  17      
      
NC by CYP 2C19 
Group  
n Mean SD SE  
Hetero  3 238.413 308.426 178.0696  
Homo FAM  4 107.430 22.310 11.1550  
Homo V  10 79.651 38.318 12.1173  
      
Source of variation  SSq DF MSq F p 
CYP 2C19 Group  58406.192 2 29203.096 1.99 0.1729 
Within cells  204960.450 14 14640.032   
Total  263366.642 16    
 
Table 4.3.6 1-way ANOVA analysis of the effect on Norclomipramine 
metabolism by a mutation in one or more alleles of the CYP2C19*2A gene 
 
Of the seventeen patients selected for study, three carry one mutated allele 
(hetero), four carry two mutated alleles (Homo FAM) and ten carry no mutated 
alleles (Homo V). The results show that there is no significant (>0.05) difference 
between number of mutated alleles and plasma concentration of 
Norclomipramine. The number of mutated alleles present does not affect ability 
to metabolise Norclomipramine.  
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4.4 Discussion 
 
 
Individualising therapy for patients being treated with pharmaceutical agents is 
fast becoming the overarching goal of clinical research in the 21
st
 century 
(Deeken, Figg et al. 2007). The pharmacogenetic differences seen in patients are 
multifactorial, such as the influences on the effect of the drug (receptors and 
target proteins) and the influences on pharmacokinetics (absorption, distribution, 
metabolism and excretion). The single most important factor is the presence of 
polymorphisms in the genes involved in drug pharmacokinetics, which can 
impact on the drug absorption, distribution, metabolism and excretion. The aim 
of this chapter was to demonstrate that mutations of the CYP450 enzymes 
responsible for metabolising Clomipramine affect response to tricyclic 
antidepressant therapy; however the principle is relevant to all chemotherapeutic 
agents and their corresponding CYP genes. The CYP genes 2D6 and 2C19 are 
responsible for the metabolism of Clomipramine and its metabolite 
Norclomipramine, respectively, and by selecting a small cohort of brain tumour 
patients it was possible to obtain plasma levels of Clomipramine (and 
Norclomipramine) and genomic DNA from fingerprick blood samples to 
examine inter-individual variation.  
 
The HPLC-MS/MS is a clinically validated method for determining the 
concentration of Clomipramine and its metabolite in plasma. The daily dose was 
not identical in all patients, but was prescribed according to body mass and 
prophylactic medications, however by correcting the plasma concentrations for 
body mass and daily dose it is clear to see the vast differences in metabolic 
capacities.  
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The maximum corrected Clomipramine plasma level was 384 mg/ml mg
-1
 kg
-
1
(GBM, Grade IV) and the minimum was 12 mg/ml mg
-1
 kg
-1
(GBM, Grade IV). 
Four of the patients included in the study (ANEC012, ANEC013, ANEC021, and 
ANEC022) had higher concentrations of Clomipramine than Norclomipramine 
but this did not correlate with genotype for the CYP genes tested, as three were 
Homo V and one was heterozygous.  
 
The maximum corrected Norclomipramine plasma level was 594 mg/ml mg
-1
 kg
-
1 
and the minimum was 19mg/ml mg
-1
 kg
-1
. This shows a large variation in 
plasma levels, and information on the ability of the individual patient to 
metabolise Clomipramine is something that a general practitioner (GP) would not 
have access to when initially prescribing. It would, in theory, be possible to 
titrate the dose over a number of weeks (whilst monitoring side effects and 
adverse reactions) to see how much Clomipramine the patient can tolerate, 
however in patients suffering from malignant glioma there is a huge degree of 
urgency. There is now the worry of a spectrum of cognitive deficiencies which 
affect between 4-75% of cancer patients following chemotherapy (Staat and 
Segatore 2005; Raffa, Duong et al. 2006). This iatrogenic phenomenon is thought 
to be caused because the agents that are used to kill neoplastic cells may be 
equally (or more) harmful to the normal tissues of the brain (Jackson 2007). Thus 
the development of a selective and more targeted therapeutic approach or 
alternatively a selective protection of normal tissue is needed.  
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In previous studies, prior to invention of PCR-based techniques to analyse CYP 
enzymes, the method of calculating the Clomipramine/Norclomipramine ratio 
was utilised to give a finite value for the amount of metabolite present in the 
plasma, and hence the proportion of parent drug that has been metabolised. In 
past studies patients were also assigned to one of three categories, extensive 
metabolisers (EMs), intermediate metabolisers (IMs) and poor metabolisers 
(PMs) according to genotype. However since the discovery of many more allele 
variations it has become apparent that the presence of one or more mutated 
alleles does not necessarily mean a decrease in the CYP enzyme activity.  
 
In CYP2D6*2X3 the presence of two mutated alleles (homozygous recessive) 
results in a functional gene and causes an increase in enzyme activity (Johansson, 
Lundqvist et al. 1993; Dahl, Johansson et al. 1995; Aklillu, Persson et al. 1996). 
In this study the Homo FAM group confers two mutated alleles and indeed this 
was the observation for this genotype, two mutated alleles resulted in an 
increased enzyme activity. As described in Figure 3.5.6.1 there are many factors 
affecting the metabolism of drugs in brain tumour patients, and any single one or 
combination of these could be affecting the plasma concentration at any one 
time.  
 
In the present study, the HPLC-MS/MS data and PCR data was combined and 
then analysed with ANOVA to see if there was any differences between the 
genotype and individual plasma concentrations of both Clomipramine and 
Norclomipramine. This would indicate a role for that particular CYP gene in the 
metabolism of the drug.  
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The data analysis on page 205 shows statistical difference in groups for the role 
of CYP2D6*2X3 and the plasma levels of norclomipramine. CYP2D6 is 
responsible for metabolising Norclomipramine to its metabolites Di-
desmethylclomipramine and 8-hydroxydesmethylclomipramine (4.1.1.2) and the 
presence of two mutated alleles results in a higher plasma concentration of 
Norclomipramine. The number of patients is so small that it would be impossible 
to draw any firm conclusions from the data obtained, however the higher 
concentrations of plasma Norclomipramine seen in patients with two mutated 
(but still functional) alleles agrees with the literature (Johansson, Lundqvist et al. 
1993; Dahl, Johansson et al. 1995; Aklillu, Persson et al. 1996). Care should be 
taken when interpreting previous studies which designate patients as EM, IM or 
PM because a mutated allele does not necessarily correspond with a non-
functional protein.  
 
From several large studies in Caucasians (1456 Europeans) it can be estimated 
that for CYP2D6, 67% of all alleles encode for enzymes with normal activity 
(Homo V), 4% encode for enzymes with decreased activity, 27% lead to non 
functional enzymes and 2% encode for increased activity (Marez, Legrand et al. 
1997; Sachse, Brockmoller et al. 1997; Griese, Zanger et al. 1998).The most 
common non-coding alleles are CYP2D6*4 (about 71% of null alleles), 
CYP2D6*5 (about 16% of null alleles), CYP2D6*3 (about 6% of null alleles) 
and CYP2D6*6 (about 4% of null alleles) all the other non coding alleles are rare 
and have a prevalence of 1% or lower of the non coding alleles.  
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Allelic variants that encode for enzymes with decreased activity are rare in 
Caucasians and the most common alleles are CYP2D6*9 and CYP2D6*10, each 
accounting for about 2% of all alleles. Two null-alleles in the CYP2C19 gene, *2 
and *3, have been described to account for approximately 87% of all PMs in 
Caucasians and 100% of all PMs in Orientals (De Morais, Wilkinson et al. 1994; 
De Morais, Wilkinson et al. 1994). In addition, three non-coding alleles 
(CYP2C19*4, CYP2C19*5 and CYP2C19*6) have been described but the 
frequencies of these alleles are expected to be below 1% in Caucasians (Ibeanu, 
Goldstein et al. 1998). Deficiency of CYP2C19 occurs with a prevalence of PMs 
of 2-5% among white Europeans, Black Africans 4-5%, Black Americans 6% 
and 12% to 23% among Orientals (Bertilsson 1995). 
 
4.4.1 The results of the CYP2D6 and 2C19 PCR for determining number 
of mutated alleles and the effect on metabolism of Clomipramine 
hydrochloride 
 
The aim of the genotyping assay was to analyse whole blood samples (for which 
paired plasma samples had been obtained) to see if it were feasible to extract 
genomic DNA of high enough quality to demonstrate mutations of CYP450 
enzymes. There are variations in the level of Clomipramine found in the plasma 
samples of patients with malignant glioma and the objective was to see if CYP 
genotype was one of the influencing factors. 
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The results of the CYP gene analysis are promising for the following reasons, 
firstly in terms of general genotyping this study shows that by taking a simple 
fingerprick blood sample it is possible to extract gDNA of suitable quality for 
RT-PCR CYP gene analysis. The protocol would need to be expanded in order to 
„screen‟ for CYP gene and metaboliser status, as genotyping for only one or two 
alleles is of limited clinical use. Because of the large number of CYP2D6 and 
CYP2C19 variants that have been described to date it would be necessary to 
carry out the screening in 384-well plates using an automated robotic 
programme.  
 
Further work to establish which of the CYP genes are responsible for 
metabolising chemotherapy used in glioma, might mean that an improved 
metabolic profile can be built up for each individual patient. It might also mean 
that more informed decisions can be made about which, for example, 
anticonvulsant or gastric reflux medication can be prescribed alongside glioma 
chemotherapy without the risk of competitive inhibition for the CYP enzymes. 
This technology would mean that drug administration can be tailored to the 
individual; this would cut costs when prescribing expensive novel agents, such as 
Gleevec, by avoiding unnecessarily high doses in patients with functional alleles 
and ensuring that the therapeutic window is reached in patients with non-
functional alleles, thus rendering the regimen worthwhile.  
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The patients selected for the PCR study were on Clomipramine doses ranging 
from 25.0 – 150 mg/day showing a high degree of variation. ANEC004 was on a 
considerably lower dose of Clomipramine than any other patient because their 
GP felt this necessary whilst receiving chemotherapy. It is not clear whether 
there are any interactions from taking Clomipramine at the same time as standard 
chemotherapy, apart from the increase in apoptosis seen in Annexin-V flow 
cytometry between Clomipramine and Imatinib in rat C6 glioma cells and 
between Clomipramine and Dexamethasone in human glioma cells (Bilir, 
Erguven et al. 2008; Higgins and Pilkington 2010). 
 
However in some reports of anecdotal patients taking the anticonvulsant 
Carbemazepine (Tegretol
®
) a higher frequency in seizures was seen when taking 
high doses of Clomipramine, this could be due to competitive inhibition of the 
CYP2D6 enzymes which are responsible for metabolising both Clomipramine 
and Carbemazepine (Ingelman-Sundberg 2005). Patients taking sodium 
valproate-based anticonvulsants such as Epilim
®
 did not appear to experience 
any difference in frequency of seizures when taking Clomipramine. This could 
be due to the fact that sodium valproate and Valproic acid are metabolised by 
CYP2C9, 2A6 and 2B6 (Kiang, Ho et al. 2006). The suitability of the dose is 
difficult to determine as Clomipramine is prescribed alongside other medication, 
such as anticonvulsants, steroids, anti-emetics and other cytotoxics, however in 
an ideal situation patients would take as much Clomipramine as they could 
manage (the maximum we have observed so far is 200mg/day) without too many 
side effects.  
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It is possible to take into consideration the route of metabolism for each drug 
and, where known, the CYP enzymes involved, to ensure that there are no 
fundamental adverse effects such as competitive inhibition.  
 
One difficulty in this cohort of patients is the presence of „perceived‟ side effects. 
Patients may associate any adverse events with Clomipramine however the very 
nature of the disease, its location in parts of the brain that relate to memory, 
speech, balance and other vital functions, means that side effects such as 
impaired speech and partial seizures can be perturbed by surgical resection or 
tumour progression. There are a wide range of side effects seen in the patients 
studied, tiredness, dry mouth and lethargy are some of the milder, and more 
specific and readily identifiable, effects and tend to subside after two to four 
weeks of taking Clomipramine.  
 
The observation of a reduction in the milder side effects tends to coincide with 
the point at which a steady state plasma concentration is achieved. The seizures 
and „jerks‟ seen in other patients could be due to any number of factors, but it 
would be pertinent to check if these patients were on a Carbemazepine-based 
anticonvulsant (see Table 4.2.2), and the possibility of changing over to a 
valproate formulation. Where side effects such as weight gain have been reported 
(Table 4.2.2) this could be associated with adjuvant administration of a steroid 
(such as Dexamethasone) which is prescribed to brain tumour patients to reduce 
oedema (and intracranial pressure) prior to surgery.  
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5 Is the norepinephrine transporter, a molecular target for 
tricyclic antidepressants, expressed in glioma cells? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 216 
5.1 Introduction 
 
In addition to examining the genetic variation in CYP450 genes responsible for 
the metabolism of Clomipramine and Norclomipramine, is also important to 
examine if there is genetic variation in the expression of drug transporter genes, 
see Figure 3.5.6.1, in this case the NET. The NET is thought to allow the 
tricyclic antidepressants entry to the tumour cell, and it is possible to examine 
protein and mRNA production of the NET SLC6A2 gene to see if they are 
expressed in an individual tumour or not. Knowledge of genotype corresponding 
to a particular chemotherapeutic drug is of limited use in a clinical setting 
without also knowing if the drug can gain entry to the tumour cells.  
 
The presence of the NET on astrocytes (Inazu, Takeda et al. 2003) may indicate 
that glial cells are involved in the regulation of noradrenergic activity. Astrocytes 
contain two transport systems (a sodium-dependent neuronal transporter and a 
sodium-independent extra neuronal transporter, only an antibody against the 
neuronal NET is commercially available) that can remove monoamine 
neurotransmitters (serotonin, norepinephrine and dopamine) from the synaptic 
cleft by transporters present in the plasma membrane. Since glial cells contain 
monoamine oxidase, it is likely that astrocytes play an important role in 
regulating extracellular monoamine concentrations. This uptake system may play 
a part in removing excess monoamines and prevent uncontrolled spreading of 
nerve signals.  
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The fact that glial cells are able to remove excess norepinephrine and degrade it 
using monoamine oxidase (which is present on the mitochondrial membrane) 
might indicate that they exert significant control of norepinephric activity (Inazu, 
Takeda et al. 2003). To date, it has been demonstrated that both the neuronal and 
extra-neuronal forms of the NET are present in normal human brain astrocytes 
(Inazu, Takeda et al. 2003). It has not however been investigated if the neuronal 
NET is present on human malignant glioma cells, the presence of a cellular 
transporter known to be inhibited by the tricyclic antidepressants might go some 
way toward explaining the cytotoxic effect of antidepressants on brain tumour 
cells. While it has been demonstrated that upon entry to the cells Clomipramine 
exerts its effect via complex III of the mitochondrial respiratory chain (Daley 
2001), it has not been discovered how Clomipramine hydrochloride enters the 
cell or the events taking place between the plasma membrane and the 
mitochondrial membrane. Because the presence of NET on human glioma cells 
has not been investigated it is unclear if the presence of NE affects glioma cell 
survival. It is known that normal human astrocytes are able to degrade NE via 
monoamine oxidase-B turnover (Pietrangeli and Mondovi 2004; Toninello, 
Pietrangeli et al. 2006), and it is also suggested that monoamine oxidase may 
play a role in cell signalling (Ou, Chen et al. 2006). It has been postulated that 
the serotonin transporter (SERT; solute carrier family 6 member 4; SLC6A4) 
may act not merely as a transport protein but also as a signal transducer (Fanburg 
and Lee 1997; Lee, Wang et al. 2001). However when investigated as an anti-
tumour target it was shown that while it is present on B-cells, demonstrated via 
Western blotting, antidepressants affect malignant cells independently of this 
transporter (Meredith, Holder et al. 2005).  
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Because the tricyclic antidepressants act via inhibition of the SERT and NET, in 
particular Norclomipramine which preferentially blocks the NET transporter, it 
might be possible that if the NET was present on brain tumour cells and the 
tricyclic antidepressants inhibited the extra neuronal transporter in the same way 
they do the neuronal transporter, that by reducing the availability of NE to the 
tumour cell it alters the monoamine oxidase signal and triggers caspase-3 
mediated apoptosis.   
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5.2 Methodology 
5.2.1 Details of samples stained with the norepinephrine transporter 
antibody via immunohistochemistry 
 
 
Patient Identifier Age Sex Tumour Type 
TORC07-0003 49 F Normal human brain control 
TORC07-0009 45 F Oligodendroglioma (II) 
TORC07-0010 43 M Diffuse Astrocytoma (II/III) 
TORC07-0011 82 F Anaplastic Meningioma 
TORC07-0012 43 F Recurrent GBM (IV) 
TORC07-0013 39 M Schwannoma of spinal nerve root 
TORC07-0014 41 M Recurrent GBM (IV) 
TORC07-0015 45 M Anaplastic Oligodendroglioma (III) 
TORC07-0016 72 F GBM (IV) 
TORC07-0017 52 F Metastatic mammary ductal carcinoma 
TORC07-0018 74 M GBM (IV) 
TORC07-0019 59 F Recurrent GBM (IV) 
TORC07-0020 48 F Myxoid Degenerate Meningioma 
TORC07-0021 66 F GBM (IV) 
TORC07-0022 73 F Meningioma 
TORC07-0023 72 F Meningioma 
TORC07-0024 69 M GBM (IV) 
 
Table 5.2.1 Details of the samples selected for IHC staining with the NET 
antibody 
 
Sections were taken from one normal human brain control and sixteen tumour 
paraffin blocks (ten primary brain tumours, four Meningiomas, a secondary 
tumour and one cranial nerve tumour). The normal human brain control was non-
neoplastic brain tissue removed during surgical resection of a brain tumour; it is 
not ethically possible to obtain normal brain tissue for research and it was not 
possible to access to post mortem tissue from a brain bank, so this was the best 
alternative control tissue available. 
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5.2.2 Immunoperoxidase staining of the NET 
 
In brief, sections were dewaxed according to the method outlined in section 
2.3.15 then placed straight into a mixture of alcohol and H202 to block 
endogenous peroxidase. The slides were then incubated in pH 6.0 citrate buffer 
(25.0 ml citric acid, 175.0 ml sodium citrate and 1800 ml distilled water) and 
placed in a pressure cooker for thirty minutes. The sections were then covered 
with avidin blocker, rinsed and covered with biotin blocker prior to application 
of the primary antibody (as described in section 2.3.18). The slides were loaded 
onto a Dako Autostainer (Dako, UK). The programme consisted of thirty minutes 
incubation with the primary antibody, fifteen minutes incubation with the 
secondary antibody, fifteen minutes incubation with streptavidin-HRP and finally 
five minutes incubation with DAB. Once the programme had completed the 
sections were counterstained with eosin, dehydrated and cleared as outlined in 
sections 2.3.17 and 2.3.16. 
 
5.2.3 Immunocytochemical staining of the NET 
 
 
To visualise the presence of the norepinephrine transporter (NET) on human 
brain tumour cells, cultures of DK-MG, SNB-19, UPMC and UPAB were grown 
on glass coverslips, fixed and stained, CC-2565 normal human astrocytes were 
also included in the assay as a normal brain control and SH-SY5Y 
Neuroblastoma cells (which are known to express the NET) were used as a 
positive control. Monolayer cell cultures were harvested (as described in 2.2.4) 
and seeded into 6-well culture plates; each well contained a sterile coverslip onto 
which 2,000 cells pipetted and left to adhere for twenty-four hours.  
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The media from the wells was then removed, and the cells washed with sterile 
phosphate-buffered saline (PBS). The cells were stained according to the method 
outlined in 2.3.20 using the monoclonal NET antibody (MAB5620 Chemicon; 
1:250 as determined by in-house titration) and Alexfluor488 conjugated 
secondary antibody (1:500, raised in a goat).  
 
5.2.4 Isolation and visualisation of the norepinephrine transporter protein 
via Western blotting 
 
Isolation and visualisation of the NET protein was carried out via western 
blotting according to the protocol outlined in 2.3.22.2. Briefly, cells lysates were 
prepared from CC-2565, SH-SY5Y, SNB-19, DK-MG, UPAB, UPJM and 
UPMC in 1.0 ml RIPA buffer containing 10 µl protease inhibitor cocktail (both 
from Thermo Fisher). The blots were blocked to prevent non-specific binding, 
probed with a monoclonal anti-mouse NET antibody at a dilution of 1:1000 
(MAB5620, Chemicon) before incubating with a secondary HRP-conjugated 
anti-mouse antibody at a dilution of 1:5000. The resulting protein bands were 
visualised using a chemiluminescent ECL plus kit and imaging station.  
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5.2.5 Isolation and qualification of messenger RNA encoding the SLC6A2 
(Norepinephrine Transporter) Gene 
 
 
To examine gene expression of the SLC6A2 gene, which encodes the neuronal 
NET, cell lysates were prepared from CC-2565, SH-SY5Y, SNB-19, DK-MG, 
UPAB, UPJM and UPMC in 1.0ml RA1 buffer (Machery Nagel) containing 10 
µl beta-mercaptoethanol. The RNA was extracted from the cell lysates according 
to the method outlined in 2.3.23.2, quantified using a Nanodrop 
spectrophotometer (2.3.14) and reverse transcribed to cDNA according to the 
method outlined in 2.3.23.3. Complementary DNA, obtained by the method 
described in section 2.3.23.3 was amplified in 96-well plates by qRT-PCR on an 
Applied Biosystems 7500HT (Applied Biosystems, UK). All samples were run 
with a control GAPDH primer (a housekeeping gene ubiquitously expressed in 
all cells; Hs_02758991_g1 Applied Biosystems) and the test NET primer 
(Hs_01567442_m1, Applied Biosystems). Complementary DNA extracted from 
control Neuroblastoma cell line SH-SY5Y was run as a positive control, and 
wells run with the omission of template DNA served as a no-template negative 
control. Each PCR reaction had a final volume of 20µl comprising 9µl cDNA 
(100ng per well or nuclease-free water if a no-template control), 1µl of Taqman 
primer (Applied Biosystems, UK) diluted ten-fold in Taqman Universal Master 
Mix. Each two-step PCR cycle comprised of denaturing (15 seconds at 92
o
C) and 
annealing/extending (90 seconds at 60
o
C). At the end of each run a final melt 
curve cycle was performed (cooling to 50
o
C and then increasing stepwise 1
o
C to 
95
o
C) was performed to exclude the presence of primer-dimer artefacts. The 
results were analysed and statistical tests carried out according to the methods 
described in section 4.2.4.  
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5.3 Results 
 
5.3.1 Norepinephrine Transporter IHC Staining 
 
 
Of the sixteen tumours selected for study (alongside one normal human brain 
control, details of samples can be found on page 219, analysis by IHC of fifteen 
tumours showed positivity for the NET transporter and one tumour was negative. 
The normal human brain control showed positivity for the NET in neurones. 
Four of the seventeen tumours (TORC07-0009, Oligodendroglioma II; TORC07-
0012, recurrent GBM IV; TORC07-0019, recurrent GBM IV; TORC07-0022, 
Meningioma) showed limited immunoreactivity, in some cases due to poor 
fixation (these samples had been delayed in transit from theatres and so fixation 
in formalin was not as rapid as for all other samples). One tumour (TORC07-
0021, GBM grade IV) was negative for the NET transporter. Only one patient 
(TORC07-0019) was taking Clomipramine, adjuvantly to standard radiotherapy 
and chemotherapy, at the time that brain tumour tissue for this study was 
obtained. Clinical data showed that this patient was able to tolerate 
Clomipramine extremely well and was on a daily dose of 200 mg per day. There 
is no discernable pattern between tumour type or grade and presence of the NET 
protein. Expression of the NET is difficult evaluate via IHC due to differences in 
the quality of staining and the only way to quantify the expression of the 
transporter would be to perform absolute real-time PCR using primers for the 
NET gene.  
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5.3.1.1 Results showing IHC staining of the NET in: TORC07-0003 (normal 
human brain control; A), TORC07-0024 (GBM; C) and TORC07-0016 (GBM; 
E). 
Corresponding negative controls are on the right hand side (B, D & F). TORC07-
0003 shows clear positive staining for the extra-neuronal NET on the neuronal 
processes (arrows) and this section shows the „neuropil‟: an area of neurones 
with many overlapping processes. TORC07-0024 demonstrates 
immunoreactivity (brown staining) on glioma cell membranes and negativity on 
vascular endothelia and blood vessels (blue staining). This tissue shows 
enhanced cellularity and microvascular proliferation typical of a high grade 
tumour. TORC 07-0041 shows brown immunoreactivity present in the glioma 
cell cytoplasm. Vacuolation and nuclear atypia (again, typical in a GBM) are also 
present. All images were captured on a Zeiss Axiocam MRC using Axiovision 
Capture software and scale bars have been applied. 
50µm 
80µm 
100µm 
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5.3.1.2 Results showing immunohistochemistry staining of the NET in: 
TORC07-0018 (GBM; A), TORC07-0012 (GBM; C) and TORC07-0021 (GBM; 
E). 
Corresponding negative controls are on the right hand side (B, D & F).TORC07-
0018 shows some positivity for the NET as demonstrated by brown stippled 
surface immunoreactivity. TORC07-0012 shows limited immunoreactivity for 
the NET, the large blood vessels suggest oedematous tissue and dark brown dots 
indicate infiltration of white blood vessel components, possibly microglia. There 
is some faint cytoplasmic staining, but due to fixation problems the quality is 
poor. TORC07-0021is negative for the NET on glioma cells. The 
immunoreactivity present is on neurones; there are no apparent mitoses or 
microvascular proliferation suggesting that this section has been taken from an 
area of lower grade within the tumour.  
50 µm 
100 µm 
50 µm 
 226 
 
A 
 
B 
 
C 
 
D 
 
5.3.1.3 Results showing immunohistochemistry staining of the NET in: 
TORC07-0014 (GBM; A) and TORC07-0019 (GBM; C). 
 
Corresponding negative controls are on the right hand side (B & D).TORC07-
0014 shows positive cytoplasmic staining for the NET and eccentric nuclei with 
astrocytes. TORC07-0019 is a recurrent GBM that shows faint 
immunoreactivity, probably due to the poor quality of the FFPE block. This 
section also contains many blood vessels. All images were captured on a Zeiss 
Axiocam MRC using Axiovision Capture software and scale bars have been 
applied.  
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5.3.1.4 Results showing immunohistochemistry staining of the NET in: 
TORC07-0011 (Meningioma; A), TORC07-0020 (Meningioma; C) and 
TORC07-0023 (Meningioma; E). 
 
Corresponding negative controls are on the right hand side (B, D & F).TORC07-
0011 shows meningothelial cells positive for the NET and vascular endothelium 
negative for the NET. TORC07-0020 shows positivity for the NET on 
meningothelial cells, indicated by brown immunoreactivity. TORC07-0023 
shows positivity for the NET on meningothelial cells. The dark spots are the cell 
nuclei and there are many blood vessels present (blue). All images were captured 
on a Zeiss Axiocam MRC using Axiovision Capture software and scale bars have 
been applied.  
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5.3.1.5 Results showing immunohistochemistry staining of the NET in: 
TORC07-0015 (Anaplastic oligodendroglioma; A), TORC07-0013 
(Schwannoma; C) and TORC07-0022 (Meningioma; E). 
 
Corresponding negative controls are on the right hand side (B, D & F). TORC07-
0015 shows strong positivity for the NET, shown by the extensive brown 
immunoreactivity. The connective tissue has stained light blue. TORC07-0040 
shows diffuse faint brown immunoreactivity. TORC07-0042 demonstrates clear 
positivity of meningothelial cells for the NET. All images were captured on a 
Zeiss Axiocam MRC using Axiovision Capture software and scale bars have 
been applied. 
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5.3.2 Norepinephrine transporter staining via immunocytochemistry 
 
 
All cells selected for analysis via ICC, four GBM (two cell lines and two early 
passage cultures), the control SH-SY5Y Neuroblastoma and normal human 
astrocytes CC-2565 (see Table 2.3.1), showed immunoreactivity for the NET 
transporter. There is no discernable pattern between tumour type or grade and 
presence of the NET transporter. Expression of the NET is difficult to quantify 
via ICC due to differences in the quality of staining and however the results do 
confirm that the cells used in this study express the NET. UPJM was not 
available for ICC staining.  
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Figure 5.3.2.1 Immunocytochemical staining of the norepinephrine transporter in 
Glioblastoma multiforme, normal human astrocytes and Neuroblastoma 
 
Neuroblastoma SH-SY5Y (A), normal human astrocytes CC-2565 (B), GBM 
established cell line DK-MG (C), GBM established cell line SNB-19 (D), early 
passage GBM UPAB (E) and early passage UPMC (F) were visualised using 
ZEISS LCM710 microscope and a X40 magnification oil immersion lens. The 
images were captured using ZEN2009 acquisition software and sixteen averages 
of fluorescence taken per picture. The Neuroblastoma SHSY-5Y acts as a control 
for NET staining, all cells show some degree of positivity for the NET and 
results correlate with the findings via IHC (see 5.3.1). The reaction product is 
dense and compact but cytoplasmic and probably overlying the nuclei in some 
cases (see bottom left of image A for an example of green stippled fluorescence 
overlying the nucleus).It is useful to stain established cell lines because only 
malignant cells are able to survive many serial passages in vitro. When staining 
primary cultures or some early passage cultures, there may be other cells types 
present (for example normal astrocytes, neurones and fibroblasts). It is 
impossible to quantify immunoreactivity via this staining method; however the 
findings qualify the presence of the NET on malignant glioma cells and provide 
further evidence that Clomipramine is a suitable candidate for inducing apoptosis 
in glioma cells.  
 
 
 
 
 231 
5.3.3 Isolation and visualisation of norepinephrine transporter protein via 
western blotting 
 
The evidence for the presence of the NET on glioma cells presented in sections 
5.3.1 and 5.3.2 are further supported by the observation that all five glioma 
(SNB-19, DK-MG, UPAB, UPMC and UPJM, see Table 2.3.1) expressed the 
NET protein via western blot. The control Neuroblastoma (SH-SY5Y) and 
normal human astrocytes (CC-2565) also expressed the NET protein and these 
findings agree with the literature (Takeda, Inazu et al. 2002; Inazu, Takeda et al. 
2003; Inazu, Takeda et al. 2003; Inazu, Takeda et al. 2003; Vaidyanathan, 
Affleck et al. 2007). Differences in the expression pattern were observed; all cell 
lysates probed for NET revealed a band with an apparent molecular weight of 46 
kDa. This band is consistent with the weight of the unglycosylated form of the 
NET protein However, an additional band migrating at around 80 kDa was 
observed in DK-MG, SNB-19, UPAB and SH-SY5Y and this second band is 
consistent with the glycosylated form of the NET protein.  
 
 
 
 
 
 
 
Figure 5.3.3.1 Western blot analysis of the norepinephrine transporter protein 
expression in five glioma samples (see Table 2.3.1) 
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Glycosylation of proteins is an enzymatic, post-translational, process whereby N-
linked glycans are attached to the protein structure. The protein structure gains 
stability by the addition of the carbohydrate group and is able to fold correctly; 
therefore the N-glycosylated form of the NET protein is more stable. The 
unglycosylated form of NET protein degrades more rapidly. Unglycosylated 
proteins have reduced transport activity however ligand recognition is not 
affected. Tumour cells often carry an impairment in the processing of proteins to 
the fully glycosylated form (Melikian, Ramamoorthy et al. 1996). It is of interest 
the NET protein is expressed in all tumours analysed via Western blot, in 
addition to the normal human astrocytes and Neuroblastoma, however the 
presence of glycosylated and unglycosylated forms of the protein differed 
amongst these samples. It is difficult to say whether these findings support the 
hypothesis that expression of the NET influences sensitivity to tricyclic 
antidepressants, without exposing some tumours that do not express the NET to 
tricyclic antidepressants, however all tumours studied here tumours do have the 
potential to respond to norepinephrine.  
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5.3.4 Detection of mRNA encoding the Norepinephrine transporter 
SLC6A2 gene expression 
 
Real-time PCR was used to assess the levels of the genes encoding the NET 
expressed in five glioma (SNB-19, DK-MG, UPAB, UPMC and UPJM), normal 
human astrocytes (CC-2565) and a Neuroblastoma (SH-SY5Y). The 
representative RT-PCR results indicate that the control Neuroblastoma cells 
express the NET whereas all other cells tested do not. The detection of NET in 
the control sample and detection of GAPDH housekeeping gene in all samples 
shows the assay and primers to be functioning correctly; however it does not 
correlate with the presence of functional NET protein demonstrated by the 
Western blotting technique. The NET primers used in this assay span exons 7 
and 8 in the SLC6A2 gene however there might be one or more splice variants 
present in the RNA (see 1.29.2); the resulting mRNAs are different (and would 
not be detected by the primer chosen in this study) however proteins are still 
translated (albeit of differing isoforms) and identified via Western blot.  
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5.4 Discussion 
5.4.1 The presence of the NET, and molecular alterations in the gene that 
encodes it, on human glioma cells 
 
The IHC staining of sixteen tumours (and one normal human brain control) 
demonstrated immunoreactivity of the neuronal NET in thirteen cases (figures 
5.3.1.1, 5.3.1.2, 5.3.1.3, 5.3.1.4 & 5.3.1.5). Meningioma TORC07-0022, 
Oligodendroglioma TORC07-0009 and Metastatic breast adenocarcinoma 
TORC07-0017 were negative for the NET, and did not demonstrate any 
immunoreactivity. The normal human brain control also shows 
immunoreactivity, in particular neuronal immunoreactivity. Evidence suggests 
that this application of the NET antibody (Chemicon, MAB 5620) in glioma IHC 
appears to be the first of its kind. The microscope used and type of staining 
performed provides limited information; it is not possible to see the exact 
location of immunoreactivity within the cell membranes or organelles. 
Verification that the neuronal NET is present on glioma cells has not been 
demonstrated before according to the literature. Given the small number of 
tumours in this study and the preparations used, there is no discernable link 
between tumour grade and degree of immunoreactivity for these samples. 
However a larger study, perhaps with the inclusion of one type of tumour only, 
might lead to a more definitive link between NET distribution and activity in 
glioma.  
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Immunocytochemistry (Figure 5.3.2.1) performed on the same cells that were 
exposed to tricyclic antidepressants in chapter three demonstrated presence of the 
NET on glioma, normal human astrocytes and Neuroblastoma cells. Western 
blotting, see Figure 5.3.3.1, performed using the same antibody as the IHC and 
ICC protocols, identified 80 kDa bands of glycosylated NET in all tumours and 
additional smaller bands of unglycosylated NET in four tumours (three glioma 
and one Neuroblastoma).  
Mature mRNA encoding for the NET could not be detected via RT-PCR (see 
5.3.4) despite the necessary control samples validating that the assay and primers 
were working correctly. As described in 1.29.2, splice variants in the SLC6A2 
gene might be responsible for the expression of alternative mRNA which would 
not be identified by the primers.  
The human NET gene (SLC6A2) is localized to chromosome 16q12.2 (Bruss, 
Kunz et al. 1993; Gelernter, Kruger et al. 1993), spans >45 kb and consists of 14 
exons separated by 13 introns, with consensus sequences for RNA splicing at 
each exon–intron junction (Porzgen, Bonisch et al. 1995). In 1995 Porzgen et al. 
identified exon 14, which encodes the carboxy-terminal previously reported by 
Pacholczyk et al. in 1991 (Pacholczyk, Blakely et al. 1991). Many individual 
exons encode a single intra- or extracellular domain and transmembrane domain 
as a common feature with other members of the Na+/Cl
-
-dependent 
neurotransmitter transporter family. Rapid amplification of cDNA ends (RACE), 
primer extension and ribonuclease protection experiments revealed a newly 
identified exon and multiple transcription start sites for the human NET gene at 
the 5V-flanking region (Kim, Kim et al. 1999).  
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The protein-coding region thus begins within exon 2. A number of splice variants 
in the NET gene have been identified: NET1a, NET1b, NET2a and NET2b. The 
former two cause intracellular retention of the protein (Bauman and Blakely 
2002). Functional expression was only observed in NET1a and NET2a 
(Kitayama, Morita et al. 2001; Kitayama, Kumagai et al. 2002). At present, there 
is no useful probe (antibody) to specifically identify NET splice variant proteins 
(Burton, Kippenberger et al. 1998).  
5.4.2 Future direction of studies on the norepinephrine transporter and 
tricyclic antidepressant activity 
An ideal future study would be to quantify the expression of the NET transporter 
in a tumour (either via IHC or PCR) and to use the ATP-TCA to determine the 
IC50 and Index SUM for the same tumour in parallel, to see if there is a 
correlation between expression of the transporter and efficacy of the tricyclic 
antidepressants with higher NET-affinity.  
5.4.3 Antidepressant activity and inhibition of neurotransmitters 
 
The debate remains, after forty years of research, as to whether inhibition of 
noradrenaline or serotonin is the most important factor in conferring 
antidepressant efficacy and there is still no definitive answer. However, the 
inhibition of noradrenaline/norepinephrine does appear to be more important 
than inhibiting serotonin in conferring tumour cell death. When screening the 
antidepressant drugs in chapter three it was evident that Norclomipramine and 
Nortriptyline were the most effective of the eight agents tested at evoking tumour 
cell death in vitro.  
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When comparing equilibrium dissociation constant (Kd; binding affinity for 
SERT and NET) values for the agents tested (where available) it would appear 
that both Norclomipramine and Nortriptyline have a higher binding affinity for 
the NET than the SERT.  
Generic Name Human SERT Kd(nM) Human NET Kd(nM) 
Amitriptyline 4.3 35.0 
Clomipramine 0.3 38.0 
Desipramine 17.6 0.8 
Doxepin 68.0 29.5 
Imipramine 1.4 37.0 
Norclomipramine *40.0 *0.45 
Nortriptyline 18.0 4.4 
Table 5.4.1 Antidepressant binding affinities for the serotonin transporter and 
norepinephrine: relevance to the ability of the tricyclics to induce apoptosis in 
glioma 
Data taken from (Tatsumi, Groshan et al. 1997) and *(Hyttel 1994) showing the 
equilibrium dissociation constants (Kd ) in nM. The drugs that are more selective 
for the NET than the SERT are highlighted in bold. The data shows that 
Norclomipramine and Nortriptyline are the most selective for the NET and this 
correlates with our observation in vitro that they are the most effective at causing 
tumour cell death. Although Desipramine was not screened in this study the data 
has been included to show the potential of this antidepressant in causing tumour 
cell death, if indeed the preference for NET over SERT is linked to ability to the 
initiation of apoptotic cell death.  
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5.4.4 Drawbacks of using tricyclic antidepressants as glioma therapy 
 
A possible drawback of using antidepressants in brain tumour therapy is the 
apparent down-regulation of associated transporters following chronic 
administration. In a study performed using human embryonic kidney (HEK) -293 
cells stably transfected with the human NET (hNET) it was shown that a 21-day 
incubation with Desipramine was sufficient to reduce the specific binding of 
[3H]nisoxetine in membrane homogenates in a concentration-dependent manner 
to 77% (Zhu, Blakely et al. 1998). These findings imply that the down-regulation 
is due to a selective reduction in hNET protein levels, presumably through a 
translational reduction or enhanced degradation of the hNET protein. Northern 
blotting indicated that exposure of the HEK-293 cells to Desipramine did not 
significantly alter mRNA levels. This data is however of limited clinical 
relevance since the cells used were from kidney and did not contain the native 
NET. Instead they were transfected with hNET cDNA under the control of the 
CMV promoter (Boshart, Weber et al. 1985). However it is possible that in a 
clinical setting down-regulation of the NET in brain tumour patients could pose a 
problem. An initial clinical trial may involve monitoring the expression of the 
NET during chronic administration of, for example, Nortriptyline. Indeed it is 
suggested that the expression of glial NET and SERT may be monitored via the 
expression on blood platelets (Uebelhack, Franke et al. 2006). This could provide 
a useful peripheral biomarker system for monitoring the transporter expression 
without the need for invasive procedures. There would be limited relevance for 
determining mRNA levels in platelets, since it is the protein levels that are 
affected, but binding ability could be monitored using radioactive ligands.  
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5.4.5 The significance of increased monoamine oxidase activity in glioma 
 
In Parkinson‟s disease a genetically-based or environmentally-produced defect in 
mitochondrial respiration and the monoamine oxidase clearance of clearance of 
the neurotransmitter dopamine from the cytosol of neurons is thought to 
contribute to the development or progression of the disease (Cassarino and 
Bennett 1999). The increased activity of dopamine causes an increased flux of 
hydrogen peroxide (H202), derived as a consequence of MAO activity, therefore 
H202-mediated damage is a possibility (Cohen, Farooqui et al. 1997).  
 
It is possible that a similar scenario exists for brain tumours, and that defects in 
the mitochondria of glioma cells, which prefer a hypoxic environment (Kaur, 
Khwaja et al. 2005), cause increased activity of MAO in clearing NE. It is known 
that MAO-generated H202 oxidises glutathione (GSH) to glutathione disulfide 
(GSSG), and GSSG reacts spontaneously with thiol groups in proteins to form 
protein-mixed disulfides (Holmgren 1985; Rabenstein and Millis 1995). If the 
affected protein thiols are essential for a particular activity, that function is 
suppressed (e.g. succinate dehydrogenase, NADH dehydrogenase, ATPase, 
isocitrate dehydrogenase and succinate-supported mitochondrial electron 
transport) (Berridge and Tan 1993; Benard and Balasubramanian 1995). 
Therefore the thiol redox state is an important determinant of mitochondrial 
function, which, in turn, affects cellular viability (Reed 1990; Meister 1995).  
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Further studies are required before it can be postulated that the NET transporter 
provides the much sought-after link between the action of tricyclic 
antidepressants and apoptotic cell death. Whilst we know that Clomipramine 
exerts its effects through complex III of the mitochondrial respiratory chain, it is 
not known what events take place between the cell membrane transporter that 
allow the influx of the TCAs into the tumour cells and the outer mitochondrial 
membrane. However the fact that the intracellular concentration of biogenic 
amines, such as NE, determine whether a cell undergoes apoptosis is a key factor 
(Toninello, Salvi et al. 2004). It is tempting to postulate, since normal human 
glial cells have the ability to remove excesses of circulating neurotransmitters 
from the synaptic cleft (to protect surrounding neurons), that glioma cells (some 
of which prefer a hypoxic environment, particularly glioma stem cells) thrive on 
the high turnover of NE and ROS produced from MAO degradation of NE. There 
is evidence to show that apoptosis protection afforded by high concentrations of 
biogenic amines may be related to their scavenger effect on reactive oxygen 
species and interaction with the MPTP (Toninello, Salvi et al. 2004). The results 
of one study performed on rat glioma cells showed that norepinephrine may 
afford protection against apoptosis through interaction with beta adrenoceptors 
(Canova, Baudet et al. 1997). Catecholamines such as NE are able to modulate 
VEGF, an angiogenic cytokine, through ß-adrenergic receptors (ARs). Recently 
NE has been shown to upregulate VEGF, matrix metalloproteinases (MMPs) and 
interleukins -8 and -6 (IL8; IL6) in human melanoma cell lines (Yang, Sood et al. 
2006; Yang, Kim et al. 2009). This is relevant to brain tumours as cells 
comprising the CNS and epidermal melanocytes have the same embryological 
origin, from the neural crest  (Gilbert 2008). 
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Taking together the knowledge that oxygen sensing takes place at complex III of 
the electron transport chain (Chandel, Budinger et al. 1997; Chandel 2002; Bell, 
Emerling et al. 2005; Brunelle, Bell et al. 2005; Bell and Chandel 2007), and 
evidence that Clomipramine exerts its effect via complex III (Daley 2001), it 
might be possible that by inhibiting the entry of NE into the tumour cell (through 
the use of tricyclic antidepressants such as Nortriptyline and Desipramine) the 
hypoxic environment may be disrupted and apoptosis triggered due to subsequent 
protein-s thiolation of GSH in the tumour cell which suppresses one or more of 
the enzymes comprising the electron transport complexes, namely complex III 
(Cohen, Farooqui et al. 1997). There is also the possibility that removing NE 
from the tumour cell (through blockade of the NET) downregulates VEGF and 
angiogenesis, as has been shown in melanoma (Yang, Sood et al. 2006; Yang, 
Kim et al. 2009).  
There is evidence to suggest that transformed cells use ROS signals to drive 
proliferation and other events required for tumour progression. This confers a 
state of increased basal oxidative stress, making them vulnerable to 
chemotherapeutic agents that further augment ROS generation or that weakens 
the antioxidant defences of the cell. In this respect, tumour cells may well die via 
apoptosis through the same systems that they require to thrive (Schumacker 
2006). 
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5.4.6 Future studies & development strategies associated with the 
norepinephrine transporter 
 
The next step in this research would be to investigate the effect of blockade or 
silencing of the NET. It is possible to design small interfering RNAs (siRNAs) 
against the NET that associate with the RNA-induced silencing complex (RISC) 
and cleave mRNA. If the NET was „knocked out‟ then downstream experiments 
would reveal any biological impact and indicate whether the NET is involved in 
the action of the tricyclic antidepressants. It is also important to confirm that 
brain tumour cells generate more ROS than normal brain cells and if the 
thioredoxin antioxidant system is paradoxically amplified in malignant cells.  
 
Finding new techniques for individualising patient therapy is a priority as the 
response to any given drug is highly variable across patient cohorts. This 
research is extremely relevant in oncology research as here, as in many other 
areas of therapeutics, chemotherapy needs to be performed within a narrow 
therapeutic index, balancing drug efficacy with significant drug toxicity.  
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6 The effects of tricyclic antidepressants on pro- and anti-
apoptotic markers in glioma 
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6.1 Introduction 
 
Malignant glioma are characterised by an intrinsic resistance to apoptosis, and 
the ability of component cells to efficiently repair DNA damage. Increasing 
evidence suggests that this is a fundamental mechanism by which gliomas evade 
elimination when treated with both conventional and targeted therapies. 
Increasingly, research is being focussed upon understanding the molecular 
mechanisms because a growing body of evidence would suggest that alterations 
in the apoptotic pathways are modulators of gliomagenesis and response to 
therapy.  
 
Traditional cancer treatments, radiotherapy and chemotherapeutics, induce 
apoptosis only as a secondary effect of the damage they cause to vital cellular 
components. These treatments affect most proliferating cells without distinction 
between malignant or normal types. Therefore Clomipramine, and other 
tricyclics that exert an effect on tumour cells only, is an attractive candidate for 
glioma therapy. It has been shown in chapter 3 that tricyclic antidepressants have 
the ability to induce apoptosis in glioma cells (see 3.4) and previous studies 
indicate that Clomipramine has a direct effect on the mitochondrion (Daley, 
Wilkie et al. 2005). However it has not yet been shown whether Clomipramine is 
able to modulate the expression of apoptotic markers, which might further direct 
its use as a neo-adjuvant or adjuvant therapy. Tumour cells acquire specific anti-
apoptotic mutations in the course of their malignant transformation, however 
they remain primed for apoptosis because of their underlying aberrant phenotype, 
therefore modulating the expression of apoptotic markers is a promising 
approach for glioma therapy.  
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6.1.1 A hypothesis-driven approach to design an apoptosis gene set 
 
It has long been a goal of cancer research to produce predictive molecular assays 
capable of widespread use.  Single genes are rarely useful, unless they happen to 
be the targets of the drugs concerned, but until recently it has been difficult to 
produce predictive multigene signatures.  Currently, there are two possible 
approaches to the generation of multigene signatures for predictive 
chemosensitivity testing.  The first is to screen very large numbers of genes using 
hybridisation arrays to generate signatures that correlate with clinical outcome 
(Wigle, Jurisica et al. 2002). The second is to take an hypothesis-driven approach 
to generate gene sets based on knowledge of the pathways involved in resistance 
and sensitivity to individual drugs (Kikuchi, Daigo et al. 2003).   In this study the 
latter approach has been taken using a pre-designed apoptotic gene set loaded 
onto 384-well cards. The genes included in this study are: Akt, Bad, Bax, Bcl-xL, 
Bcl-2, Bid, c-FLIP, Fas, Fas-L, HIF-1α, Hsp60, Hsp70, Hsp90, IAP2, MCJ, 
NFkB, p53, Survivin and XIAP. This gene set was not intended to be 
comprehensive, but to include apoptosis-related genes.  
 
6.1.2 The role of heat shock proteins and co-chaperones in apoptosis and 
cell death 
 
Methylation-controlled J protein (MCJ) is a newly identified member of the DnaJ 
family of co-chaperones. Co-chaperones associate with the heat shock protein 70 
(Hsp70) family of chaperones (Hsp90, Hsp70, and Hsp70) through these 
conserved domains and participate in protein folding and trafficking (Young, 
Hoogenraad et al. 2003).  
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Hypermethylation-mediated transcriptional silencing of the MCJ gene has been 
associated with increased resistance to chemotherapy in ovarian cancer. 
However, the biology and function of MCJ remains elusive. The MCJ protein, 
which localises to the mitochondria, has been shown to contribute to the 
chemosensitivity of tumours, and it stimulates Hsp70 ATPase activity 
(Hernandez Alvarado, Chien et al. 2006). MCJ was included in the apoptosis 
gene study because of its localisation to the mitochondria and association with 
Hsp70.  
 
Heat shock or stress response is a cellular adaptive response, which helps 
maintain cellular homeostasis under stress. Among the many changes in cellular 
activity and physiology, the most remarkable event in stressed cells is the 
production of a highly conserved set of proteins, the Heat Shock or Stress 
Proteins (HSPs) (Schlesinger 1986).  
 
Hsp90, which acts as a chaperone for unstable signal transducers to keep them 
poised for activation, interacts with phosphorylated Akt and promotes NFkB 
mediated inhibition of apoptosis; in addition it also blocks some steps in the 
apoptotic pathways. Interaction of Hsp90 and Akt leads to both promotion of cell 
survival through inactivation of Bad and caspase-9, and inhibition of apoptosis 
via NFkB (Ozes, Mayo et al. 1999).  
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Hsp70 is mostly anti-apoptotic and acts at several levels such as inhibition of 
translocation of Bax into mitochondria (Stankiewicz, Lachapelle et al. 2005), 
release of cytochrome C from mitochondria, formation of the apoptosome and 
inhibition of activation of initiator caspases (Tesniere, Panaretakis et al. 2008). 
When located inside cells Hsp70 inhibits apoptosis at multiple levels. Hsp70 may 
interact with Apaf-1 thereby inhibiting the formation of the apoptosome (the 
caspase-9-activating complex) that is required for post-mitochondrial activation 
(Beere, Wolf et al. 2000). Hsp70 also modulates JNK, NFkB and Akt signalling 
pathways in the apoptotic cascade. In contrast, Hsp60 has both anti- and pro-
apoptotic roles. Cytosolic Hsp60 prevents translocation of the pro-apoptotic 
protein Bax into mitochondria and thus promotes cell survival but it also 
promotes maturation of procaspase-3, essential for caspase mediated cell death 
(Arya, Mallik et al. 2007). 
 
6.1.3 The regulation of hypoxia-inducible factor in normoxic and hypoxic 
conditions 
 
The principal regulator of transcriptional responses to hypoxia is the hypoxia-
inducible factor (HIF) family of transcription factors. HIF is a heterodimeric 
complex comprised of an oxygen-regulated α subunit (HIF-α) (Semenza, Nejfelt 
et al. 1991; Semenza and Wang 1992). HIF-α is constitutively transcribed, and 
the protein continuously translated, however under normoxia it is rapidly 
degraded by the ubiquitin-proteasome system. Under hypoxic conditions HIF-α 
protein is not degraded and so accumulation allows it to heterodimerise and 
translocate to the nucleus (Huang, Arany et al. 1996; Huang, Gu et al. 1998).  
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The HIF-1α family member is an oxygen sensing transcription factor which 
requires the mitochondrial electron transport chain, in particular complex III, for 
stabilisation via an oxidant signal generation under hypoxic conditions (Talks, 
Turley et al. 2000; Sowter, Raval et al. 2003). 
 
6.1.4 Cellular form of FLICE-inhibitory protein 
 
The cellular form of FLICE-inhibitory protein (c-FLIP), which has also been 
analysed in this study, blocks death receptor-induced apoptosis and has been 
implicated in tumour progression. c-FLIP interacts with caspase-8, thereby 
preventing activation of the caspase cascade. A study of c-FLIP levels, alongside 
caspase-8 would be useful for agents that induce the extrinsic pathway of 
apoptosis.  
 
6.1.5 Prophylactic medications that may influence the ability to induce 
apoptosis in glioma 
 
As previously shown in chapter 4, see Table 4.2.2, patients with glioma 
frequently take prophylactic medications alongside chemo- and radio-therapy to 
reduce tumour-related side effects. Anticonvulsant drugs, such as Carbemazepine 
and Valproic acid, are taken to reduce the frequency of seizures and steroid drugs 
such as Dexamethasone are taken to reduce cerebral oedema. It is important to 
screen prophylactic agents for any influence they may have on the induction of 
apoptosis in tumour cells, to assess whether they would work synergistically or 
antagonistically with a tricyclic antidepressant, in addition to examining what 
effect they have on CYP450 enzymes as described in chapter 4.  
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6.2 Methods 
 
In this study quantitative RT-PCR has been used to examine the expression of 
several apoptosis-related genes thought to be involved in resistance to some 
chemotherapeutic agents used in brain tumours.  Three cohorts have been tested: 
 
a) Seventeen FFPE samples were screened for apoptotic gene expression 
b) SNB-19, DK-MG and UPAB (see Table 2.3.1) were incubated with 25% 
TDC (see 2.3.12) Clomipramine, Norclomipramine or Nortriptyline for 48 
hours 
c) DK-MG was incubated with 100% TDC Dexamethasone, Valproic acid or 
Procarbazine for 48 hours (see 2.3.12) 
Firstly seventeen FFPE tumour samples were screened using the TLDA cards to 
establish if the technique was feasible in glioma, secondly three tumours were 
exposed to three tricyclic antidepressants to see if apoptotic gene expression 
changed over 48-hours (the number of test agents was limited to three due to the 
number of samples that could be tested in one card) and thirdly DK-MG was 
exposed to Dexamethasone, Valproic acid and Procarbazine (two prophylactic 
agents and one agent used as part of the PCV regimen, see 1.7.2). The number of 
samples that could be carried out were limited by the high-cost of the assay (to 
run each sample costs approximately £200.00).  
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6.2.1 Patients and Samples 
 
6.2.1.1 Formalin-fixed paraffin-embedded tissue samples 
 
A series of 17 brain tumour samples were obtained from surgical specimens, 
from Hurstwood Park Neurological Centre, with patient consent.  All patients 
had formalin-fixed paraffin-embedded (FFPE) material taken for histology.  This 
provided a source of material for qRT-PCR, and immunohistochemistry. The 
age, sex and tumour type for each patient studied are given in Table 6.2.1.  
 
6.2.1.2 Exposing tumour cells to tricyclic antidepressants or prophylactic 
agents 
 
Glioma cells SNB-19, UPAB and DK-MG were propagated in tissue culture 
flasks according to the method outlined in 2.2.1, harvested according to 2.2.4 and 
seeded into 6-well plates at a density of 10,000 cells per ml. Each well of the 
plate contained 2.0 mls of cell suspension, into which the relevant tested agent 
was added (see 2.3.12 for test concentrations). The plates were incubated at 
37
o
C/5% CO2 for 48-hours before harvested and lysing in 1.0 ml RA1 Buffer 
(Machery Nagel) containing 10 µl beta-mercaptoethanol.  
 
6.2.2 Histology 
 
Haematoxylin and eosin staining (2.3.17) was performed on the seventeen FFPE 
patient samples prior to analysis with qRT-PCR microarray (Figure 6.2.2.1). The 
stained slides were used to line up the FFPE blocks with the stylet in the manual 
tissue arrayer (see 6.2.3).  
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Patient Identifier Age Sex Tumour Type 
TORC07-0003 49 F Normal human brain control 
TORC07-0009 45 F Oligodendroglioma (II) 
TORC07-0010 43 M Diffuse Astrocytoma (II/III) 
TORC07-0011 82 F Anaplastic Meningioma 
TORC07-0012 43 F Recurrent GBM (IV) 
TORC07-0013 39 M Schwannoma of spinal nerve root 
TORC07-0014 41 M Recurrent GBM (IV) 
TORC07-0015 45 M Anaplastic Oligodendroglioma (III) 
TORC07-0016 72 F GBM (IV) 
TORC07-0017 52 F Metastatic mammary ductal carcinoma 
TORC07-0018 74 M GBM (IV) 
TORC07-0019 59 F Recurrent GBM (IV) 
TORC07-0020 48 F Myxoid Degenerate Meningioma 
TORC07-0021 66 F GBM (IV) 
TORC07-0022 73 F Meningioma 
TORC07-0023 72 F Meningioma 
TORC07-0024 69 M GBM (IV) 
Table 6.2.1 Age, Sex and Tumour Type for glioma included in the pro- and anti-
apoptotic microarray study 
 
Material was obtained from 12 out of 17 sample blocks. No mRNA could be 
retrieved from TORC07-0014 (recurrent GBM), TORC07-0016 (primary GBM), 
TORC07-0017 (metastatic breast cancer), TORC07-0019 (recurrent GBM) or 
TORC07-0022 (Meningioma).  TORC07-0003 was a block of „normal‟ human 
brain tissue taken from the periphery of a tumour during standard debulking 
surgery. 
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A 
 
B 
 
C 
 
D 
 
E 
 
F 
Figure 6.2.2.1 Haematoxylin and eosin staining of glioma included in the pro- 
and anti-apoptotic microarray assay 
A selection of tumours, representing all types included in the study (see table 
6.2.1): Glioblastoma multiforme - A shows microvascular proliferation, 
vacuolation an endothelial cells surrounding the blood vessels. Glioblastoma 
multiforme - B has large neoplastic glia with eccentric nuclei and extensive 
eosinophilic cytoplasm. Erythrocytes can clearly be seen within the two large 
blood vessels. Meningioma – C demonstrates parallel arrays of swirling 
meningothelial cells. Psammomatous meningioma – D has the same features as C 
but in addition has psammoma bodies scattered amongst the meningothelial cells. 
Oligodendroglioma – E comprises small cells with dark nuclei, the cells have a 
„honeycomb‟ appearance and cytoplasmic vacuolation. Astrocytoma grade II/III 
– F is a highly cellular neoplasm, with large blood vessels present.  
  
50 µm 
50 µm 50 µm 
50 µm 50 µm 
50 µm 
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6.2.3 Extraction of mRNA from FFPE tumour tissue for use in the pro- 
and anti-apoptotic microarray study 
 
The haematoxylin and eosin (H&E) stained sections of selected formalin-fixed 
paraffin-processed blocks of brain tumour core tissue, previously marked with 
tumour areas of interest (AOI) by a Neuropathologist, were matched and overlaid 
onto the corresponding FFPE block.  The manual tissue arrayer (Beecher 
Instruments Inc, MTA1) fitted with a punch stylet 0.6 mm in diameter was 
aligned over the desired AOI, and punched out from the block. The stylet was 
decontaminated (Ambion DNA& RNA Zap) and cleaned (70% alcohol) between 
each FFPE block.  A minimum of two 0.6 mm punches were obtained from each 
block and placed in a sterile labelled 1.5 ml microcentrifuge tube. The tubes were 
then heated at 70 ˚C in a Stuart SBH200D heating block for 20 minutes. Excess 
paraffin wax was subsequently removed from the tissue using a sterile fine-tip 
plastic Pasteur pipette.   
 
Pre-warmed xylene (1.0 ml) was added to the tube and heated at 50 ˚C for 10 
minutes.  The microfuge tube was removed from the heating block, centrifuged 
at 12,000rpm (12 000g) for 2 minutes in a Sanyo MSE Microcentaur centrifuge.  
Waste xylene was then removed using a fine-tip pipette; the samples were 
washed two additional times with xylene. After the final wash the tissue had 
uncurled. Residual xylene was removed by the addition of 1.0 ml of 100% 
ethanol, and then the dewaxed sections were allowed to stand for 10 minutes at 
room temperature.  Following centrifugation at 12,000 rpm (12000g) for 5 
minutes the ethanol was removed by pipette, and the process repeated once again 
with 100% ethanol.  
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The microfuge tube lids were opened to allow the ethanol to evaporate 
completely at room temperature for 10 minutes, prior to protease digestion.  
 
Protease digestion was performed by use of an Ambion Recoverall kit™.  
Digestion buffer (200 µl) was added to each tube tissue sample to rehydrate the 
tissue, followed by the addition of protease (4 µl) and incubated for 3 hours at 
50˚C, with occasional flicking of the tube to encourage digestion.  240 µl of the 
Ambion RecoverAll™ Isolation Additive was added to the microfuge tube, 
which was then vortex mixed for 20 seconds and allowed to stand for 15 minutes 
at room temperature. The tubes were pulse spun in a microfuge at 12,000 rpm 
(12000g) for 30 seconds,  after ensuring that the liquid was at the bottom of the 
tube, the lysate was then passed ≥ 5 times through a 0.8 mm needle (21 gauge) 
fitted to a 1.0 ml sterile polypropylene syringe to break up any large pieces of 
tissue. The resulting lysate were then stored at -20˚C for RNA extraction. 
 
The stored lysate samples were thawed gently at +4
0
C before the RNA was 
extracted according to the method described in 2.3.23.2 and reverse transcribed 
to synthesise complementary DNA according to the method outlined in 2.3.23.3.  
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6.2.4 Extraction of mRNA from fresh tumour cells for use in the pro- and 
anti-apoptotic microarray study 
 
The RNA was extracted from the cell lysates (prepared according to 6.2.4) 
according to the method outlined in 2.3.23.2, quantified using a Nanodrop 
spectrophotometer (2.3.14) and reverse transcribed to cDNA according to the 
method outlined in 2.3.23.3. 
 
6.2.4.1 Constructing a standard curve 
 
 
To ensure reproducibility of the TLDA microarray card protocol a quality control 
tumour cDNA sample was made using fifty different tumours, both CNS and 
non-CNS. In brief, four 10 µm sections were cut from each of fifty tumour 
blocks and transferred into sterile eppendorf tubes. They were processed in the 
same manner as all other test samples according to the methods outlined in 
sections 6.2.3 and 2.3.23.3. The cDNA was then pooled and split into 40 µl 
aliquots and stored at -80
o
C.  
 
Prior to running the test tumour samples four dilutions of the QC cDNA were 
prepared, specifically 600, 300, 150 and 75 ng/µl of cDNA. The four samples 
were then pipetted into a TLDA card and run under a standard curve programme. 
The slope and R2 values for each gene were checked to ensure that the cards 
were operating correctly and that the fluorophore had not undergone any 
degradation during storage at +4
o
C.  
 
 
 256 
6.2.4.2 Polymerase Chain Reaction (PCR) using Taqman Low Density 
Arrays 
 
TLDA cards are 384-well microfluidic cards containing four sets of 96 identical 
genes. The 96 genes are split into two rows of 48, each with a loading port. The 
card contains a control housekeeping gene, 18S. The genes of interest to this 
study were related to apoptosis, and details of those selected for analysis are 
detailed in Table 6.2.2 below. Samples can be pipetted into the ports and 
subsequent centrifuging loads 1µl per well. The cards were run according to the 
manufacturer‟s instructions.  Each test sample (cDNA + mastermix) was made 
up with Taqman x2 Universal Master Mix with UNG Amperase (ABI, 4364338) 
and mixed with an equal volume of tumour cDNA (previously diluted with 
nuclease-free water to give 600ng/µl) to give a final concentration of 300 ng/µl.  
Four samples could be tested in one card (4 x 96 genes) by pipetting 100 µl into 
each of two ports (200 µl per sample required in total per card) of the 384 well 
cards.  
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Target Alternative Name 
Gene 
accession 
number ABI Assay ID 
APAF1 APAF1L NM_181861 Hs00559421_m1 
Bad Bcl2 antagonist of cell death NM_004322 Hs00188930_m1 
Bax Bcl2 associated X protein NM_004324 Hs00180269_m1 
Bcl2 - NM_000633 Hs00153350_m1 
Bcl-x(L) Bcl2L1 NM_138578 Hs00236329_m1 
Bid - NM_197966 Hs00609630_m1 
c-FLIP CFLAR NM_003879 Hs00153439_m1 
Fas 
TNF receptor superfamily, 
member 6 NM_000043 Hs00163653_m1 
Fas-L FASLG NM_000639 Hs00181225_m1 
HIF1A Transcription factor NM_001530 Hs00153153_m1 
HSP60 HSPD1 (Protein Folding) NM_002156 Hs01866140_g1 
HSP70 HSPA4 (Protein Folding) NM_002154 Hs00382884_m1 
HSP90 HSPCA (Protein Folding) NM_005348 Hs00743767_sH 
IAP2 BIRC2 NM_001166 Hs00357350_m1 
MCJ  DNAJC15; Hsp50 NM_013238 Hs00387763_m1 
NFkB NFKB1 NM_003998 Hs00231653_m1 
p53 TP53 NM_000546 Hs00153349_m1 
Survivin BIRC5 NM_001168 Hs00153353_m1 
XIAP BIRC4 NM_001167 Hs00236913_m1 
Table 6.2.2 The apoptosis genes included in the study 
 
To ensure quality control the master mix and nuclease-free water was aliquoted 
into sterile eppendorf tubes within a class II laminar flow hood designated for 
„clean‟ work only, i.e. an environment where no nucleic acid work was carried 
out. The tubes were then closed and transferred to a class II laminar flow hood 
designated for cDNA work only prior to the addition of the relevant volumes of 
cDNA. To check the reproducibility of the assay, purity of samples and operator 
accuracy a positive control (QC cDNA) and a „blank‟ (omission of cDNA and 
substitution with nuclease-free water) were included in the first card run. The 
loaded TLDA card was then placed, port upwards, into a balanced centrifuge 
(Sorvall Legend T, DJB Labcare) and spun at 2000rpm/380g to fill the card.   
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This was checked and the card spun again at 2000rpm/380g to remove any air 
bubbles. The card was then placed in a TLDA slide sealer, sealed, and the 
loading ports cut from the card before it was loaded into an AB 7900HT thermal 
cycler.  PCR was performed for 90 min with the following conditions: AmpErase 
UNG Activation for 2 min at 50 °C; AmpliTaq Gold DNA Polymerase 
Activation for 10 min at  94.5 °C ; followed by 40 cycles each of Melt 
Anneal/Extend for 30 sec at 97°C and 1 min at 59.7°C The „Auto Threshold 
Cycle‟ function was performed at the end of the run and resulting Ct data from 
the TLDA card was transferred to a Microsoft Excel spreadsheet, controls 
checked, and the data transferred to a Microsoft Access database for further 
analysis. 
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6.3 Results 
 
Real time PCR is the most sensitive technique for detecting mRNA (an 
indication that transcription is taking place) compared to Northern blotting and 
the RNase protection assay (the two other commonly used assay for quantifying 
mRNA levels) and is sensitive enough to enable quantitation of RNA from a 
single cell (Dharmaraj 2011). Of the seventeen patient samples selected for the 
study, only twelve had detectable levels of housekeeping genes via qRT-PCR. 
Eleven of these were tumours and one was the normal brain control. In the five 
remaining samples, no housekeeping genes were detected so these samples were 
not analysed.  It was assumed that this was due to the processing of these 
particular samples, whereby they had been stored in 10% buffered formalin for a 
number of months to years. Some of the samples had been transported to the 
laboratories in culture media before fixation in formalin (so a portion of the fresh 
tissue could be used for culturing) and this may have affected the quality of the 
nucleic acids. The presence of nucleases in all eukaryotic cells, particularly 
RNases, which are fairly small, compact proteins containing several cysteine 
residues that form numerous intramolecular disulfide bonds, causes problems 
when transporting biopsy tissue for analysis unless the RNases have previously 
been denatured (Srinivasan, Sedmak et al. 2002). Because of the delay in 
embedding the samples the RNA may have fragmented, due to the RNases 
ubiquitously found in fresh cells, so despite the qualification of both RNA and 
cDNA by the Nanodrop Spectrophotometer the quality of the cDNA template 
was too poor for analysis. In the twelve samples that were successfully analysed 
via qRT-PCR the housekeeping gene was present, 18S. 
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6.3.1 Constructing a standard curve to ensure efficiency of primers 
corresponding to pro- and anti-apoptotic genes of interest in glioma 
 
Before running any tumour test cDNA samples the standard curves (Figure 
6.3.1.1; Figure 6.3.1.2; Figure 6.3.1.3) were checked to ensure that slope and R2 
values correlated with those of historical standard curves (Figure 6.3.1.4). This is 
a measurement of primer efficiency, and in turn the efficiency of identifying the 
genes of interest. If the fluorophore or primers are faulty then it can be picked up 
prior to running any valuable test cDNA. The plots generated are Ct values 
against log dilution and for relative quantification the amount of cDNA is not 
required. For a 10-fold dilution you should expect a shift of 3.33 cycles to the 
right because efficiency = 10^(-1/slope)-1. If the slope value is less than -4 
(which equates to 77% efficiency) then there is an error that needs to be rectified 
before proceeding with test samples.  
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Figure 6.3.1.1 The standard curve for housekeeping gene 18S used to check 
primer efficiency of the pro- and anti-apoptotic gene set selected for glioma 
The screen capture shows the slope value (-2.91) and R2 value (0.93) 
respectively. The slope value should be as near to -3.3 as possible because this 
represents 100% efficiency. The R2 value should be as near to 1 as possible, 
these two values and the plots themselves show that the standard curve was very 
accurate. There are no outliers and the values obtained are consistent with that of 
historical standard curves run on the 7900HT.  
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Figure 6.3.1.2 The standard curve for c-FLIP  used to check primer efficiency of 
the pro- and anti-apoptotic gene set selected for glioma 
 
The standard curve screen capture for c-FLIP shows a slope of -4.25 and an R2 
value of 0.999, these are deemed accurate according to historical data obtained 
for the 7900HT.  
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Figure 6.3.1.3 The standard curve for Fas  used to check primer efficiency of the 
pro- and anti-apoptotic gene set selected for glioma 
 
The screen capture for Fas shows a slope of -3.18 and an R2 value of 0.99 which 
is deemed accurate according to historical data obtained for the 7900HT.  
 
 
To ensure the accuracy and reproducibility of the microarray cards and the 
efficiency of the housekeeping gene an audit was performed on QC data for 
housekeeping gene 18S. Each time the QC pooled cDNA sample was run on a 
card the values for 18S were stored and compared over 18 months.  
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Figure 6.3.1.4 A timeplot of the Ct values for housekeeping gene 18S run using 
the QC pooled cDNA sample 
 
The number of samples (n) was 42, the mean was 23.1, CV was 2.98% and the p-
value (at 95% confidence interval) was 9.52. This shows that the variance in Ct 
values was low over an 18-month time period, and indicates that reproducibility 
of the assay is high.  
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6.3.2 Analysing pro- and anti-apoptotic gene expression data in seventeen 
formalin-fixed paraffin-embedded glioma test samples 
 
 
To calculate relative gene expression of the test samples when compared to the 
housekeeping gene, the comparative method, which is based upon the 
exponential description of the PCR process assuming constant amplification 
efficiency equal to 1, was used. Data was first manipulated by calculating 2^-Ct 
for each gene and then standardised by dividing the 2^-Ct values by that for the 
housekeeping gene, 18S. The values were then transformed using the natural log 
of the standardised value, which assumes normal distribution, was then 
calculated to give relative gene expression.  
 
To analyse the quality of the data obtained a whisker and box plot was 
constructed (see Figure 6.3.2.1), this is a histogram-like method for plotting data 
to show the accuracy of the values obtained and compare expression of the genes 
across all samples tested.  
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Figure 6.3.2.1 The box and whisker plot for pro and anti-apoptotic TLDA values obtained for all glioma test samples 
The box represents 1/2 of the Ct values and is constructed using the first and third quartiles for each gene. The median value should intersect 
across the middle. The lines or „whiskers‟ represent the minimum and maximum values (the range). The data shows that the Ct values obtained 
for the pro- and anti-apoptotic genes are skewed and there is variation in the Ct values obtained. This also indicates a large degree of 
heterogeneity in the samples tested because the range of expression varies greatly. 
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
22.00
24.00
26.00
28.00
30.00
32.00
34.00
36.00
38.00
40.00
42.00
18
s
A
kt
A
PA
F1
B
ad B
ax
B
cl
-x
(L
)
B
cl
2
B
id
c-
FL
IP
Fa
s
Fa
s-
L
H
IF
1A
H
SP
70
H
SP
90
IA
P2
M
C
J
N
Fk
B
p5
3
Su
rv
iv
in
XI
A
P
Apoptotic Genes of Interest
C
t 
V
a
lu
e
s
Quartile 1 Min Median Max Quartile 3
           
 267 
The values on page 268 were either negative (expressed at levels lower than the 
housekeeping gene, 18S) or positive (expressed at levels higher than the 
housekeeping gene). The normal brain sample expressed five genes (Akt, Bid, c-
FLIP, Hsp70 and Hsp90) at levels lower than the housekeeping gene 18S and the 
remaining pro- and anti-apoptotic genes (Bcl-2, Bcl-xL, IAP2, Survivin, Bax, 
XIAP, Fas, Fas-L, HIF-1a and MCJ) came up as „undetermined‟ meaning that 
the levels were so low they could not be detected by the assay. Genes that are 
undetected by the TLDA assay are expressed, but not upregulated. Of eleven 
tumours tested, only TORC07-0009, TORC07-0011, TORC07-0015, TORC07-
0018 and TORC07-0021 had detectable upregulation of the pro- and anti-
apoptotic genes. These are all chemotherapy naïve tumours; if these tumours had 
been exposed to chemo- or radio-therapy prior to analysis there might be 
acquired chemoresistance and upregulation of anti-apoptotic genes present and 
downregulation of the pro-apoptotic genes that were detected in this study (Bid 
and Bax) (Sarkaria, Kitange et al. 2008; Oliva, Nozell et al. 2010). 
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Table 6.3.1 A table of pro- and anti-apoptotic genes that were upregulated in five of the glioma tested via TLDA microarray 
On the left hand side are the names of pro- and anti-apoptotic genes included in this study, across the top are the five tumours for which genes 
were detected. The genes that were upregulated in the five tumours presented here are shown in blue. Genes that are not relevant to the tumour 
are blacked out. TORC07-0009 displays the greatest number of upregulated anti-apoptotic genes, suggesting a resistant phenotype. The genes 
represent susceptibility to apoptosis, and therefore susceptibility to mitochondrially-targeting agents such as Clomipramine.  
 
  TORC07-0009 TORC07-0011 TORC07-0015 TORC07-0018 TORC07-0021 
  Oligodendroglioma Anaplastic 
Meningioma 
Anaplastic 
Oligodendroglioma 
GBM GBM 
        
Bcl-2           
Bcl-xL           
IAP2           
Survivin           
Bax           
Bid           
XIAP           
Fas           
Fas-L           
HIF-1a           
Hsp70           
Hsp90           
MCJ           
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The data indicates that it is possible to extract mRNA, of high-enough quality for 
detection of nucleotide sequences specific to pro-and anti-apoptotic genes of 
interest, from FFPE brain tumour tissue. The quality of the material that can be 
obtained is largely dependent on the fixation process, in particular the time taken 
between surgery and placing the sample into buffered formalin. 
 
Factors that affect mRNA 
retrieval and quality 
Recommendations 
Tissue autolysis    Cut samples into small pieces 
 
 Place fresh samples in DMEM + antibiotic for 
transport 
 
 Transport in cooled container 
 
 Start fixation within 24 hours of resection  
 
Nucleic acid degradation 
via endogenous nucleases 
Efficiency of cDNA 
synthesis 
 Avoid over fixation – 24 hours maximum to 
avoid irreversible crosslinks 
 
 Store FFPE blocks at 4oC – minimises 
fragmentation of RNA 
 
 Do not store pre-cut sections – sections should 
be taken from blocks as required and used 
immediately (exposure to light and air affects 
RNA quality) 
 
RNA integrity  Isolate RNA within a year after fixation and 
embedding for optimal nucleic acid retrieval 
 
Table 6.3.2 A summary of factors that affect the quality of mRNA obtained from 
FFPE glioma biopsies for use in TLDA microarray 
The time taken between steps to obtain fresh surgical biopsy tissue, fixation and 
extraction of mRNA determines the quality of cDNA that can be synthesised for 
examining the expression of pro- and anti-apoptotic genes in glioma(von Ahlfen, 
Missel et al. 2007). Looking at the number of samples in which housekeeping 
genes were detected, the most influential time period in this study appears to be 
between placing the samples in buffered formalin and embedding in paraffin, 
overfixation resulting in irreversible cross links and poor quality of nucleic acid 
retrieval.  
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If a large enough number of samples could be taken and studied it might be 
possible to create a signature of apoptosis genes that are upregulated or 
downregulated in certain tumour types. A larger sample group would yield better 
quality of data and potential statistical significances between gene expression and 
tumour type or tumour grade of malignancy. Because of the advances in 
oncology tumours are detected sooner and, as with somatic cancers, the amount 
of tissue available for researchers to perform chemosensitivity tests on will 
become smaller. This means that molecular tests, capable with only small 
amounts of nucleic acid from fresh or FFPE tissue need to be developed.  
 
 
 
6.3.3 Analysing pro- and anti-apoptotic gene expression changes in cells 
incubated with tricyclic antidepressants 
 
 
Each tumour had been exposed to Clomipramine, Norclomipramine, 
Nortriptyline alongside a negative control (untreated cells with omission of any 
test agents) to enable comparative expression to be calculated via the same 
method outlined in 6.3.2. The Ct values obtained for each test agent were first 
normalised against the housekeeping gene, then the values obtained for 
corresponding negative controls were subtracted from the values obtained for test 
samples to show change in expression of mRNA following drug exposure. The 
results shown are pro-apoptotic changes in expression following drug exposure 
compared to the untreated control, to evaluate if any of the three agents acts pro-
apoptotically. For some genes a Ct value was „undeterminable‟, and therefore 
these genes were not actively being translated into a functional product.  
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Figure 6.3.3.1 The change in expression of apoptosis-related genes following 
exposure of glioma cell line SNB-19 to three tricyclic antidepressants 
 
The results shown are those in favour of the SNB-19 cells undergoing apoptosis; 
therefore they either represent an upregulation in pro-apoptotic genes or 
downregulation of anti-apoptotic genes. Bid and p53, the expression of which 
promotes apoptosis, were upregulated following exposure to Clomipramine. C-
FLIP, Hsp70, Hsp90 and Survivin were downregulated following Clomipramine 
exposure, c-FLIP, Hsp-70, Hsp-90, IAP2 and Survivin were downregulated 
following Norclomipramine exposure and Hsp70 and XIAP were downregulated 
following Nortriptyline exposure. HIF-1α is involved in resistance to apoptosis 
and was upregulated following exposure to all three tricyclics and shows 
response, and adaptation, of the tumour to drug exposure.  
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Figure 6.3.3.2 The change in expression of apoptosis-related genes following 
exposure of glioma early passage culture UPAB to three tricyclic antidepressants 
 
The results shown are those in favour of the UPAB cells undergoing apoptosis; 
therefore they either represent an upregulation in pro-apoptotic genes or 
downregulation of anti-apoptotic genes. Bad and MCJ were upregulated 
following exposure to Clomipramine, p53 was upregulated following exposure to 
Clomipramine and MCJ was upregulated following exposure to Nortriptyline. 
Hsp90 and HIF-1α were downregulated following Norclomipramine exposure, 
Bcl-xL, Bcl-2, c-FLIP, HIF-1α, Hsp90, IAP2, Survivin and XIAP were 
downregulated following exposure to Clomipramine and c-FLIP and XIAP were 
downregulated following Nortriptyline exposure. When UPAB cells were 
exposed to Nortriptyline HIF-1α was upregulated, which is the same effect when 
SNB-19 was incubated with the same agent.  
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Figure 6.3.3.3 The change in expression of apoptosis-related genes following 
exposure of glioma cell line DK-MG to three tricyclic antidepressants 
 
Following exposure to Clomipramine, Fas, HIF-1α and p53 were upregulated in 
DK-MG, whereas Hsp60, Hsp90 and IAP2 were downregulated. Following 
exposure to Norclomipramine, Fas, HIF-1α and MCJ were upregulated and c-
FLIP, Hsp60, Hsp90 and Survivin were downregulated. Following exposure to 
Nortriptyline, Fas, HIF-1α and MCJ were upregulated whereas c-FLIP, Hsp60 
and Survivin were downregulated. All changes, apart from those seen in HIF-1α, 
are in favour of apoptosis. The upregulation of HIF-1α is a response to drug 
exposure and indicates the tumour is resisting apoptosis.  
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The changes observed in all three tumours, when exposed to tricyclic 
antidepressants, show changes in expression which favours apoptosis. Even 
though the upregulation of HIF-1α does not pertain to increased susceptibility to 
apoptosis it was included in the data because it is a marker that requires complex 
III for stabilisation and was functionally expressed in all tumours and in the two 
cell lines was upregulated in response to cellular stress, i.e. drug exposure. In 
UPAB HIF-1α was downregulated, compared to the untreated control, following 
exposure to Clomipramine and Norclomipramine. It is difficult to isolate and 
explain the observations of a single gene, and further reinforces the need for 
studies on multiple genes of interest.  
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6.3.4 Analysing pro- and anti-apoptotic gene expression changes in DK-
MG incubated with Dexamethasone, Valproic acid and Procarbazine 
 
 
Figure 6.3.4.1 The change in expression of apoptosis-related genes in glioma cell 
line DKMG following exposure to procarbazine, dexamethasone or valproic acid 
 
Incubating glioma cell line DKMG with Procarbazine for 24 hours resulted in 
downregulation of ten anti-apoptotic markers, of particular interest are Bcl-xL, 
Bcl-2 and XIAP which were not affected following incubation with tricyclic 
antidepressants (see 6.3.3). HIF1-α was downregulated following Procarbazine 
exposure, suggested reversal of drug resistance adaptation and MCJ was 
upregulated suggesting chemosensitivity of this tumour. Looking at this data, 
Procarbazine would be a useful agent to combine with a tricyclic antidepressant, 
particularly Clomipramine (incubation with which resulted in the lowest 
expression change for HIF1-α, see 6.3.3) therefore exposing DKMG to 
Procarbazine for 24 hours prior to Clomipramine might demonstrate a synergistic 
effect. The effect of DEX on DKMG cells is also quite evident, with a visible 
downregulation of Bcl-xL, IAP2 and XIAP; however unlike following 
Procarbazine exposure, Bcl-2 is not affected.  
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Like Procarbazine, DEX downregulated HIF1-α and upregulated MCJ, which 
indicates sensitivity to chemotherapy. Dexamethasone, unlike Procarbazine, is a 
prophylactic prescribed to many glioma patients and data showing its pro-
apoptotic properties indicates that it needs further investigation. Valproic acid, 
like DEX, is a prophylactic anti-seizure medication prescribed to some glioma 
patients (see data in Table 4.2.2) and when DKMG was exposed to this agent the 
pro-apoptotic proteins Bad, Bax and Bid were upregulated whereas the anti-
apoptotic proteins XIAP and Bcl-2 were downregulated compared to the 
untreated control cells. The modulation of these proteins is in favour of the cells 
undergoing apoptosis, and therefore represents a pro-apoptotic effect.  
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6.4 Discussion 
Cancer is a complex process of changes in gene expression and altered regulatory 
pathways leading to severe changes as tumours develop. Mutations can act in 
different steps in cell division, motility, adherence or invasion, all of which 
contribute to cancer (Rempel 1998). A change in the splicing pattern of a gene 
(through the addition of extra base pairs) can affect different steps in the life of a 
cell. This can be cell growth, adhesion, migration, invasion and cell death. 
Additionally, the ways in which splicing is regulated can be altered leading to 
subsequent tumour formation. In normal human cells tumour suppressors keep 
cell growth in check and the proteins that regulate splicing are present in normal 
amounts. This chapter demonstrated the technical procedures required to 
examine apoptotic gene expression patterns in glioma and the effect that three 
tricyclic antidepressants, two clinically-relevant prophylactic medications and a 
traditional chemotherapy agent had on glioma cells. 
 
6.4.1 The role of Survivin in apoptosis of glioma 
 
Survivin, one of the apoptosis inhibitor proteins, has been detected in most 
cancers in humans (Grzybowska-Izydorczyk, Cebula et al. 2010; Kalliakmanis, 
Kouvidou et al. 2010; Kim, Kim et al. 2010; Rodriguez-Berriguete, Fraile et al. 
2010; Small, Keerthivasan et al. 2010; Stenner, Weinell et al. 2010; Taubert, 
Heidenreich et al. 2010; Adamkov, Halasova et al. 2011; Bayram, Akkiz et al. 
2011; Carrasco, Stamm et al. 2011; Jha, Shukla et al. 2011; Lechler, Renkawitz 
et al. 2011; Miura, Fujibuchi et al. 2011; Oliveras-Ferraros, Vazquez-Martin et 
al. 2011; Qian, Xi et al. 2011).  
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In addition, two splice variants (survivin-2B and survivin-deltaEx3) have been 
identified. The downregulation of Survivin was demonstrated in DKMG cells 
following exposure to Procarbazine, Norclomipramine and Nortriptyline (see 
6.3), in UPAB following exposure to Clomipramine and in SNB-19 following 
exposure to Norclomipramine and Clomipramine. Therefore Survivin is a target 
for tricyclic antidepressant therapy in glioma. The results agree with one study 
where nine cell lines were tested, and Glioblastoma cell lines showed the highest 
levels of Survivin expression. The relative expression level of survivin-
deltaEx3/Survivin was significantly higher in malignant than in benign brain 
tumour samples. Expression patterns were dominant for survivin-deltaEx3 in 
malignant brain tumours and dominant for survivin-2B in benign ones. 
Quantifying the levels of Survivin and its splice variants is useful for the 
prediction of the cell biological malignancy of glioma, independent of their 
pathological features (Yamada, Kuroiwa et al. 2003). It is also useful for 
demonstrating tumours in which a tricyclic antidepressant might be a useful 
therapy.  
 
6.4.2 The role of Bcl-2 family proteins of modulating apoptosis in glioma 
 
Because of their critical role in modulating the intrinsic apoptotic pathway, the 
Bcl-2 family of proteins and others have been studied in human glioma cell lines. 
Whilst both pro- and anti-apoptotic members have been shown to be expressed, 
the number of tumours upregulating genes is low. This might be due to the 
tumours being chemotherapy naïve.  
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Paradoxically, an overexpression of anti-apoptotic proteins has been found in 
lower-grade Astrocytoma, compared with GBMs (Steinbach and Weller 2004). 
This could be a sampling artefact, and difficulty in selecting an AOI has been 
demonstrated in this study (Figure 6.2.2.1) with tumours demonstrating 
heterogeneous cell populations or it may be a bad prognostic indicator for certain 
groups of lower grade glioma (therefore further cases are required). Recurrent 
GBMs have been shown to exhibit upregulation of anti-apoptotic proteins Bcl-2 
and Bcl-xL, and down regulation of pro-apoptotic Bax (Steinbach and Weller 
2004). In this study the most compelling data on the Bcl-2 family results from 
exposing cells to tricyclic antidepressants, to drive a chemoresistant response. 
Slight changes were observed following exposure of UPAB to Clomipramine 
(Figure 6.3.3.2); however the most evident changes in expression were noted 
following exposure to Dexamethasone and Procarbazine (see Figure 6.3.4.1).  
 
6.4.3 Upregulation of Bax, Bcl-xL and IAP2 suggests caspase blockade in 
TORC07-0021 
 
There was upregulation of pro-apoptotic mRNA Bax and anti-apoptotic protein 
Bcl-xL (when compared to the normal brain sample). This would suggest that the 
ability to undergo MOMP in this tumour remained intact. Unfortunately no data 
was obtained for Bid in this tumour, but the data does show upregulation of IAP2 
which is an inhibitor of caspase activation. In TORC07-0021 it could be 
postulated that resistance to apoptosis would be conferred by blockage of caspase 
activation by IAP2. It might be possible, in this instance, to use an agent that 
mimics the function of Smac and releases the IAPs from blocking caspase 
activation.  
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6.4.4 Upregulation of Bcl-2, Bcl-xL, IAP2 and Survivin suggests resistance 
of TORC07-0009 to undergo intrinsic pathway of apoptosis 
 
Higher levels of Bcl-2 in HGG have been shown to correlate positively with 
survival (McDonald, Ironside et al. 2002). In TORC07-0009 (grade II 
Oligodendroglioma) Bcl-2 has been up-regulated (compared to normal brain) and 
as a single gene is impossible to discriminate between whether it is an anti-
apoptotic marker or extended survival marker. Because this tumour has been 
analysed against a series of related apoptosis genes it is possible to build up a 
profile. The pro-apoptotic proteins Bax and Bid are not upregulated, suggesting 
the inability to undergo MOMP. There is upregulation of anti-apoptotic Bcl-xL 
and Bcl-2, and upregulation of IAP2 and Survivin (which are both IAPs). This 
would suggest that the balance tilts in favour of blockade of intrinsic apoptosis. 
There is upregulation of Fas and Fas-L suggesting that the receptor and ligand 
through which extrinsic apoptosis is mediated is intact. This represents a target in 
this tumour, if it were possible to induce extrinsic apoptosis while simultaneously 
activating Bid either through caspase-8 cleavage, or even directly, it may be 
possible to manipulate the intersection of the intrinsic pathway and bypass all the 
cellular blockades. It is, after all, generally accepted that the use of a single agent 
will confer little or no benefit because it is necessary to combine both an inducer 
and an inhibitor to steer the cascade in the direction away from blockade.  
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6.4.5 Detection of Bid in TORC07-0015 suggests proteins required for 
mitochondrial outer membrane permeabilisation are upregulated 
 
TORC07-0015 (grade III Oligodendroglioma) showed an upregulation of pro-
apoptotic Bid suggesting that MOMP could take place in this tumour, however 
the upregulation of XIAP and IAP2 show that apoptosis would be blocked at the 
caspases. Because Fas-L is up-regulated but the Fas receptor is not, it would not 
be possible to induce the extrinsic pathway of apoptosis through this particular 
death receptor. Both MCJ and Hsp90 are up-regulated in this tumour; MCJ is the 
co-chaperone protein for anti-apoptotic chaperone protein Hsp90, yet was found 
to be expressed in cells that are sensitive to chemotherapy (Hatle, Neveu et al. 
2007). Again, this demonstrates the need for a multigene approach towards 
profiling tumours. As „stand alone‟ markers proteins mean an entirely different 
interpretation to when they are up-regulated and analysed alongside other 
proteins. The MCJ protein is also up-regulated in TORC07-0021 (GBM) but 
alongside the up-regulation of Bax would appear favourable in terms of 
sensitivity to chemotherapy.  
 
6.4.6 Upregulation of anti-apoptotic genes in TORC07-0018 suggest a 
resistance to undergo caspase-dependent apoptosis 
 
There was an upregulation of the inhibitors of apoptosis IAP2 and XIAP in 
TORC07-0018 (grade IV GBM) and also an upregulation in the Fas receptor. 
This would suggest that if a stress signal was received, the intrinsic pathway of 
apoptosis could be triggered but the caspases are inhibited by the IAPs. Again, a 
Smac analogue might reverse the blocking action of the IAPs in this tumour.  
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6.4.7 Upregulation of MCJ in TORC07-0011 might indicate sensitivity to 
chemotherapy 
 
TORC07-0011 (Anaplastic Meningioma) showed upregulation of just one gene, 
the MCJ protein. The MCJ protein was shown to be downregulated in a series of 
ovarian tumours that were resistant to standard chemotherapeutic agents 
(Hernandez Alvarado, Chien et al. 2006). This may indicate that TORC07-0011 
is sensitive to chemotherapy, as it also has no upregulation of anti-apoptotic 
genes.  
 
6.4.8 Exposure to tricyclic antidepressants, Procarbazine, Dexamethasone 
and Valproic acid modulates the expression of apoptotic genes in 
Glioblastoma multiforme 
 
Following exposure to Clomipramine, Norclomipramine and Nortriptyline, three 
GBMs exhibited changes in the expression of pro-apoptotic genes and following 
exposure to Procarbazine, Dexamethasone and Valproic acid changes in pro-
apoptotic genes were observed in DK-MG. Forty-eight hour exposure was 
sufficient to elicit changes in gene expression in the GBMs tested and the 
concentrations tested were clinically achievable. All agents tested showed 
modulation of apoptosis-related genes and should therefore be studied in more 
detail as to the influence they may have on the success or failure of a 
chemotherapy regime. Other novel agents that have been shown to modulate the 
expression of apoptosis-related genes are gamma linolenic acid (GLA), which 
upregulated Bax in C6 glioma cells (and also downregulated the DNA repair 
gene Ku80), and boswellic acid which showed a slight downregulation of Bcl-2 
in LN-18 cells (Glaser, Winter et al. 1999; Benadiba, Miyake et al. 2009).  
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Boswellic acid was investigated for use as an alternative to Dexamethasone in 
the treatment of tumour-associated oedema in glioma, as Dexamethasone is 
reported to affect the cytotoxicity of traditional chemotherapy agents, however 
Dexamethasone might prove useful if given in combination with Clomipramine. 
The study showed that boswellic acid compared favourably with Dexamethasone 
(Kirste, Treier et al. 2011). 
 
6.4.9 Using an antisense approach to target anti-apoptotic protein Bcl-2 in 
glioma 
 
Several preclinical studies have demonstrated the feasibility of targeting Bcl-2 in 
glioma using an antisense approach. Antisense directed at Bcl-2 or Bcl-xL 
resulted in glioma cell death and sensitisation to the effects of chemo- and radio-
therapy (Guensberg, Wacheck et al. 2002; Jiang, Zheng et al. 2003; Zhu, Li et al. 
2003). Clinical trials of Oblimersen, an anti Bcl-2 agent, in melanoma have 
shown that whilst it can be administered with no significant toxicity but minimal 
antitumour activity was demonstrated (Bedikian, Millward et al. 2006). This lack 
of clinical activity observed in vivo reinforces the fact that single agents, both 
antisense and standard chemotherapy, generally confer little benefit because of 
the high degree of „intelligence‟ of these aggressive tumours. Bcl-2 is only one 
member of a family of proteins that collectively impart a tumourigenic effect. 
This is especially true for the malignant glioma where no single anti-apoptotic 
protein is responsible for blocking the apoptotic cascade and data in 6.3 provides 
further evidence that Bcl-2 family proteins are upregulated and downregulated 
with no set pattern.  
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6.4.10 Other approaches to target the Bcl-2 family in glioma 
 
A more feasible approach for malignant glioma would be an agent capable of 
targeting the Bcl-2 family in a broader manner. Walensky et al. demonstrated this 
approach by developing peptides with a hydrocarbon „staple‟ that facilitated 
successful inhibition of Bcl-2 in vitro and in animal models (Walensky, Kung et 
al. 2004). HA14-1 represents the first small molecule inhibitor to be reported to 
possess anti-glioma activity in preclinical studies. It was demonstrated to 
enhance glioma cells to radio- and chemotherapy via inhibition of Bcl-2 binding 
to Bax (Manero, Gautier et al. 2006). This would allow the cell to undergo 
MOMP and allow the release of cytochrome C and Smac into the cytosol.  
 
Several small molecule inhibitors are now in clinical development, the 
compound that has progressed furthest to date is ABT-737 (Abbott Laboratories, 
Abbott IL), a small molecule that simultaneously and efficiently inhibits Bcl-2, 
Bcl-xL and Bcl-w (Oltersdorf, Elmore et al. 2005). So far it has not been tested 
in glioma, but has activity against multiple haematological malignancies and 
small-cell lung cancer (Oltersdorf, Elmore et al. 2005; Konopleva, Contractor et 
al. 2006; Del Gaizo Moore, Brown et al. 2007; Kang, Kang et al. 2007; Kline, 
Rajkumar et al. 2007; Kohl, Hellinger et al. 2007; Trudel, Stewart et al. 2007). 
The difficulty in treating glioma, not necessarily seen in somatic tumours, is the 
heterogeneity of the subpopulations of cells comprising the tumours and the 
heterogeneity between patients. ABT-737 may work in patients with 
upregulation of Bcl-2, Bcl-xL and Bcl-w but not in patients with up-regulated 
IAPs. Therefore screening patients for their apoptotic gene signature would be of 
clinical value.  
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It would also be important to screen patients for apoptosis gene expression before 
and after treatment, since recurrent glioma are likely to have altered their 
expression and become resistant in order to establish an unbalanced apoptotic 
protein ratio for a second time. From the data obtained in this study, together 
with that reported by others, there is the suggestion that the general susceptibility 
of the cell to undergo apoptosis may be an important determinant of tumour 
chemosensitivity, outweighing more specific mechanisms (Cree, Knight et al. 
2002). The qRT-PCR method can be performed with a few nanograms of RNA 
extracted from FFPE tissue.   
 
6.4.11 Findings from the study of cell death-associated genes in glioma in 
relation to future developments 
 
All of the samples used in this study were from surgical resection material, but in 
each case we have only used two 0.6mm punches from the FFPE blocks.  Despite 
the small number of samples it was observed that many of the cell death-related 
genes contained within the card were expressed in brain tumours. The card, 
originally intended for use in non-CNS tumours, is not ideally tailored to the 
genetic profiling of brain tumours. Markers such as TGF-beta 1 and –beta 2 
should be included in a card specific for brain tumours, along with invasion 
markers such as GD3.  
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6.4.12 Susceptibility to apoptosis in vitro as a marker for chemosensitivity 
 
Bcl-2 expression has been studied extensively in various brain tumours 
(Krajewski, Krajewska et al. 1997; Watanabe, Tachibana et al. 1997) but no link 
to biological function or expression has been found. In one study of eight adult 
GBM patients Bcl-2 had no correlation with survival (Sano, Lin et al. 1999). So 
far Bcl-2 has no predictive value as a standalone marker, in a drug sensitivity 
study Bcl-2 lacked predictive value (Weller, Rieger et al. 1998) but all these 
studies have assessed the potential of Bcl-2 as a single gene. Its value in 
predicting drug sensitivity might be revealed when studied as part of the whole 
Bcl-2 family.  
 
6.4.13 Technical limitations and practical considerations of profiling pro- 
and anti-apoptotic markers in glioma samples 
 
From a technical point of view, this approach to sampling tumours for apoptosis 
profiling has limited uses. When designing a brain-specific TLDA card it is 
important to select the genes most relevant to the pathogenesis of the tumours. 
Investigations have recently been explored into the potential value of targeted 
therapy with Imatinib in recurrent Oligodendroglioma, based on observations of 
PDGFR overexpression and PDGF-alpha gene amplification in these neoplasms 
(Vredenburgh, Desjardins et al. 2007), coupled with the known inhibitory 
activity of Gleevec on the PDGFR-associated tyrosine kinase signalling 
pathways. It would, therefore, be of use to include PDGFR on a future TLDA 
card. This technique requires only a small amount of tissue to be able to extract 
enough mRNA for the TLDA card.  
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The quality of the nucleic acids extracted from FFPE samples was of poor 
enough quality in some tumours, due to both fixation issues and the necrotic 
nature of the tumour core, however the quality of nucleic acids extracted from 
fresh cells was high.  While the size of other tumour types, and therefore tissue 
available for research, decreases as radio- and chemo-therapy approaches 
improve (they may be given before surgery is considered) this technique may 
prove useful. Certainly in lung tumours, where a trans-thoracic needle biopsy 
would be taken, a method for profiling many genes from a few nanograms of 
RNA would be useful. However for brain tumours debulking surgery is standard 
care, to relieve intracranial pressure and oedema, so there is no issue with the 
amount of tumour tissue available for testing. Perhaps a better method for brain 
tumours would be to extract nucleic acids directly from fresh tissue, rather than 
archival FFPE blocks. Future comparison of pre- and post-chemotherapy 
apoptotic gene expression might prove useful, if it were possible to get parallel 
samples from the same patient.  
 
6.4.14 Individual response to therapy 
 
Despite small numbers and limited data this study clearly demonstrates that no 
two tumours are the same, and therefore there is a case for not treating patients 
with „standard‟ modalities. Hence, there should not be a „one size fits all‟ 
approach to the treatment of brain tumours as they are individual in each patient. 
The mix of sub-populations of cells generates differing characteristics and the 
ratios of the various cell sub-types determines biological behaviour and response 
to therapy (Pilkington 2005).  
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In summary, this study suggests that future studies on the comparison of 
quantitative data from the ATP-TCA, with that from qRT-PCR, would have the 
advantage that relatively small numbers of tumours would be required to obtain 
data on the genes relevant to resistance and sensitivity to pro-apoptotic and other 
related agents which may show anti-glioma activity. This may prove to be 
particularly useful to investigate the mechanisms of sensitivity and resistance for 
drugs which are rarely used as single agents in specific tumour types, and for 
new drugs which have not yet entered the clinic.   This approach spends less time 
and is less labour intensive than individually analysing single genes by real-time 
relative quantity PCR; it provides a significant advance for multivariate gene 
analysis, which can offer much more information about clinical outcome and 
chemosensitivity than examination of individual genes.  
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7 The potential applications of tricyclic antidepressants in 
glioma therapy 
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There are many chemotherapeutic agents available for the treatment of brain 
tumours, described in the introduction, some of which have been in use for many 
years and some that, although known and well studied, have only recently been 
approved by NICE. None of these new agents has however, made any significant 
impact on median survival times, with only modest improvements seen in 
concomitant radiotherapy and Temozolomide. Indeed, in the most recent clinical 
trials for radiotherapy plus concomitant and adjuvant Temozolomide versus 
radiotherapy alone in Glioblastoma showed that the addition of Temozolomide 
did not yield any advantage (Linz 2010). Personalised medicine uses information 
specific to each patient in order to optimise therapeutic regime. The goal is to use 
genomic, proteomic, transcriptomic, epigenomic and other comprehensive 
profiles to select the most suitable target for the most efficacious agents. 
Molecular diagnostics provide important information regarding specific 
mutations, such as the SNPs, and aberrant molecular pathways, such as those in 
the apoptotic cascade. Personalised medicine has had success in other cancers, 
for example HER2 overexpression in breast cancer to guide Herceptin™ therapy 
and the detection EGFR mutations to guide Tarceva™ in non-small cell lung 
cancer. As yet this type of approach does not exist for glioma, although tests for 
MGMT promoter methylation have been in use for clinical trials (to guide the 
use of TMZ) it is not yet the standard of care and genomic profiles do not form 
part of the decision-making process. 
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7.1 Tricyclic antidepressants are able to induce cell death effectively in 
glioma 
 
Clomipramine is, in many ways, an ideal candidate for chemotherapy for brain 
tumours because of its lipophilic properties, which means it can cross the B-BB 
and has a twenty-four hour half life. Steady state concentrations can currently be 
achieved in man in vivo after a two week dose escalation. In addition, it 
sequesters at high levels in the brain and triggers apoptosis via the mitochondrial 
pathway. A major drawback of Clomipramine and indeed many other oral 
chemotherapeutic agents is non-compliance. Anecdotal data from patients taking 
Clomipramine shows that sometimes a dose is missed or patients attribute their 
perceived side-effects to Clomipramine and decide to reduce the dose without 
consulting their oncologist. In 1988 a Japanese research group implanted 
subcutaneous Clomipramine osmotic mini-pumps into nude male rats and 
measured both blood levels and brain levels of Clomipramine over seven days. A 
steady state concentration was achieved after only two days and regional brain 
distribution was observed (Kurata, Kurachi et al. 1988). A delivery system such 
as this might prove effective in brain tumour patients, to avoid such non-
compliance.  
 
The question when considering Clomipramine for brain tumour patients is; what 
level can be achieved at the tumour site? The plasma levels reported in chapter 4 
demonstrate the metabolic capacity of the individual patient, but it is not known 
how these levels relate to those at the tumour site. The mean Clomipramine 
concentration was 69.7 µM ± 94.3 ng/ml mg
-1
 kg
-1
, and the range was 12.29 – 
384.4 ng/ml mg
-1
 kg
-1
.  
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The mean Norclomipramine concentration was 107.9 ± 132.49 ng/ml mg
-1
 kg
-1
, 
and the range was 18.97 – 593.96 ng/ml mg-1 kg-1. Therefore the levels that can 
be achieved in plasma, when converted to micromoles range from 0.19 – 1.14 
µM. The concentrations of Clomipramine tested in chapter three would appear 
high compared to the levels that can be achieved in plasma (the IC50s for 
Clomipramine ranged from 15.79 – 46.66 µM, the mean concentration was 25.83 
± 11.61 µM) but evidence from Weigmann et al. suggests there may be a fold 
increase in Clomipramine concentrations crossing the B-BB (in rats there was a 
12.5 fold increase in the concentration of Clomipramine and a 7.4 fold increase 
in the concentration of Norclomipramine) (Weigmann, Hartter et al. 2000).  
 
When considering the plasma levels that were achieved in rats (converted to µM 
are 1.27 µM Clomipramine and 6.17 µM Norclomipramine), they are 
considerably lower than what was achieved in the rat brain (converted to µM are 
15.92 µM Clomipramine and 47.32 µM Norclomipramine) (Kurata, Kurachi et 
al. 1988). So it may follow that the levels that can be achieved in the brain, in 
man, are a number of fold higher than those in plasma and therefore the levels 
tested in chapter three are clinically relevant. This evidence supports the concept 
of specific uptake into the brain.  
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It is tempting to speculate, in light of the recently presented research (Walker, 
Muir et al. 2009) that tricyclics such as Clomipramine may not only be used in 
treatment strategies but can actually protect against cancers including those of 
the brain. In this large retrospective cohort study of GP clinic data, patients on 
regular tricyclic drug treatment regimens were considerably less likely to develop 
tumours of the brain and colon. Therefore it would be scientifically relevant to 
propose a prospective, blind, controlled trial to test this hypothesis further.  
 
Funding for clinical treatment studies, however, would be a huge challenge 
because the tricyclic antidepressants are generic drugs and industry support 
would be limited. It is commonly believed that trials of drugs such as 
Clomipramine cannot take place without industry support and because it is not 
financially attractive to the pharmaceutical industry the initial studies would need 
to be charity-funded, small-scale phase I and II trials. To date, Clomipramine 
(and Nortriptyline) has been offered as an additional treatment for some cancers, 
such as Glioblastoma, but the initiation of a small cohort dose-escalation study in 
patients with GBM should be considered as important in developing effective 
strategies in treating patients with this devastating and resistant malignancy.  
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7.2 Cytochrome P450 genotype influences chemosensitivity in malignant 
glioma 
 
The outcome of glioma chemotherapy is determined by the interplay of several 
gene products that influence the pharmacokinetics and pharmacodynamics of 
agents, including drug disposition, specifically drug transporters and drug 
metabolism. The genotype of a patient needs to be determined only once for any 
given gene, since it does not change apart from in very rare somatic mutations, 
and if interpreted according to diagnosis and treatment options may provide 
clinical relevance. One of the biggest challenges in defining pharmacogenomic 
traits in malignant glioma is the need for patients who have the same diagnosis 
and have received the same treatment. As highlighted in this study, patient 
tumour samples are difficult to obtain and the degree of heterogeneity is large. A 
larger sample group is required to provide further insight into the prognostic 
value of CYP450 genotyping and drug metabolism.  
 
In recent years, significant progress has been achieved in the individualisation of 
chemotherapy due to a plethora of new chemotherapeutic drugs and agents for 
targeted therapy (Morokoff and Novak 2004; Norden, Drappatz et al. 2008; Dai, 
Jiang et al. 2010; Krakstad and Chekenya 2010). However, response rates and 
overall survival rates have not improved significantly for brain tumours. This 
may be due at least in part to the enormous genetic heterogeneity within brain 
tumours, even between tumours of the same type (Pilkington 2005) and one 
hypotheses of this study was that the CYP2D6 and CYP2C19 genotype of brain 
tumour patients influences chemosensitivity in malignant glioma.  
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Moreover, besides individual somatic mutations or combinations of these in 
malignant brain tumours, the genetic background of each individual patient 
appears to have a major impact on treatment response and overall survival 
(Deeken, Figg et al. 2007).  
 
It is now feasible to screen up to 1 million SNP genotypes at a time and the 
possibility of purchasing custom made micro arrays facilitates the screening of 
selected patient groups for susceptibility genotypes with the purpose of 
elucidating the question on finding the optimal individual treatment. Likewise, 
the next generation sequencing methodologies hold the power to allow selection 
of relevant SNP genotypes for each individual, thereby improving the cancer 
therapy considerably and diminishing the therapy side effects as much as 
possible. Establishment of a precise diagnosis based upon the individual genomic 
profile combined with histopathological tumour characteristics comprises 
important parameters for selection of optimal, individual treatment for cancer 
patients in which drug resistance and severe side effects are obstacles for a 
successful treatment and recovery. SNP genotypes have been associated with the 
patient's ability to metabolise chemotherapeutic drugs, optimize the cell DNA 
repair and escape severe side effects of the treatment. Today only a limited 
number of SNP genotype associations have been established but the 
technological advances will without doubt increase the number significantly over 
the next few years. 
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The future of research for malignant glioma requires focus on individualising 
treatment regimes for each patient; it is clear from the heterogeneity seen in CYP 
genes, metabolic capacities, expression of drug transporters and sensitivity of 
tumours to antidepressants (in this study) that these tumours are extremely 
heterogeneous and one single approach will not be effective. Because of the 
rapid cellular adaptation seen in fast-growing primary and recurrent brain 
tumours it is best to avoid monotherapies, and so developing combinations of 
synergistic agents would be the next stage in this research.  
 
7.3 Norepinephrine transporter expression in glioma influences sensitivity 
to tricyclic antidepressants 
 
The present study has demonstrated the presence of the NET transporter on 
human normal brain astrocytes (see 5.3.1.1), which supports the findings of 
others that glial cells assist in the degradation of excess catecholamines and 
protect surrounding neurones (Inazu, Takeda et al. 2003). It has also been shown 
that human brain tumour cells express the NET transporter (see 5.3.1.2, 5.3.1.3, 
5.3.1.4 & 5.3.1.5), and so we can postulate they also possess active monoamine 
oxidase isoenzymes.  
Glioma cells are able to inhibit antioxidant systems which remove ROS; when 
levels of ROS exceed the attenuation capacity of antioxidant enzymes such as 
superoxide dismutase (SOD) the proliferative rate exceeds, the reduction-
oxidation (REDOX) balance of the cell is altered and can lead to ROS-induced 
changes in genomic DNA (Hodge, Peng et al. 2005).  
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7.3.1 Targeting reactive oxygen species and cellular oxidant stress through 
the Norepinephrine transporter 
 
 
Reactive oxygen species and cellular oxidant stress has long been associated with 
cancer, however the nature of this association is complex and paradoxical: 
(1) ROS and oxidant stress may induce glioma. According to the 
mitochondrial paradigm of cancer, mutations in mitochondrial genes 
encoding parts of the electron transport chain can lead to an increase in 
ROS generation. Mounting evidence supports the idea that ROS triggers 
malignant transformation by amplifying genomic instability (Wallace 
2005) and might, therefore, mean that norepinephrine is an etiological 
factor in the development of glioma 
(2) Tumour cells generate more ROS than normal cells, possibly due to 
higher metabolic rates, and some forms of cancer may be associated with 
increased ROS signalling (Szatrowski and Nathan 1991). This provides 
an attractive target for agents that target the electron transport chain 
(3) The thioredoxin antioxidant system, responsible for maintaining the 
balance of ROS production, is overexpressed in malignant cells. 
Paradoxically thioredoxin reductase-1 (TR-1), which maintains an 
environment required for effective DNA binding of transcription factors 
and subsequent gene expression is over expressed in a variety of 
malignant tumours and a loss of TR-1 is associated with a reversal of 
tumour phenotype and a decrease in tumourigenicity (Hirota, Murata et 
al. 1999; Yoo, Xu et al. 2006).  Silencing of the TR-1 gene in addition to 
use of a tricyclic antidepressant might prove an effective combination in 
glioma. 
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(4) Some chemotherapeutic agents may be selectively toxic to tumour cells 
because they augment oxidant stress and push these already stressed cells 
beyond their limit. This common effect suggests that neoplastic cells may 
be more vulnerable to oxidant stress because they function with a 
heightened basal level of ROS-mediated signalling, which is required for 
the increased rate of growth. If this is the case, then a chemotherapeutic 
agent such as Clomipramine that increases ROS generation may push a 
tumour cells beyond the breaking point of lipid peroxidation and the 
scavenging of electrons from the cell membrane lipids causes irreversible 
cell membrane damage (Adachi, Zhang et al. 2004). 
 
Antioxidants, such as superoxide dismutase (SOD), catalase and glutathione 
peroxidase, breakdown ROS produced by the electron transport chain and if it 
were possible to combine Clomipramine (or Nortriptyline) with an agent that 
inhibits the activity of one of the enzymes responsible for ROS breakdown it 
might further stress the tumour cell and initiate MOMP, leading to subsequent 
apoptosis. An alternative approach would be to silence the gene responsible for 
the production of the antioxidant enzymes, using small interfering RNAs 
(siRNAs) however this would need to be a tumour-specific effect. One study 
showed that phenylethyl isothiocyanate augments oxidant stress by decreasing 
oxidant scavenging and manifests in a decreased mitochondrial potential 
(Trachootham, Zhou et al. 2006); this may be a suitable candidate for combining 
with an antidepressant.  
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7.3.2 Targeting the norepinephrine transporter and mitochondrial 
superoxide dismutase 
Reductions in the levels of SOD have been detected in tumours; however it is 
possible to restore antioxidant activity using a mimic such as Mangafodipir 
(Alexandre, Nicco et al. 2006). Combination of a tricyclic antidepressant, which 
may limit the entry of NE into the glioma cells that express the NET, with an 
agent that increases mitochondrial SOD (MnSOD; SOD-2) activity in glioma, 
might restore normal REDOX and antioxidant activity, and therefore 
susceptibility to apoptosis 
7.3.3 Targeting the norepinephrine transporter and monoamine oxidase 
 
It might be possible to combine PCZ with Clomipramine in the ex-vivo ATP-
TCA study. PCZ inhibits monoamine oxidase (which in turn reduces NE 
degradation and ROS production) and the combination of this agent with one that 
blocks entry of norepinephrine into the tumour cell, i.e. Clomipramine, might 
cause greater disruption to cellular homeostasis and have a pro-apoptotic effect.  
7.3.4 Targeting the Norepinephrine transporter and protein kinase C 
 
Lithium carbonate is a mood stabiliser that is used to treat bi-polar disorder and 
augment antidepressant therapy. Apart from its main function in reducing 
norepinephrine levels and increasing serotonin levels, which it does via protein 
kinase C (PKC) suppression, lithium regulates the c-jun N-terminal pathway 
(Chen, Masana et al. 2000). In normal brain cells the suppression of PKC would 
simply reduce the levels of NE available to neurones but in tumour cells it causes 
cell cycle arrest. Because PKC is no longer activated, the levels of cAMP 
decrease and in turn so does the turnover of ATP (Chuang 2005).  
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It might be possible to combine a tricyclic antidepressant with lithium, the aim 
being that the tricyclic antidepressant would block the entry of NE into tumour 
cells that express the NET (thereby disrupting ROS production and oxygen 
sensing at complex III, possibly activating MOMP) and lithium would decrease 
the level of NE available. Studies by Bilir et al. have shown that a combination 
of Clomipramine and lithium chloride enhanced the effect of Vinorelbine in 
Neuroblastoma cell line SH-SY5Y (Bilir, Erguven et al. 2010). Because NE is 
transported into the cell by transporters other than the NE-transporter, reducing 
the availability of the neurotransmitter could potentially increase the degree of 
cell kill. Since lithium is usually effective after chronic administration, in a 
clinical setting it would be appropriate to administer lithium prior to an 
antidepressant in order for NE levels to be decreased effectively.  
 
ROS and tumour biology are part of a complex equilibrium and it is not clear 
whether oxidants are required for tumour growth, and if oxidant stress can be 
exploited therapeutically. The heightened state of basal oxidative stress makes 
them vulnerable to chemotherapeutic agents, and it would seem that tumour cells 
may die by the same systems they require.  
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7.4 Mitochondria are a potential target for therapy in malignant glioma 
 
Evasion of cell death is a hall mark of human cancers and a major cause of 
treatment failure (Hanahan and Weinberg 2000; Fulda 2009). The lack of 
efficacy of established therapeutic regimen is due, in part, to the blockade of cell 
death pathways (Fulda and Debatin 2006). Therefore drugs that activate cell 
death machinery and target one of the many cascades that converge on the 
mitochondria are attractive for use in glioma. On one hand mitochondria are 
critical for the survival of glioma cells, but also they govern the intrinsic pathway 
of apoptosis and are key regulators of cell death. Mitochondrial functions are 
frequently altered in glioma (Gogvadze, Orrenius et al. 2008) so mitochondrially-
targeted compounds represent a promising approach to chemotherapy-refractive 
malignant glioma. Recently modifications in the generation of ROS have been 
linked to chemoresistance which further supports the theory that mitochondria 
are a target for glioma (Kroemer and Pouyssegur 2008; Bellance, Lestienne et al. 
2009). Cancer cell mitochondria are structurally and functionally different to 
their normal counterparts, mutations in mitochondrial DNA (mtDNA) result in 
ROS overproduction and inefficient ATP production, moreover (Modica-
Napolitano and Singh 2004; Bellance, Lestienne et al. 2009), tumour cells have 
extensive metabolic reprogramming that renders them more susceptible to 
mitochondrial perturbation than non-established cells (Gogvadze, Orrenius et al. 
2008; Kroemer and Pouyssegur 2008). The reversal of apoptotic cascade 
blockade and activation of intrinsic cell death machinery such as MOMP 
represents a strategy to target malignant glioma (Galluzzi, Larochette et al. 2006; 
Armstrong 2007; Gogvadze, Orrenius et al. 2009).  
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Conceptually, gene expression profiles describe the transcriptional processes 
within a cell of a given type or state. It is this variation in transcription between a 
healthy and cancerous cell of the same type that provides useful information. The 
utility of this technique is that it does not typically rely on a single gene, but 
rather the clustering of several genes that highlight disease versus non-disease 
profiles. It has been shown in chapter 6 that a number of pro- and anti-apoptotic 
genes were expressed in malignant glioma samples, and that it is possible to 
modulate the expression using tricyclics and prophylactic agents. It is 
increasingly evident that the sophisticated cell death machinery present in 
normal, non-neoplastic, cells has the potential to function normally in tumour 
cells if the equilibrium between pro- and anti-apoptotic proteins could be 
restored through the use of agents such as those tested in chapters 3 and 6. The 
problem however is not simply as a result of overexpression of a single protein, 
rather the aberrant switching on and off of a series of related genes by the tumour 
itself and evidence in chapter 6 to show clusters of pro- and anti-apoptotic gene 
expression support this theory.  
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7.4.1 Potential applications of combined extrinsic and intrinsic pro-
apoptotic therapy in glioma 
 
Looking at the data in chapter 6, it might be feasible to twin one of the tricyclic 
antidepressants (see 2.3.12) with a recombinant ligand that activates the extrinsic 
apoptotic pathway via death receptors. Preclinical studies have shown that 
TRAIL has the ability to induce apoptosis in vitro with a subsequent anti-glioma 
effect. Some tumours remained resistant when it was trialled as a monotherapy 
but when used in combination with doxorubicin, Etoposide and TMZ an additive 
effect was noted (Fulda, Wick et al. 2002). Because of the efficacy of the 
tricyclics, which target the intrinsic apoptotic pathway, it might be possible to 
demonstrate an additive effect when combining them with a recombinant TRAIL 
ligand in vitro. So far there has been no clinical testing of death receptors (DRs) 
in glioma due to major concerns over toxicity, in particular the effect of TRAIL 
on human hepatocytes, but fortunately this effect is not universal to all DRs 
(Fulda, Wick et al. 2002).  
 
Using a monoclonal antibody directed towards the DRs (Rieger, Ohgaki et al. 
1999; Kaliberov, Stackhouse et al. 2004; Goldsmith and Hogarty 2005; Ricci and 
Zong 2006; Fiveash, Gillespie et al. 2008; Nagane, Shimizu et al. 2010) would 
be an option for future studies however it would need to be administered intra-
operatively during surgery because it would not be able to cross the B-BB and it 
still may not reach the „guerrilla‟ cells.  
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The Fas ligand and receptor were included in markers screened in glioma (see 
6.3.2) and was only found to be present in two tumours, therefore using a 
monoclonal antibody targeted to a single DR would not be effective in all 
tumours and screening tumours for their apoptotic gene expression patterns to 
direct therapy might prove useful.  
 
In addition to the clinical trial carried out using Oblimersen (see 6.4.9), work has 
been done on targeting various proteins that contribute to the apoptotic cascade. 
One group, using an adenovirus expressing-antisense Hsp70, found that by 
blocking the anti-apoptotic chaperone protein both triggered caspase-independent 
apoptosis and caused an immune response (Nylandsted, Wick et al. 2002). The 
drawbacks to this study were that they used a high-passage homogeneous cell 
line (which have been shown in chapter three to be under extra stress from 
immortalisation, see 3.5, i.e. more prone to undergo apoptosis and not as 
representative of in vivo apoptosis mechanisms as using primary cells). They also 
took a cell line cultured in serum back to a serum-free microenvironment and 
only targeted one protein. Without data showing the expression of Hsp70 in the 
xenografts following application of the adenovirus it is difficult to say whether or 
not Hsp70 was actually depleted. This could have been done via a TLDA 
microarray card, using either FFPE or collagenase-digested mouse brains. 
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7.4.2 Targeting the mitochondria with Clomipramine and a cathepsin 
inhibitor 
 
Cathepsins are lysosomal cysteine peptidases and are part of a large family of 
lysosomal enzymes that traffick between various intra-cellular organelles and 
participate in general protein catabolism. They contribute to cancer progression 
and appear strongly associated with tumour cell invasiveness, through their 
proteolytic action on the extra cellular matrix (ECM). Both cathepsins –B and –L 
protect the cell from apoptosis through their action upstream of caspase-3, on 
Bcl-2. This has been demonstrated by the transfection of anti-sense 
oligonucleotides into IPTP cells, which resulted in induction of apoptosis 
(detected via caspase-3 activity) (Levicar, Dewey et al. 2003). In a clinical 
setting cathepsins are useful both as predictive markers for response to 
chemotherapy, tumours expressing high levels of cathepsins would not readily 
undergo apoptosis, and for designing inhibitors against them to be used as an 
adjuvant therapy. Moreover, Cathepsin L inhibitors such as stefin-A and stefin-B 
have been shown to increase apoptosis in malignant glioma cells treated with 
Clomipramine (Levicar, Dewey et al. 2003) by lowering the apoptotic threshold. 
The results shown in chapter 4 (Table 4.3.1), for the concentrations of 
Clomipramine in plasma samples, are much lower than the concentrations 
required to initiate apoptosis in the Annexin V assay (Figure 3.3.1.1) and 
therefore combining Clomipramine with an inhibitor that lowers the apoptotic 
threshold, such as one that targets cathepsin L, might prime the cells to undergo 
apoptosis more readily.  
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7.4.3 Targeting the mitochondria and gangliosides 
 
Drug-based approaches to induce apoptosis in the mitochondrion carry huge 
potential for cancer therapy but there are also ways of triggering apoptosis by 
modulating endogenous processes. Gangliosides are acidic glyco-sphingolipids 
present during early foetal development of the brain, with GD3 being the 
predominant species (Kracun, Rosner et al. 1992). In neoplastic tissues 
gangliosides, including GD3, are overexpressed. They are located in the cell 
membrane and are responsible for adhesive, migratory and invasive properties in 
tumour cells (Merzak, Koochekpour et al. 1995). Normally in non-neoplastic 
tissue an overexpression of GD3 would result in endocytosis and subsequent 
mitochondrially-mediated apoptosis. However, tumour cells are able to acetylate 
GD3 into GD3
A
 via sialate-9-O-transferase. This process is crucial to the survival 
of the tumour cell. GD3
A
 expression represents a suitable target for glioma 
therapy because this ganglioside is not expressed in normal mature glial cells; the 
expression in mature glial cells is unique to tumours. When the GD3 acetylation 
is reversed, via the 9-O-acetylases, the restored balance of unmodified GD3 
triggers the cell to undergo apoptosis (Malisan, Franchi et al. 2002).  
 
It is possible to block GD3 production by targeting GD3 synthase; this can be 
with antisense oligonucleotides (Birkle, Gao et al. 2000), specific monoclonal 
antibodies (Hedberg, Dellheden et al. 2000) or imino sugars with structural 
similarity to N-butyldeoxynojirimycin (Kyriazis 2005).  
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The Annexin V assay is the most suitable method for visualising apoptosis and it 
might be possible to transfect glioma cells with antisense oligonucleotides, or 
expose cells for twenty-four hours to a monoclonal antibody or imino sugar 
before repeating the same experiment detailed in 2.3.6 to see if apoptosis occurs 
with lower concentrations of Clomipramine than was seen in Figure 3.3.1.1.  
 
7.4.4 Targeting mitochondria through growth factor withdrawal 
 
Growth factor withdrawal has been well described as a mechanism for triggering 
the intrinsic pathway and initiating apoptosis (Letai 2006). Several growth factor 
receptor tyrosine kinases (RTKs) are implicated in gliomagenesis, are thought to 
inhibit apoptosis and are a rational therapeutic target. Truncation of EGFR is the 
most common genetic abnormality in adult HGGs, whereas EGFR 
overexpression has been demonstrated in up to 85% of cases (Andersson, Guo et 
al. 2004). Other work that has been carried out recently involves the growth 
factors, such as EGF and VEGF as well as PTEN (Sano, Lin et al. 1999; Wedge, 
Kendrew et al. 2005). 
 
GBMs often express EGFRvIII, a genomic deletion variant of EGFR which 
persistently activates the P13K pathway resulting in an anti-apoptotic blockade. 
This pathway is also regulated via the PTEN tumour suppressor gene. Multiple 
studies have shown that targeting of the EGFR constitutes possible successful 
anti-glioma strategies, and inhibition leads to activation of a pro-apoptotic 
pathway (Nagane, Coufal et al. 1996; Nagane, Levitzki et al. 1998).  
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However the first small-molecule inhibitors, such as Erlotinib and Gefinitib, have 
shown disappointing results when tested in HGG. Investigations into the poor 
response rate revealed that tumours appearing to express the EGFRvIII mutation 
did not necessarily transmit the anti-proliferative and pro-apoptotic EGFR 
signals because of an associated intact inhibitory PTEN signal (Mellinghoff, 
Wang et al. 2005). This again demonstrates the need to determine the expression 
of more than one protein at a time; single genes are rarely useful since they 
interact with many others.  
 
Recently an oral, highly potent VEGF signalling inhibitor (Recentin™; 
Cediranib) has been trialled in patients with acute myeloid leukaemia. Unlike 
Avastin, Recentin has activity against VEGFR-1, -2 and -3 with additional 
activity against c-Kit (Wedge, Kendrew et al. 2005). This agent has potential for 
use in brain tumours and has the ability to block angiogenesis; however blockade 
of VEGF and angiogenesis would reduce oxygen levels and provide the perfect 
hypoxic environment in which stem cells can thrive. Recentin would need to be 
combined with a second agent, possibly one that targets the HIF pathways. 
Reducing HIF activity in cancer stem cells may promote their differentiation (see 
6.1.3), thereby reducing their ability to repopulate tumours after chemo- and 
radio- therapies. To test this theory, it would be necessary to ablate the function 
of HIF-1α and HIF-2α in tumour models (Semenza 2003; Keith and Simon 
2007). 
 
 
 309 
The phase III randomised, active-controlled, clinical trial SAPPHIRE is currently 
underway in patients with recurrent or refractory Anaplastic Astrocytoma. 
Trabedersen (AP 12009), a novel synthetic antisense oligodeoxynucleotide that 
acts via inhibition of TGF-ß2 (Vallieres 2009) is used to treat patients via 
convection enhanced delivery directly to the brain. An antisense agent such as 
this, which reverses immune suppression and restores immune surveillance, 
could potentially be combined with an agent such as Clomipramine. Better still, 
if a similar antisense approach using TGF-1, which modulates growth factor 
mediated glioma invasion (Merzak, McCrea et al. 1994) would be of value 
following Avastin® or Recentin® anti-angiogenesis therapy. Both could 
potentially be used in tandem with Clomipramine and this approach would 
support the hypothesis that mitochondria are a suitable target in glioma therapy.  
 
7.4.5 Stem cell properties in glioma: implications for targeting the 
mitochondria 
 
At present, tumour cells with stem cell-like characteristics have been described 
within several malignancies including brain tumours (Galli, Binda et al. 2004; 
Singh, Hawkins et al. 2004; Yuan, Curtin et al. 2004). The development of new 
cell culture methods, including the in vitro growth of neurospheres and 
multicellular tumour spheroids, and new antigenic markers of stem cells and 
glial/neuronal cell precursor cells, including nestin, Musashi-1 and CD133, have 
led to a reappraisal of the histological classification and origins of CNS tumours 
(Pilkington 2005).  
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These cancer stem cells generally constitute only a minor fraction of the bulk of 
the mass, but may have an essential role in tumour maintenance. This subset of 
cells, previously described in Glioblastoma, are capable of long-term 
proliferation, self-renewal and multi-potency in vitro under conditions normally 
used for neural cell growth (Galli, Binda et al. 2004; Yuan, Curtin et al. 2004). 
The marker CD133 distinguishes a sub-population of brain tumour cells showing 
stem cell-like characteristics. It was originally suggested that tumour formation 
in vivo can be solely attributed to a small fraction of CD133+ glioma cells 
(Singh, Clarke et al. 2003), however this has been subsequently refuted (Wang, 
Sakariassen et al. 2008). To determine whether CD133+ cells were chemo-
resistant, CD133+ cells were isolated from primary cultures of Glioblastoma, 
previously exposed to Temozolomide (Liu, Yuan et al. 2006). The anti-apoptotic 
genes Bcl-2, Bcl-xL, c-FLIP, IAP2, XIAP, NAIP and Survivin were expressed at 
greater levels than autologous cells. Compared to the autologous cells, CD133+ 
cells expressed >30-fold high levels of the DNA repair protein MGMT, which is 
an acknowledged predictor of response to alkylating agents. Finally, when 
autologous primary and recurrent tumour tissues were compared, there was a 
significant increase in CD133+ expression observed upon tumour recurrence, 
suggesting that conventional chemotherapy may facilitate survival of the 
CD133+ cells.  
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Although additional markers in addition to CD133 are required to accurately 
recognise cancer stem cells in the brain, these cells form a major target for novel 
therapies. The finding is that CD133+ populations can be triggered under 
hypoxic culture conditions (Griguer, Oliva et al. 2008) and that anti-angiogenesis 
therapies such as Avastin® result in creating a hypoxic environment within 
glioma. This activates and disseminates CD133+ cancer stem cells suggesting 
that mitochondrial function in these cells is different from that of standard brain 
tumour cells. Exploiting MOMP and the NET, therefore, provide a better target 
for these cells than DNA-acting alkylating agents currently in use for the 
treatment of glioma (Pilkington, Parker et al. 2008).  
 
The discovery of a chemo-resistant sub-population within Glioblastoma may 
indicate a novel target for therapy. Because of the adaptation of cancer stem-like 
cells following conventional chemotherapy to a more resistant phenotype, it is 
clear that a different approach would be required. Traditional agents target the 
bulk of the tumour but fail to eradicate the stem cell component; the 
tumourigenic stem-like cells then adapt, proliferate and up-regulate anti-
apoptotic proteins. Therefore targeting the mitochondria of malignant glioma is a 
suitable approach and tricyclic antidepressants are suitable candidates for 
therapy.  
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There are many possible approaches to overcome the stem cell-like sub-
population:  
 
1. reverse drug/radiation resistance (see 1.8.7) 
2. differentiate the cancer stem cells (see 1.4.1) 
3. block the stem cell niche (see 1.8.6) 
4. target cell surface antigens (see 1.8.5) 
5. mitochondrial-based therapies (see 1.9) 
 
The aspect analysed in this thesis, the intrinsic mitochondrial pathway associated 
therapies, specifically the tricyclic antidepressants, which may be used in various 
combinations, have recently been used to target CD133+ cells from malignant 
paediatric GBM under both hypoxic and normoxic culture conditions. Growth 
under hypoxic conditions was seen to protect against tricyclic-drug mediated 
apoptosis whilst CD133+ GBM-derived populations were also more resistant to 
Clomipramine than CD133- GBM-derived cells (Pilkington & Donovan, 
unpublished observations). In order to combat CD133+ cancer stem cells from 
glioma it might, therefore, be necessary to modulate oxygen conditions and then 
further investigate the mitochondria of these cells with regard to function of 
mitochondrial DNA mutations.  
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7.5 Future directions of research in malignant glioma 
 
 
The search for an improved, more specific and less toxic approach to treating 
malignant glioma is being conducted at a remarkable pace, with strategies 
simultaneously being focussed upon angiogenesis, epigenetics, glioma stem cells 
and tumour immunology. There is substantial evidence from this study that 
Clomipramine (and indeed Nortriptyline) might be beneficial in human 
malignant brain tumours (see 3.3.1 & 3.4). There are forty years of 
pharmacokinetic and toxicity data from its use as an antidepressant, this would 
support an easy translation to early phase clinical trial. Clomipramine could be 
tested in both malignant glioma and malignant melanoma, which would further 
reinforce its evaluability as a potential chemotherapeutic agent. It is unknown 
whether previously studied dose ranges will achieve the necessary cytotoxic 
intra-tumoural concentrations of Clomipramine and, in addition, the nutritional 
and metabolic profile of patients with cancer differs from those in published 
Clomipramine papers for use in depression. It is for this reason that 
Clomipramine needs to be administered on an individual basis.  
 
Current DNA microarrays allow us to simultaneously determine gene expression 
analysis of all known genes, and large-scale gene expression studies have 
provided new molecular classifications for certain brain tumours, for example 
Oligodendroglioma and the use of 1p19q. The results of the TLDA microarray 
are interesting since Oligodendroglioma are generally more sensitive to DNA-
acting alkylating agents, where there is loss of heterozygosity (LOH) on 1p19q.  
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Based upon this co-deletion, Oligodendroglioma are treated with chemotherapy 
but astrocytic tumours without LOH on 1p19q are not. Clomipramine is a 
potential chemotherapeutic agent for use in these tumours without LOH on 
1p19q.  
 
Research into GBM should focus upon the mechanisms by which these 
aggressive tumours evade current treatment regimens, to develop novel agents 
and provide innovative therapeutic strategies. Increasing evidence would suggest 
that aberrations in the apoptotic pathway in the glioma are vital modulators of 
both gliomagenesis and response to therapy (Cavaliere and Newton 2006). The 
expression of anti-apoptotic proteins is an important physiological safeguard to 
prevent cellular destruction and the proteins that govern this phenomenon play a 
role in the pathogenesis of malignant brain tumours (Fulda and Debatin 2006; 
Fulda 2007; Fulda 2008; Fulda 2010; Fulda 2010; Fulda, Galluzzi et al. 2010). 
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9.1 Annexin V data showing apoptosis occurring in glioma cells treated 
with clomipramine hydrochloride 
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Figure 9.1.The Annexin-V flow cytometry data showing apoptosis occurring in 
tumour SNB-19 incubated with 20µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.1The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour SNB-19 incubated with 40µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.2The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour SNB-19 incubated with 60µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-3 hour samples (C-E respectively), 
whereas apoptosis is starting to occur in the 4-6 hour samples (F-H respectively). 
The negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
 
 
 385 
 
 
 
 
 
 
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
D 
 
 
 
 
 
 
 
 
 
E 
 
 
 
 
 
 
 
 
 
F 
 
 
 
 
 
 
 
 
 
G 
 
 
 
 
 
 
 
 
 
H 
 
Figure 7.4.5.3The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour SNB-19 incubated with 80µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is apoptosis in all samples (C-H respectively. The negative 
control histogram was divided into three sections, live, dead and apoptotic 
ensuring that <2% cells were contained within the apoptotic area and then the 
template grid was pasted onto all test histograms to obtain percentage values for 
apoptosis.  
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Figure 7.4.5.4The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour DK-MG incubated with 20µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis. 
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Figure 7.4.5.5The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour DK-MG incubated with 40µM clomipramine 
 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.6The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour DK-MG incubated with 60µM clomipramine 
 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.7The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour DK-MG incubated with 80µM clomipramine 
 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.8The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour DK-MG incubated with 100µM clomipramine 
 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.9The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour UPAB incubated with 20µM clomipramine 
 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.10The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour UPAB incubated with 40µM clomipramine 
 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.11The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour UPAB incubated with 60µM clomipramine 
 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
 
 394 
 
 
 
 
 
 
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
D 
 
 
 
 
 
 
 
 
 
E 
 
 
 
 
 
 
 
 
 
F 
 
 
 
 
 
 
 
 
 
G 
 
 
 
 
 
 
 
 
 
H 
 
Figure 7.4.5.12The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour UPAB incubated with 80µM clomipramine 
 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.13The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour UPAB incubated with 100µM clomipramine 
 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.14The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour UPMC incubated with 20µM clomipramine 
 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.15The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour UPMC incubated with 40µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.16The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour UPMC incubated with 60µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.17The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour UPMC incubated with 80µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.18The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour UPMC incubated with 100µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.19The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour UPJM incubated with 20µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.20The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour UPJM incubated with 40µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is apoptosis in the 4-6 hour samples (C-E respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.21The Annexin-V flow cytometry data showing apoptosis occurring 
in tumour UPJM incubated with 40µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is apoptosis in the 2-6 hour samples (C-G respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.22The Annexin-V flow cytometry data showing apoptosis occurring 
in CC-2565 incubated with 20µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.23The Annexin-V flow cytometry data showing apoptosis occurring 
in CC-2565 incubated with 40µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.24The Annexin-V flow cytometry data showing apoptosis occurring 
in CC-2565 incubated with 60µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.25The Annexin-V flow cytometry data showing apoptosis occurring 
in CC-2565 incubated with 80µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis.  
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Figure 7.4.5.26The Annexin-V flow cytometry data showing apoptosis occurring 
in CC-2565 incubated with 100µM clomipramine 
The graphs show that compared to the negative control (A) and the positive 
control (B) there is no apoptosis in the 1-6 hour samples (C-H respectively). The 
negative control histogram was divided into three sections, live, dead and 
apoptotic ensuring that <2% cells were contained within the apoptotic area and 
then the template grid was pasted onto all test histograms to obtain percentage 
values for apoptosis. 
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9.2 IC50Macro (Excel) 
 
Used in the ATP-TCA assay (see 2.3.10) 
 
If Inh6.25 < 49.99 and Inh12.5> 50 and Inh25> 50 is true, then x = 6.25; 
if false, x = 0 
If Inh6.25 < 49.99 and Inh12.5< 49.99 and Inh25> 50 and Inh50> 50 is 
true, then x = 12.5; if false, x = 0 
If Inh12.5< 49.99 and Inh25<49.99 and Inh50> 50 and Inh100> 50 is true, 
then x = 25; if false, x = 0 
If Inh25< 49.99 and Inh50<49.99 and Inh100> 50 and Inh200> 50 is true, 
then x = 50; if false, x = 0 
If Inh50<49.99 and Inh100< 49.99 and Inh200> 50 is true, then x = 100; 
if false, x = 0 
If Inh100< 49.99 and Inh200> 50 is true, then x = 200; if false, x = 0 
y1 = (x) 
If Inh6.25 < 49.99 and Inh12.5> 50 and Inh25> 50 is true, then x = 
Inh6.25; if false, x = 0 
If Inh6.25 < 49.99 and Inh12.5< 49.99 and Inh25> 50 and Inh50> 50 is 
true, then x = Inh12.5; if false, x = 0 
If Inh12.5< 49.99 and Inh25<49.99 and Inh50> 50 and Inh100> 50 is true, 
then x = Inh25; if false, x = 0 
If Inh25< 49.99 and Inh50<49.99 and Inh100> 50 and Inh200> 50 is true, 
then x = Inh50; if false, x = 0 
If Inh50<49.99 and Inh100< 49.99 and Inh200> 50 is true, then x = 
Inh100; if false, x = 0 
If Inh100< 49.99 and Inh200> 50 is true, then x = Inh200; if false, x = 0 
y2 = (x) 
If Inh6.25 > 50 and Inh12.5> 50 is true, then x = 6.25; if false, x = 0 
If Inh6.25 < 50 and Inh12.5> 50 and Inh25> 50 is true, then x = 12.5; if 
false, x = 0 
If Inh6.25 < 50 and Inh12.5< 50 and Inh25> 50 and Inh50> 50 is true, then 
x = 25; if false, x = 0 
If Inh6.25 < 50 and Inh12.5< 50 and Inh25< 50 and Inh50> 50 and Inh100> 
50 is true, then x = 50; if false, x = 0 
If Inh12.5< 50 and Inh25< 50 and Inh50< 50 and Inh100> 50 and Inh200> 
50 is true, then x = 100; if false, x = 0 
If Inh12.5< 50 and Inh25< 50 and Inh50< 50 and Inh100< 50 and Inh200> 
50 is true, then x = 100; if false, x = 0 
y3 = (x) 
If Inh6.25 > 50 and Inh12.5> 50 is true, then x = Inh6.25; if false, x = 0 
If Inh6.25 < 50 and Inh12.5> 50 and Inh25> 50 is true, then x = Inh12.5; if 
false, x = 0 
 410 
If Inh6.25 < 50 and Inh12.5< 50 and Inh25> 50 and Inh50> 50 is true, then 
x = Inh25; if false, x = 0 
If Inh6.25 < 50 and Inh12.5< 50 and Inh25< 50 and Inh50> 50 and Inh100> 
50 is true, then x = Inh50; if false, x = 0 
If Inh12.5< 50 and Inh25< 50 and Inh50< 50 and Inh100> 50 and Inh200> 
50 is true, then x = Inh100; if false, x = 0 
If Inh12.5< 50 and Inh25< 50 and Inh50< 50 and Inh100< 50 and Inh200> 
50 is true, then x = Inh200; if false, x = 0 
y4 = (x) 
 
IC50 = ((50-y4)/(y2-y4)*(y1-y3))+y3 
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